Note: Descriptions are shown in the official language in which they were submitted.
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
METHODS AND COMPOSITIONS FOR WEED CONTROL
This application claims benefit under 35U5C 119(e) of United States
provisional application
serial no. 61/534,066 filed 09/13/2011, herein incorporated by reference in
it's entirety. The
sequence listing that is contained in the file named "40_21(58636)B seq
listing.txt", which is
400,732 bytes (measured in operating system MS-Windows) and was created on 7
Sept 2012, is
filed herewith and incorporated herein by reference.
FIELD
The invention relates generally to the field of weed management. More
specifically, the
invention relates to 4-hydroxyphenyl-pyruvate-dioxygenase genes in weedy
plants and
compositions containing polynucleotide molecules for modulating their
expression. The
invention further provides methods and compositions useful for weed control.
BACKGROUND
Weeds are plants that compete with cultivated plants in an agronomic
environment and
cost farmers billions of dollars annually in crop losses and the expense of
efforts to keep weeds
under control. Weeds also serve as hosts for crop diseases and insect pests.
The losses caused
by weeds in agricultural production environments include decreases in crop
yield, reduced crop
quality, increased irrigation costs, increased harvesting costs, reduced land
value, injury to
livestock, and crop damage from insects and diseases harbored by the weeds.
The principal
means by which weeds cause these effects are: 1) competing with crop plants
for water,
nutrients, sunlight and other essentials for growth and development, 2)
production of toxic or
irritant chemicals that cause human or animal health problem, 3) production of
immense
quantities of seed or vegetative reproductive parts or both that contaminate
agricultural products
and perpetuate the species in agricultural lands, and 4) production on
agricultural and
nonagricultural lands of vast amounts of vegetation that must be disposed of.
Herbicide tolerant
weeds are a problem with nearly all herbicides in use, there is a need to
effectively manage these
weeds. There are over 365 weed biotypes currently identified as being
herbicide resistant to one
I
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
or more herbicides by the Herbicide Resistance Action Committee (HRAC), the
North American
Herbicide Resistance Action Committee (NAHRAC), and the Weed Science Society
of America
(WSSA).
The 4-hydroxyphenyl-pyruvate-dioxygenase (HPPD) is an Fe-containing enzyme,
that
catalyzes the second reaction in the catabolism of tyrosine, the conversion of
4-
hydroxyphenylpyruvate to homogentisate. This enzyme is the target of many
herbicides that
include members of the chemical families of Triketones, Isoxazoles, and
Pyrazoles.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a method of weedy plant control
comprising an
external application to a weedy plant of a composition comprising a
polynucleotide and a
transfer agent, wherein the polynucleotide is essentially identical or
essentially complementary to
an HPPD gene sequence or fragment thereof, or to the RNA transcript of said
HPPD gene
sequence or fragment thereof, wherein said HPPD gene sequence is selected from
the group
consisting of SEQ ID NO:1-32 or a polynucleotide fragment thereof, whereby the
weedy plant
growth or development or reproductive ability is reduced or the weedy plant is
made more
sensitive to an HPPD inhibitor herbicide relative to a weedy plant not treated
with said
composition. In this manner, plants that have become resistant to the
application of glyphosate
contanining herbicides may be made more susceptible to the herbicidal effects
of a glyphosate
containing herbicide, thus potentiating the effect of the herbicide. The
polynucleotide fragment
is at least 18 contiguous nucleotides, at least 19 contiguous nucleotides, at
least 20 contiguous
nucleotides or at least 21 contiguous nucleotides in length and at least 85
percent identical to an
HPPD gene sequence selected from the group consisting of SEQ ID NO:1-32 and
the transfer
agent is an organosilicone composition or compound. The polynucleotide
fragment can also be
sense or anti-sense ssDNA or ssRNA, dsRNA, or dsDNA, or dsDNA/RNA hybrids. The
composition can include more than one polynucleotide fragments, and the
composition can
include an HPPD inhibitor herbicide and/or other herbicides that enhance the
weed control
activity of the composition.
In another aspect of the invention, polynucleotide molecules and methods for
modulating
HPPD gene expression in weedy plant species are provided. The method reduces,
represses or
otherwise delays expression of an HPPD gene in a plant comprising an external
application to a
2
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
weedy plant of a composition comprising a polynucleotide and a transfer agent,
wherein the
polynucleotide is essentially identical or essentially complementary to an
HPPD gene sequence
or fragment thereof, or to the RNA transcript of the HPPD gene sequence or
fragment thereof,
wherein the HPPD gene sequence is selected from the group consisting of SEQ ID
NO:1-32 or a
polynucleotide fragment thereof. The polynucleotide fragment fragment is at
least 18 contiguous
nucleotides, at least 19 contiguous nucleotides, at least 20 contiguous
nucleotides at least 21
contiguous nucleotides in length and at least 85 percent identical to an HPPD
gene sequence
selected from the group consisting of SEQ ID NO:1-32 and the transfer agent is
an
organosilicone compound. The polynucleotide fragment can also be sense or anti-
sense ssDNA
or ssRNA, dsRNA, or dsDNA, or dsDNA/RNA hybrids.
In a further aspect of the invention, the polynucleotide molecule containing
composition
of the invention may be combined with other herbicidal (co-herbicides)
compounds to provide
additional control of unwanted plants in a field of cultivated plants.
In a further aspect, the polynucleotide molecule composition may be combined
with any
one or more additional agricultural chemicals, such as, insecticides,
fungicides, nematocides,
bactericides, acaricides, growth regulators, chemosterilants, semiochemicals,
repellents,
attractants, pheromones, feeding stimulants, biopesticides, microbial
pesticides or other
biologically active compounds to form a multi-component pesticide giving an
even broader
spectrum of agricultural protection.
BRIEF DESCRIPTION OF THE FIGURES
The following drawings form part of the present specification and are included
to further
demonstrate certain aspects of the present invention. The invention may be
better understood by
reference to one or more of these drawings in combination with the detailed
description of
specific embodiments presented herein. The invention can be more fully
understood from the
following description of the figures:
Figure 1. Treatment of Amaranthus palmeri plants with ssDNA trigger
polynucleotides and
HPPD inhibitor herbicide, Mesotrione.
DETAILED DESCRIPTION
3
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Provided are methods and compositions containing a polynucleotide that provide
for
regulation, repression or delay of HPPD (4-hydroxyphenyl-pyruvate-dioxygenase)
gene
expression and enhanced control of weedy plant species amd importantly HPPD
inhibitor
herbicide resistant weed biotypes. Aspects of the method can be applied to
manage various
weedy plants in agronomic and other cultivated environments.
The following definitions and methods are provided to better define the
present invention
and to guide those of ordinary skill in the art in the practice of the present
invention. Unless
otherwise noted, terms are to be understood according to conventional usage by
those of ordinary
skill in the relevant art. Where a term is provided in the singular, the
inventors also contemplate
aspects of the invention described by the plural of that term.
By "non-transcribable" polynucleotides is meant that the polynucleotides do
not comprise
a complete polymerase II transcription unit.
As used herein "solution" refers to homogeneous mixtures and non-homogeneous
mixtures such as suspensions, colloids, micelles, and emulsions.
Weedy plants are plants that compete with cultivated plants, those of
particular
importance include, but are not limited to important invasive and noxious
weeds and herbicide
resistant biotypes in crop production, such as, Amaranthus species -A. albus,
A. blitoides, A.
hybridus, A. palmeri, A. powellii, A. retroflexus, A. spinosus, A. tube
rculatus, and A. viridis;
Ambrosia species - A. trifida, A. artemisifolia; Lolium species -L.
multiflorum, L. rigidium, L
perenne; Digitaria species -D. insularis; Euphorbia species -E. heterophylla;
Kochia species -
K. scoparia; Sorghum species -S. halepense; Conyza species -C. bonariensis, C.
canadensis, C.
sumatrensis; Chloris species -C. truncate; Echinochola species - E. colona, E.
crus-galli;
Eleusine species -E. indica; Poa species -P. annua; Plantago species -P.
lanceolata; Avena
species - A. fatua; Chenopodium species - C. album; Setaria species ¨ S.
viridis, Abutilon
theophrasti, Ipomoea species, Sesbania, species, Cassia species, Sida species,
Brachiaria,
species and Solanum species.
Additional weedy plant species found in cultivated areas include Alopecurus
myosuroides, Avena sterilis, Avena sterilis ludoviciana, Brachiaria
plantaginea, Bromus
diandrus, Bromus rigidus, Cynosurus echinatus, Digitaria ciliaris, Digitaria
ischaemum,
Digitaria sanguinalis, Echinochloa oryzicola, Echinochloa phyllopogon,
Eriochloa punctata,
Hordeum glaucum, Hordeum leporinum, Ischaemum rugosum, Leptochloa chinensis,
Lolium
4
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
persicumõ Phalaris minor, Phalaris paradoxa, Rottboellia exalta, Setaria
faberi, Setaria viridis
var, robusta-alba schreiber, Setaria viridis var, robusta -purpurea, Snowdenia
polystachea,
Sorghum sudanese, Alisma plantago-aquatica, Amaranthus lividus, Amaranthus
quitensis,
Ammania auriculata, Ammania coccinea, Anthemis cotula, Apera spica-venti,
Bacopa
rotundifolia, Bidens pilosa, Bidens subaltemans, Brassica tournefortii, Bromus
tectorum,
Camelina microcarpa, Chrysanthemum coronarium, Cuscuta campestris, Cyperus
difformis,
Damasonium minus, Descurainia sophia, Diplotaxis tenuifolia, Echium
plantagineum, Elatine
triandra var, pedicellata, Euphorbia heterophylla, Fallopia convolvulus,
Fimbristylis miliacea,
Galeopsis tetrahit, Galium spurium, Helianthus annuus, Iva xanthifolia,
Ixophorus unisetus,
Ipomoea indica, Ipomoea purpurea, Ipomoea sepiaria, Ipomoea aquatic, Ipomoea
triloba,
Lactuca serriola, Limnocharis flava, Limnophila erecta, Limnophila
sessiliflora, Lindemia
dubia, Lindemia dubia var, major, Lindernia micrantha, Lindemia procumbens,
Mesembryanthemum crystallinum, Monochoria korsakowii, Monochoria vaginalis,
Neslia
paniculata, Papaver rhoeas, Parthenium hysterophorus, Pentzia suffruticosa,
Phalaris minor,
Raphanus raphanistrum, Raphanus sativus, Rapistrum rugosum, Rotala indica var,
uliginosa,
Sagittaria guyanensis, Sagittaria montevidensis, Sagittaria pygmaea, Salsola
iberica, Scirpus
juncoides var, ohwianus, Scirpus mucronatus, Setaria lutescens, Sida spinosa,
Sinapis arvensis,
Sisymbrium orientale, Sisymbrium thellungii, Solanum ptycanthum, Sonchus
asper, Sonchus
oleraceus, Sorghum bicolor, Stellaria media, Thlaspi arvense, Xanthium
strumarium, Arctotheca
calendula, Conyza sumatrensis, Crassocephalum crepidiodes, Cuphea
carthagenenis, Epilobium
adenocaulon, Erigeron philadelphicus, Landoltia punctata, Lepidium virginicum,
Monochoria
korsakowii, Solanum americanum, Solanum nigrum, Vulpia bromoides, Youngia
japonica,
Hydrilla verticillata, Carduus nutans, Carduus pycnocephalus, Centaurea
solstitialis, Cirsium
arvense, Commelina diffusa, Convolvulus arvensis, Daucus carota, Digitaria
ischaemum,
Echinochloa crus-pavonis, Fimbristylis miliacea, Galeopsis tetrahit, Galium
spurium,
Limnophila erecta, Matricaria perforate, Papaver rhoeas, Ranunculus acris,
Soliva sessilis,
Sphenoclea zeylanica, Stellaria media, Nassella trichotoma, Stipa neesiana,
Agrostis stolonifera,
Polygonum aviculare, Alopecurus japonicus, Beckmannia syzigachne, Bromus
tectorum, Chloris
inflate, Echinochloa erecta, Portulaca oleracea, and Senecio vulgaris. It is
believed that all
plants contain a phytoene desaturase gene in their genome, the sequence of
which can be isolated
and polynucleotides made according to the methods of the present invention
that are useful for
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
regulation, suppressing or delaying the expression of the target HPPD gene in
the plants and the
growth or development of the treated plants.
A cultivated plant may also be considered a weedy plant when they occur in
unwanted
environments. For example, corn plants growing in a soybean field. Transgenic
crops with one
or more herbicide tolerances will need specialized methods of management to
control weeds and
volunteer crop plants. The present invention enables the targeting of a
transgene for herbicide
tolerance to permit the treated plants to become sensitive to the herbicide.
For example,
transgene HPPD DNA sequences in transgenic events that include FG72.
A "trigger" or "trigger polynucleotide" is a polynucleotide molecule that is
homologous
or complementary to a target gene polynucleotide. The trigger polynucleotide
molecules
modulate expression of the target gene when topically applied to a plant
surface with a transfer
agent, whereby a plant treated with said composition has its growth or
development or
reproductive ability regulated, suppressed or delayed or said plant is more
sensitive to a EPSPS
inhibitor herbicide as a result of said polynucleotide containing composition
relative to a plant
not treated with a composition containing the trigger molecule. Trigger
polynucleotides disclosed
herein are generally described in relation to the target gene sequence and
maybe used in the
sense (homologous) or antisense (complementary) orientation as single stranded
molecules or
comprise both strands as double stranded molecules or nucleotide variants and
modified
nucleotides thereof depending on the various regions of a gene being targeted.
It is contemplated that the composition of the present invention will contain
multiple
polynucleotides and herbicides that include but not limited to HPPD gene
trigger polynucleotides
and an HPPD inhibitor herbicide and anyone or more additional herbicide target
gene trigger
polynucleotides and the related herbicides and anyone or more additional
essential gene trigger
polynucleotides. Essential genes are genes in a plant that provide key enzymes
or other proteins,
for example, a biosynthetic enzyme, metabolizing enzyme, receptor, signal
transduction protein,
structural gene product, transcription factor, or transport protein; or
regulating RNAs, such as,
microRNAs, that are essential to the growth or survival of the organism or
cell or involved in the
normal growth and development of the plant (Meinke, et al., Trends Plant Sci.
2008
Sep;13(9):483-91). The suppression of an essential gene enhances the effect of
a herbicide that
affects the function of a gene product different than the suppressed essential
gene. The
6
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
compositions of the present invention can include various trigger
polynucleotides that modulate
the expression of an essential gene other than HPPD.
Herbicides for which transgenes for plant tolerance have been demonstrated and
the
method can be applied, include but are not limited to: auxin-like herbicides,
glyphosate,
glufosinate, sulfonylureas, imidazolinones, bromoxynil, delapon, dicamba,
cyclohezanedione,
protoporphyrionogen oxidase inhibitors, 4-hydroxyphenyl-pyruvate-dioxygenase
inhibitors
herbicides. For example, transgenes and their polynucleotide molecules that
encode proteins
involved in herbicide tolerance are known in the art, and include, but are not
limited to an 5-
enolpyruvylshikimate-3-phosphate synthase (EPSPS), for example, as more fully
described in
U.S. Pat. Nos. 7,807,791 (SEQ ID NO:5); 6,248,876 Bl; 5,627,061; 5,804,425;
5,633,435;
5,145,783; 4,971,908; 5,312,910; 5,188,642; 4,940,835; 5,866,775; 6,225,114
Bl; 6,130,366;
5,310,667; 4,535,060; 4,769,061; 5,633,448; 5,510,471; U.S. Pat. No. Re.
36,449; U.S. Pat. Nos.
RE 37,287 E; and 5,491,288; tolerance to sulfonylurea and/or imidazolinone,
for example, as
described more fully in U.S. Pat. Nos. 5,605,011; 5,013,659; 5,141,870;
5,767,361; 5,731,180;
5,304,732; 4,761,373; 5,331,107; 5,928,937; and 5,378,824; and international
publication WO
96/33270; tolerance to hydroxyphenylpyruvatedioxygenases inhibitiong
herbicides in plants are
described in U.S. Pat. Nos. 6,245,968 Bl; 6,268,549; and 6,069,115; US
Pat.Pub. 20110191897
and US7,312,379 SEQ ID NO:3; U57,935,869; U57,304,209, SEQ ID NO:1, 3,5 and
15;
aryloxyalkanoate dioxygenase polynucleotides, which confer tolerance to 2,4-D
and other
phenoxy auxin herbicides as well as to aryloxyphenoxypropionate herbicides as
described, for
example, in W02005/107437; U57,838,733 SEQ ID NO:5;) and dicamba-tolerance
polynucleotides as described, for example, in Herman et al. (2005) J. Biol.
Chem. 280: 24759-
24767. Other examples of herbicide-tolerance traits include those conferred by
polynucleotides
encoding an exogenous phosphinothricin acetyltransferase, as described in U.S.
Pat. Nos.
5,969,213; 5,489,520; 5,550,318; 5,874,265; 5,919,675; 5,561,236; 5,648,477;
5,646,024;
6,177,616; and 5,879,903. Plants containing an exogenous phosphinothricin
acetyltransferase
can exhibit improved tolerance to glufosinate herbicides, which inhibit the
enzyme glutamine
synthase. Additionally, herbicide-tolerance polynucleotides include those
conferred by
polynucleotides conferring altered protoporphyrinogen oxidase (protox)
activity, as described in
U.S. Pat. Nos. 6,288,306 Bl; 6,282,837 Bl; and 5,767,373; and WO 01/12825.
Plants containing
such polynucleotides can exhibit improved tolerance to any of a variety of
herbicides which
7
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
target the protox enzyme (also referred to as protox inhibitors).
Polynucleotides encoding a
glyphosate oxidoreductase and a glyphosate-N-acetyl transferase (GOX described
in U.S. Patent
5,463,175 and GAT described in U.S. Patent publication 20030083480, dicamba
monooxygenase U.S. Patent publication 20030135879, all of which are
incorporated herein by
reference); a polynucleotide molecule encoding bromoxynil nitrilase (Bxn
described in U.S.
Patent No. 4,810,648 for Bromoxynil tolerance, which is incorporated herein by
reference); a
polynucleotide molecule encoding phytoene desaturase (crtl) described in
Misawa et al, (1993)
Plant J. 4:833-840 and Misawa et al, (1994) Plant J. 6:481-489 for norflurazon
tolerance; a
polynucleotide molecule encoding acetohydroxyacid synthase (AHAS, aka ALS)
described in
Sathasiivan et al. (1990) Nucl. Acids Res. 18:318-2193 for tolerance to
sulfonylurea herbicides;
and the bar gene described in DeBlock, et al. (1987) EMBO J. 6:2513-2519 for
glufosinate and
bialaphos tolerance. The transgenic coding regions and regulatory elements of
the herbicide
tolerance genes are targets in which polynucleotide triggers and herbicides
can be included in the
composition of the present invention.
The composition of the present invention include a component that is an HPPD
inhibitor
herbicide which includes but are not limited to Triketones, such as,
mesotrione, tefuryltrione,
tembotrione, and sulcotrione; Isoxazoles, such as, isoxachlortole,
pyrasulfotole, and isoxaflutole;
Pyrazoles, such as, benzofenap, pyrazolynate, topramezone and pyrazoxyfen.
Additional HPPD
inhibitors include benzobicyclon and bicyclopyrone,
Numerous herbicides with similar or different modes of action (herein referred
to as co-
herbicides) are available that can be added to the composition, for example,
members of the
herbicide families that include but are not limited to amide herbicides,
aromatic acid herbicides,
arsenical herbicides, benzothiazole herbicides, benzoylcyclohexanedione
herbicides,
benzofuranyl alkylsulfonate herbicides, carbamate herbicides, cyclohexene
oxime herbicides,
cyclopropylisoxazole herbicides, dicarboximide herbicides, dinitroaniline
herbicides,
dinitrophenol herbicides, diphenyl ether herbicides, dithiocarbamate
herbicides, halogenated
aliphatic herbicides, imidazolinone herbicides, inorganic herbicides, nitrile
herbicides,
organophosphorus herbicides, oxadiazolone herbicides, oxazole herbicides,
phenoxy herbicides,
phenylenediamine herbicides, pyrazole herbicides, pyridazine herbicides,
pyridazinone
herbicides, pyridine herbicides, pyrimidinediamine herbicides,
pyrimidinyloxybenzylamine
herbicides, quaternary ammonium herbicides, thiocarbamate herbicides,
thiocarbonate
8
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
herbicides, thiourea herbicides, triazine herbicides, triazinone herbicides,
triazole herbicides,
triazolone herbicides, triazolopyrimidine herbicides, uracil herbicides, and
urea herbicides. In
particular, the rates of use of the added herbicides can be reduced in
compositions comprising the
polynucleotides of the invention. Use rate reductions of the additional added
herbicides can be
10-25 percent, 26-50 percent, 51-75 percent or more can be achieved that
enhance the activity of
the polynucleotides and herbicide composition and is contemplated.
Representative herbicides of
the families include but are not limited to acetochlor, acifluorfen,
acifluorfen-sodium,
aclonifen, acrolein, alachlor, alloxydim, allyl alcohol, ametryn,
amicarbazone,
amidosulfuron, aminopyralid, amitrole, ammonium sulfamate, anilofos, asulam,
atraton,
atrazine, azimsulfuron, BCPC, beflubutamid, benazolin, benfluralin,
benfuresate,
bensulfuron, bensulfuron-methyl, bensulide, bentazone, benzfendizone,
benzobicyclon,
benzofenap, bifenox, bilanafos, bispyribac, bispyribac-sodium, borax,
bromacil,
bromobutide, bromoxynil, butachlor, butafenacil, butamifos, butralin,
butroxydim, butylate,
cacodylic acid, calcium chlorate, cafenstrole, carbetamide, carfentrazone,
carfentrazone-ethyl,
CDEA, CEPC, chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron,
chlorimuron-
ethyl, chloroacetic acid, chlorotoluron, chlorpropham, chlorsulfuron,
chlorthal, chlorthal-
dimethyl, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim,
clodinafop,
clodinafop-propargyl, clomazone, clomeprop, clopyralid, cloransulam,
cloransulam-methyl,
CMA, 4-CPB, CPMF, 4-CPP, CPPC, cresol, cumyluron, cyanamide, cyanazine,
cycloate,
cyclosulfamuron, cycloxydim, cyhalofop, cyhalofop-butyl, 2,4-D, 3,4-DA,
daimuron,
dalapon, dazomet, 2,4-DB, 3,4-DB, 2,4-DEB, desmedipham, dicamba, dichlobenil,
ortho-
dichlorobenzene, para-dichlorobenzene, dichlorprop, dichlorprop-P, diclofop,
diclofop-
methyl, diclosulam, difenzoquat, difenzoquat metilsulfate, diflufenican,
diflufenzopyr,
dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid,
dimethenamid-P,
dimethipin, dimethylarsinic acid, dinitramine, dinoterb, diphenamid, diquat,
diquat
dibromide, dithiopyr, diuron, DNOC, 3,4-DP, DSMA, EBEP, endothal, EPTC,
esprocarb,
ethalfluralin, ethametsulfuron, ethametsulfuron-methyl, ethofumesate,
ethoxyfen,
ethoxysulfuron, etobenzanid, fenoxaprop-P, fenoxaprop-P-ethyl, fentrazamide,
ferrous
sulfate, flamprop-M, flazasulfuron, florasulam, fluazifop, fluazifop-butyl,
fluazifop-P,
fluazifop-P-butyl, flucarbazone, flucarbazone-sodium, flucetosulfuron,
fluchloralin,
flufenacet, flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac, flumiclorac-
pentyl,
9
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
flumioxazin, fluometuron, fluoroglycofen, fluoroglycofen-ethyl, flupropanate,
flupyrsulfuron,
flupyrsulfuron-methyl-sodium, flurenol, fluridone, fluorochloridone,
fluoroxypyr, flurtamone,
fluthiacet, fluthiacet-methyl, fomesafen, foramsulfuron, fosamine,
glufosinate, glufosinate-
ammonium, glyphosate, halosulfuron, halosulfuron-methyl, haloxyfop, haloxyfop-
P, HC-
252, hexazinone, imazamethabenz, imazamethabenz-methyl, imazamox, imazapic,
imazapyr,
imazaquin, imazethapyr, imazosulfuron, indanofan, iodomethane, iodosulfuron,
iodosulfuron-methyl-sodium, ioxynil, isoproturon, isouron, isoxaben,
isoxachlortole,
isoxaflutole, karbutilate, lactofen, lenacil, linuron, MAA, MAMA, MCPA, MCPA-
thioethyl, MCPB, mecoprop, mecoprop-P, mefenacet, mefluidide, mesosulfuron,
mesosulfuron-methyl, mesotrione, metam, metamifop, metamitron, metazachlor,
methabenzthiazuron, methylarsonic acid, methyldymron, methyl isothiocyanate,
metobenzuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin,
metsulfuron,
metsulfuron-methyl, MK-66, molinate, monolinuron, MSMA, naproanilide,
napropamide,
naptalam, neburon, nicosulfuron, nonanoic acid, norflurazon, oleic acid (fatty
acids),
orbencarb, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxasulfuron,
oxaziclomefone,
oxyfluorfen, paraquat, paraquat dichloride, pebulate, pendimethalin,
penoxsulam,
pentachlorophenol, pentanochlor, pentoxazone, pethoxamid, petrolium oils,
phenmedipham,
phenmedipham-ethyl, picloram, picolinafen, pinoxaden, piperophos, potassium
arsenite,
potassium azide, pretilachlor, primisulfuron, primisulfuron-methyl,
prodiamine, profluazol,
profoxydim, prometon, prometryn, propachlor, propanil, propaquizafop,
propazine,
propham, propisochlor, propoxycarbazone, propoxycarbazone-sodium, propyzamide,
prosulfocarb, prosulfuron, pyraclonil, pyraflufen, pyraflufen-ethyl,
pyrazolynate,
pyrazosulfuron, pyrazosulfuron-ethyl, pyrazoxyfen, pyribenzoxim, pyributicarb,
pyridafol,
pyridate, pyriftalid, pyriminobac, pyriminobac-methyl, pyrimisulfan,
pyrithiobac,
pyrithiobac-sodium, quinclorac, quinmerac, quinoclamine, quizalofop,
quizalofop-P,
rimsulfuron, sethoxydim, siduron, simazine, simetryn, SMA, sodium arsenite,
sodium azide,
sodium chlorate, sulcotrione, sulfentrazone, sulfometuron, sulfometuron-
methyl, sulfosate,
sulfosulfuron, sulfuric acid, tar oils, 2,3,6-TBA, TCA, TCA-sodium,
tebuthiuron,
tepraloxydim, terbacil, terbumeton, terbuthylazine, terbutryn, thenylchlor,
thiazopyr,
thifensulfuron, thifensulfuron-methyl, thiobencarb, tiocarbazil, topramezone,
tralkoxydim,
tri-allate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, tricamba,
triclopyr,
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
trietazine, trifloxysulfuron, trifloxysulfuron-sodium, trifluralin,
triflusulfuron, triflusulfuron-
methyl, trihydroxytriazine, tritosulfuron, [3-[2-chloro-4-fluoro-5-(-methy1-6-
trifluoromethy1-
2,4-dioxo-,2,3,4-t- etrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetic acid
ethyl ester (CAS
RN 353292-3-6), 4-[(4,5-dihydro-3-methoxy-4-methy1-5-oxo)-H-,2,4-triazol--
ylcarbonyl-
sulfamoy1]-5-methylthiophene-3-carboxylic acid (BAY636), BAY747 (CAS RN 33504-
84-2),
topramezone (CAS RN 2063-68-8), 4-hydroxy-3-[[2-[(2-methoxyethoxy)methy1]-6-
(trifluoro-
methyl)-3-pyridi- nyl]carbonyll-bicyclo[3.2.]oct-3-en-2-one (CAS RN 35200-68-
5), and 4-
hydroxy-3-[[2-(3-methoxypropy1)-6-(difluoromethyl)-3-pyridinyl]carbon- y1]-
bicyclo[3.2.]oct-3-
en-2-one. Additionally, including herbicidal compounds of unspecified modes of
action as
described in CN101279950A, CN101279951A, DE10000600A1, DE10116399A1,
DE102004054666A1, DE102005014638A1, DE102005014906A1, DE102007012168A1,
DE102010042866A1, DE10204951A1, DE10234875A1, DE10234876A1, DE10256353A1,
DE10256354A1, DE10256367A1, EP1157991A2, EP1238586A1, EP2147919A1,
EP2160098A2, JP03968012B2, JP2001253874A, JP2002080454A, JP2002138075A,
JP2002145707A, JP2002220389A, JP2003064059A, JP2003096059A, JP2004051628A,
JP2004107228A, JP2005008583A, JP2005239675A, JP2005314407A, JP2006232824A,
JP2006282552A, JP2007153847A, JP2007161701A, JP2007182404A, JP2008074840A,
JP2008074841A, JP2008133207A, JP2008133218A, JP2008169121A, JP2009067739A,
JP2009114128A, JP2009126792A, JP2009137851A, US20060111241A1, US20090036311A1,
US20090054240A1, US20090215628A1, US20100099561A1, US20100152443A1,
US20110105329A1, US20110201501A1, W02001055066A2, W02001056975A1,
W02001056979A1, W02001090071A2, W02001090080A1, W02002002540A1 ,
W02002028182A1, W02002040473A1, W02002044173A2, W02003000679A2,
W02003006422A1 , W02003013247A1, W02003016308A1, W02003020704A1,
W02003022051A1, W02003022831A1, W02003022843A1, W02003029243A2,
W02003037085A1, W02003037878A1, W02003045878A2, W02003050087A2,
W02003051823A1, W02003051824A1, W02003051846A2, W02003076409A1,
W02003087067A1, W02003090539A1, W02003091217A1, W02003093269A2,
W02003104206A2, W02004002947A1, W02004002981A2, W02004011429A1,
W02004029060A1, W02004035545A2, W02004035563A1, W02004035564A1,
W02004037787A1, W02004067518A1, W02004067527A1, W02004077950A1,
11
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
W02005000824A1, W02005007627A1, W02005040152A1, W02005047233A1,
W02005047281A1, W02005061443A2, W02005061464A1, W02005068434A1,
W02005070889A1, W02005089551A1, W02005095335A1, W02006006569A1,
W02006024820A1, W02006029828A1, W02006029829A1, W02006037945A1,
W02006050803A1, W02006090792A1, W02006123088A2, W02006125687A1,
W02006125688A1, W02007003294A1, W02007026834A1, W02007071900A1,
W02007077201A1, W02007077247A1, W02007096576A1, W02007119434A1,
W02007134984A1, W02008009908A1, W02008029084A1, W02008059948A1,
W02008071918A1, W02008074991A1, W02008084073A1, W02008100426A2,
W02008102908A1, W02008152072A2, W02008152073A2, W02009000757A1,
W02009005297A2, W02009035150A2, W02009063180A1, W02009068170A2,
W02009068171A2, W02009086041A1, W02009090401A2, W02009090402A2,
W02009115788A1, W02009116558A1, W02009152995A1, W02009158258A1,
W02010012649A1, W02010012649A1, W02010026989A1, W02010034153A1,
W02010049270A1, W02010049369A1, W02010049405A1, W02010049414A1,
W02010063422A1, W02010069802A1, W02010078906A2, W02010078912A1,
W02010104217A1, W02010108611A1, W02010112826A3, W02010116122A3,
W02010119906A1, W02010130970A1, W02011003776A2, W02011035874A1,
W02011065451A1, all of which are incorporated herein by reference.
The trigger polynucleotide and oligonucleotide molecule compositions are
useful in
compositions, such as liquids that comprise the polynucleotide molecules at
low concentrations,
alone or in combination with other components, for example one or more
herbicide molecules,
either in the same solution or in separately applied liquids that also provide
a transfer agent.
While there is no upper limit on the concentrations and dosages of
polynucleotide molecules that
can useful in the methods, lower effective concentrations and dosages will
generally be sought
for efficiency. The concentrations can be adjusted in consideration of the
volume of spray or
treatment applied to plant leaves or other plant part surfaces, such as flower
petals, stems, tubers,
fruit, anthers, pollen, or seed. In one embodiment, a useful treatment for
herbaceous plants using
25-mer oligonucleotide molecules is about 1 nanomole (nmol) of oligonucleotide
molecules per
plant, for example, from about 0.05 to 1 nmol per plant. Other embodiments for
herbaceous
plants include useful ranges of about 0.05 to about 100 nmol, or about 0.1 to
about 20 nmol, or
12
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
about 1 nmol to about 10 nmol of polynucleotides per plant. Very large plants,
trees, or vines
may require correspondingly larger amounts of polynucleotides. When using long
dsRNA
molecules that can be processed into multiple oligonucleotides, lower
concentrations can be
used. To illustrate embodiments, the factor 1X, when applied to
oligonucleotide molecules is
arbitrarily used to denote a treatment of 0.8 nmol of polynucleotide molecule
per plant; 10X, 8
nmol of polynucleotide molecule per plant; and 100X, 80 nmol of polynucleotide
molecule per
plant.
The polynucleotide compositions are useful in compositions, such as liquids
that
comprise polynucleotide molecules, alone or in combination with other
components either in the
same liquid or in separately applied liquids that provide a transfer agent. As
used herein, a
transfer agent is an agent that, when combined with a polynucleotide in a
composition that is
topically applied to a target plant surface, enables the polynucleotide to
enter a plant cell. In
certain embodiments, a transfer agent is an agent that conditions the surface
of plant tissue, e. g.,
leaves, stems, roots, flowers, or fruits, to permeation by the polynucleotide
molecules into plant
cells. The transfer of polynucleotides into plant cells can be facilitated by
the prior or
contemporaneous application of a polynucleotide-transferring agent to the
plant tissue. In some
embodiments the transferring agent is applied subsequent to the application of
the polynucleotide
composition. The polynucleotide transfer agent enables a pathway for
polynucleotides through
cuticle wax barriers, stomata and/or cell wall or membrane barriers into plant
cells. Suitable
transfer agents to facilitate transfer of the polynucleotide into a plant cell
include agents that
increase permeability of the exterior of the plant or that increase
permeability of plant cells to
oligonucleotides or polynucleotides. Such agents to facilitate transfer of the
composition into a
plant cell include a chemical agent, or a physical agent, or combinations
thereof. Chemical
agents for conditioning or transfer include (a) surfactants, (b) an organic
solvent or an aqueous
solution or aqueous mixtures of organic solvents, (c) oxidizing agents, (d)
acids, (e) bases, (f)
oils, (g) enzymes, or combinations thereof. Embodiments of the method can
optionally include
an incubation step, a neutralization step (e.g., to neutralize an acid, base,
or oxidizing agent, or to
inactivate an enzyme), a rinsing step, or combinations thereof. Embodiments of
agents or
treatments for conditioning of a plant to permeation by polynucleotides
include emulsions,
reverse emulsions, liposomes, and other micellar-like compositions.
Embodiments of agents or
treatments for conditioning of a plant to permeation by polynucleotides
include counter-ions or
13
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
other molecules that are known to associate with nucleic acid molecules, e.
g., inorganic
ammonium ions, alkyl ammonium ions, lithium ions, polyamines such as spermine,
spermidine,
or putrescine, and other cations. Organic solvents useful in conditioning a
plant to permeation
by polynucleotides include DMSO, DMF, pyridine, N-pyrrolidine,
hexamethylphosphoramide,
acetonitrile, dioxane, polypropylene glycol, other solvents miscible with
water or that will
dissolve phosphonucleotides in non-aqueous systems (such as is used in
synthetic reactions).
Naturally derived or synthetic oils with or without surfactants or emulsifiers
can be used, e. g.,
plant-sourced oils, crop oils (such as those listed in the 9th Compendium of
Herbicide Adjuvants,
publicly available on the worldwide web (internet) at herbicide.adjuvants.com
can be used, e. g.,
paraffinic oils, polyol fatty acid esters, or oils with short-chain molecules
modified with amides
or polyamines such as polyethyleneimine or N-pyrrolidine. Transfer agents
include, but are not
limited to, organosilicone preparations.
An agronomic field in need of plant control is treated by application of the
composition
directly to the surface of the growing plants, such as by a spray. For
example, the method is
applied to control weeds in a field of crop plants by spraying the field with
the composition..
The composition can be provided as a tank mix, a sequential treatment of
components (generally
the polynucleotide containing composition followed by the herbicide), or a
simultaneous
treatment or mixing of one or more of the components of the composition from
separate
containers. Treatment of the field can occur as often as needed to provide
weed control and the
components of the composition can be adjusted to target specific weed species
or weed families
through utilization of specific polynucleotides or polynucleotide compositions
capable of
selectively targeting the specific species or plant family to be controlled.
The composition can
be applied at effective use rates according to the time of application to the
field, for example,
preplant, at planting, post planting, post harvest. HPPD inhibitor herbicides
can be applied to a
field at rates of 1 to 2000 g ai/ha (active ingredient per hectare or more.
The polynucleotides of
the composition can be applied at rates of 1 to 30 grams per acre depending on
the number of
trigger molecules needed for the scope of weeds in the field.
Crop plants in which weed control is needed include but are not limited to, i)
corn,
soybean, cotton, canola, sugar beet, alfalfa, sugarcane, rice, and wheat; ii)
vegetable plants
including, but not limited to, tomato, sweet pepper, hot pepper, melon,
watermelon, cucumber,
eggplant, cauliflower, broccoli, lettuce, spinach, onion, peas, carrots, sweet
corn, Chinese
14
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
cabbage, leek, fennel, pumpkin, squash or gourd, radish, Brussels sprouts,
tomatillo, garden
beans, dry beans, or okra; iii) culinary plants including, but not limited to,
basil, parsley, coffee,
or tea; or, iv) fruit plants including but not limited to apple, pear, cherry,
peach, plum, apricot,
banana, plantain, table grape, wine grape, citrus, avocado, mango, or berry;
v) a tree grown for
ornamental or commercial use, including, but not limited to, a fruit or nut
tree; or, vi) an
ornamental plant (e. g., an ornamental flowering plant or shrub or turf
grass). The methods and
compositions provided herein can also be applied to plants produced by a
cutting, cloning, or
grafting process (i. e., a plant not grown from a seed) include fruit trees
and plants that include,
but are not limited to, citrus, apples, avocados, tomatoes, eggplant,
cucumber, melons,
watermelons, and grapes as well as various ornamental plants.
Pesticidal Mixtures
The polynucleotide compositions may also be used as mixtures with various
agricultural
chemicals and/or insecticides, miticides and fungicides, pesticidal and
biopesticidal agents.
Examples include but are not limited to azinphos-methyl, acephate, isoxathion,
isofenphos,
ethion, etrimfos, oxydemeton-methyl, oxydeprofos, quinalphos, chlorpyrifos,
chlorpyrifos-
methyl, chlorfenvinphos, cyanophos, dioxabenzofos, dichlorvos, disulfoton,
dimethylvinphos,
dimethoate, sulprofos, diazinon, thiometon, tetrachlorvinphos, temephos,
tebupirimfos, terbufos,
naled, vamidothion, pyraclofos, pyridafenthion, pirimiphos-methyl,
fenitrothion, fenthion,
phenthoate, flupyrazophos, prothiofos, propaphos, profenofos, phoxime,
phosalone, phosmet,
formothion, phorate, malathion, mecarbam, mesulfenfos, methamidophos,
methidathion,
parathion, methyl parathion, monocrotophos, trichlorphon, EPN, isazophos,
isamidofos,
cadusafos, diamidaphos, dichlofenthion, thionazin, fenamiphos, fosthiazate,
fosthietan,
phosphocarb, DS P, ethoprophos, alanycarb, aldicarb, isoprocarb, ethiofencarb,
carbaryl,
carbosulfan, xylylcarb, thiodicarb, pirimicarb, fenobucarb, furathiocarb,
propoxur, bendiocarb,
benfuracarb, methomyl, metolcarb, XMC, carbofuran, aldoxycarb, oxamyl,
acrinathrin, allethrin,
esfenvalerate, empenthrin, cycloprothrin, cyhalothrin, gamma-cyhalothrin,
lambda-cyhalothrin,
cyfluthrin, beta-cyfluthrin, cypermethrin, alpha-cypermethrin, zeta-
cypermethrin, silafluofen,
tetramethrin, tefluthrin, deltamethrin, tralomethrin, bifenthrin, phenothrin,
fenvalerate,
fenpropathrin, furamethrin, prallethrin, flucythrinate, fluvalinate,
flubrocythrinate, permethrin,
resmethrin, ethofenprox, cartap, thiocyclam, bensultap, acetamiprid,
imidacloprid, clothianidin,
dinotefuran, thiacloprid, thiamethoxam, nitenpyram, chlorfluazuron,
diflubenzuron,
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
teflubenzuron, triflumuron, novaluron, noviflumuron, bistrifluoron, fluazuron,
flucycloxuron,
flufenoxuron, hexaflumuron, lufenuron, chromafenozide, tebufenozide,
halofenozide,
methoxyfenozide, diofenolan, cyromazine, pyriproxyfen, buprofezin, methoprene,
hydroprene,
kinoprene, triazamate, endosulfan, chlorfenson, chlorobenzilate, dicofol,
bromopropylate,
acetoprole, fipronil, ethiprole, pyrethrin, rotenone, nicotine sulphate, BT
(Bacillus Thuringiensis)
agent, spinosad, abamectin, acequinocyl, amidoflumet, amitraz, etoxazole,
chinomethionat,
clofentezine, fenbutatin oxide, dienochlor, cyhexatin, spirodiclofen,
spiromesifen, tetradifon,
tebufenpyrad, binapacryl, bifenazate, pyridaben, pyrimidifen, fenazaquin,
fenothiocarb,
fenpyroximate, fluacrypyrim, fluazinam, flufenzin, hexythiazox, propargite,
benzomate,
polynactin complex, milbemectin, lufenuron, mecarbam, methiocarb, mevinphos,
halfenprox,
azadirachtin, diafenthiuron, indoxacarb, emamectin benzoate, potassium oleate,
sodium oleate,
chlorfenapyr, tolfenpyrad, pymetrozine, fenoxycarb, hydramethylnon, hydroxy
propyl starch,
pyridalyl, flufenerim, flubendiamide, flonicamid, metaflumizole, lepimectin,
TPIC, albendazole,
oxibendazole, oxfendazole, trichlamide, fensulfothion, fenbendazole,
levamisole hydrochloride,
morantel tartrate, dazomet, metam-sodium, triadimefon, hexaconazole,
propiconazole,
ipconazole, prochloraz, triflumizole, tebuconazole, epoxiconazole,
difenoconazole, flusilazole,
triadimenol, cyproconazole, metconazole, fluquinconazole, bitertanol,
tetraconazole,
triticonazole, flutriafol, penconazole, diniconazole, fenbuconazole,
bromuconazole,
imibenconazole, simeconazole, myclobutanil, hymexazole, imazalil, furametpyr,
thifluzamide,
etridiazole, oxpoconazole, oxpoconazole fumarate, pefurazoate,
prothioconazole, pyrifenox,
fenarimol, nuarimol, bupirimate, mepanipyrim, cyprodinil, pyrimethanil,
metalaxyl, mefenoxam,
oxadixyl, benalaxyl, thiophanate, thiophanate-methyl, benomyl, carbendazim,
fuberidazole,
thiabendazole, manzeb, propineb, zineb, metiram, maneb, ziram, thiuram,
chlorothalonil,
ethaboxam, oxycarboxin, carboxin, flutolanil, silthiofam, mepronil,
dimethomorph, fenpropidin,
fenpropimorph, spiroxamine, tridemorph, dodemorph, flumorph, azoxystrobin,
kresoxim-methyl,
metominostrobin, orysastrobin, fluoxastrobin, trifloxystrobin, dimoxystrobin,
pyraclostrobin,
picoxystrobin, iprodione, procymidone, vinclozolin, chlozolinate,
flusulfamide, dazomet, methyl
isothiocyanate, chloropicrin, methasulfocarb, hydroxyisoxazole, potassium
hydroxyisoxazole,
echlomezol, D-D, carbam, basic copper chloride, basic copper sulfate, copper
nonylphenolsulfonate, oxine copper, DBEDC, anhydrous copper sulfate, copper
sulfate
pentahydrate, cupric hydroxide, inorganic sulfur, wettable sulfur, lime
sulfur, zinc sulfate, fentin,
16
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hypochlorite,
silver,
edifenphos, tolclofos-methyl, fosetyl, iprobenfos, dinocap, pyrazophos,
carpropamid, fthalide,
tricyclazole, pyroquilon, diclocymet, fenoxanil, kasugamycin, validamycin,
polyoxins,
blasticiden S, oxytetracycline, mildiomycin, streptomycin, rape seed oil,
machine oil,
benthiavalicarbisopropyl, iprovalicarb, propamocarb, diethofencarb,
fluoroimide, fludioxanil,
fenpiclonil, quinoxyfen, oxolinic acid, chlorothalonil, captan, folpet,
probenazole, acibenzolar-S-
methyl, tiadinil, cyflufenamid, fenhexamid, diflumetorim, metrafenone,
picobenzamide,
proquinazid, famoxadone, cyazofamid, fenamidone, zoxamide, boscalid,
cymoxanil, dithianon,
fluazinam, dichlofluanide, triforine, isoprothiolane, ferimzone, diclomezine,
tecloftalam,
pencycuron, chinomethionat, iminoctadine acetate, iminoctadine albesilate,
ambam,
polycarbamate, thiadiazine, chloroneb, nickel dimethyldithiocarbamate,
guazatine,
dodecylguanidine-acetate, quintozene, tolylfluanid, anilazine,
nitrothalisopropyl, fenitropan,
dimethirimol, benthiazole, harpin protein, flumetover, mandipropamide and
penthiopyrad.
Polynucleotides
As used herein, the term "DNA", "DNA molecule", "DNA polynucleotide molecule"
refers to a single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA)
molecule of
genomic or synthetic origin, such as, a polymer of deoxyribonucleotide bases
or a DNA
polynucleotide molecule. As used herein, the term "DNA sequence", "DNA
nucleotide
sequence" or "DNA polynucleotide sequence" refers to the nucleotide sequence
of a DNA
molecule. As used herein, the term "RNA", "RNA molecule", "RNA polynucleotide
molecule"
refers to a single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA)
molecule of
genomic or synthetic origin, such as, a polymer of ribonucleotide bases that
comprise single or
double stranded regions. Unless otherwise stated, nucleotide sequences in the
text of this
specification are given, when read from left to right, in the 5' to 3'
direction. The nomenclature
used herein is that required by Title 37 of the United States Code of Federal
Regulations 1.822
and set forth in the tables in WIPO Standard ST.25 (1998), Appendix 2, Tables
1 and 3.
As used herein, "polynucleotide" refers to a DNA or RNA molecule containing
multiple
nucleotides and generally refers both to "oligonucleotides" (a polynucleotide
molecule of
typically 50 or fewer nucleotides in length) and polynucleotides of 51 or more
nucleotides.
Embodiments of this invention include compositions including oligonucleotides
having a length
17
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
of 18-25 nucleotides (18-mers, 19-mers, 20-mers, 21-mers, 22-mers, 23-mers, 24-
mers, or 25-
mers) for example, oligonucleotides SEQ ID NO:597-1082 or fragments thereof,
or medium-
length polynucleotides having a length of 26 or more nucleotides
(polynucleotides of 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,
48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, about 65, about 70, about 75, about 80, about 85,
about 90, about 95,
about 100, about 110, about 120, about 130, about 140, about 150, about 160,
about 170, about
180, about 190, about 200, about 210, about 220, about 230, about 240, about
250, about 260,
about 270, about 280, about 290, or about 300 nucleotides), for example,
oligonucleotides SEQ
ID NO:33-596 or fragments thereof or long polynucleotides having a length
greater than about
300 nucleotides (for example, polynucleotides of between about 300 to about
400 nucleotides,
between about 400 to about 500 nucleotides, between about 500 to about 600
nucleotides,
between about 600 to about 700 nucleotides, between about 700 to about 800
nucleotides,
between about 800 to about 900 nucleotides, between about 900 to about 1000
nucleotides,
between about 300 to about 500 nucleotides, between about 300 to about 600
nucleotides,
between about 300 to about 700 nucleotides, between about 300 to about 800
nucleotides,
between about 300 to about 900 nucleotides, or about 1000 nucleotides in
length, or even greater
than about 1000 nucleotides in length, for example up to the entire length of
a target gene
including coding or non-coding or both coding and non-coding portions of the
target gene), for
example, polynucleotides of Table 1 (SEQ ID NO:1-32), wherein the selected
polynucleotides or
fragments thereof are homologous or complementary to SEQ ID NO:1-32 and
suppresses,
represses or otherwise delay the expression of the target EPSPS gene. A target
gene comprises
any polynucleotide molecule in a plant cell or fragment thereof for which the
modulation of the
expression of the target gene is provided by the methods and compositions of
the present
invention. Where a polynucleotide is double-stranded, its length can be
similarly described in
terms of base pairs. Oligonucleotides and polynucleotides of the present
invention can be made
that are essentially identical or essentially complementary to adjacent
genetic elements of a gene,
for example, spanning the junction region of an intron and exon, the junction
region of a
promoter and a transcribed region, the junction region of a 5' leader and a
coding sequence, the
junction of a 3' untranslated region and a coding sequence.
Polynucleotide compositions used in the various embodiments of this invention
include
compositions including oligonucleotides or polynucleotides or a mixture of
both, including RNA
18
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
or DNA or RNA/DNA hybrids or chemically modified oligonucleotides or
polynucleotides or a
mixture thereof. In some embodiments, the polynucleotide may be a combination
of
ribonucleotides and deoxyribonucleotides, for example, synthetic
polynucleotides consisting
mainly of ribonucleotides but with one or more terminal deoxyribonucleotides
or synthetic
polynucleotides consisting mainly of deoxyribonucleotides but with one or more
terminal
dideoxyribonucleotides. In some embodiments, the polynucleotide includes non-
canonical
nucleotides such as inosine, thiouridine, or pseudouridine. In some
embodiments, the
polynucleotide includes chemically modified nucleotides. Examples of
chemically modified
oligonucleotides or polynucleotides are well known in the art; see, for
example, US Patent
Publication 20110171287, US Patent Publication 20110171176, and US Patent
Publication
20110152353, US Patent Publication, 20110152346, US Patent Publication
20110160082, herein
incorporated by reference. For example, including but not limited to the
naturally occurring
phosphodiester backbone of an oligonucleotide or polynucleotide can be
partially or completely
modified with phosphorothioate, phosphorodithioate, or methylphosphonate
internucleotide
linkage modifications, modified nucleoside bases or modified sugars can be
used in
oligonucleotide or polynucleotide synthesis, and oligonucleotides or
polynucleotides can be
labeled with a fluorescent moiety (for example, fluorescein or rhodamine) or
other label (for
example, biotin).
The polynucleotides can be single- or double-stranded RNA or single- or double-
stranded
DNA or double-stranded DNA/RNA hybrids or modified analogues thereof, and can
be of
oligonucleotide lengths or longer. In more specific embodiments of the
invention the
polynucleotides that provide single-stranded RNA in the plant cell are
selected from the group
consisting of (a) a single-stranded RNA molecule (ssRNA), (b) a single-
stranded RNA molecule
that self-hybridizes to form a double-stranded RNA molecule, (c) a double-
stranded RNA
molecule (dsRNA), (d) a single-stranded DNA molecule (ssDNA), (e) a single-
stranded DNA
molecule that self-hybridizes to form a double-stranded DNA molecule, and (f)
a single-stranded
DNA molecule including a modified Pol III gene that is transcribed to an RNA
molecule, (g) a
double-stranded DNA molecule (dsDNA), (h) a double-stranded DNA molecule
including a
modified Pol III gene that is transcribed to an RNA molecule, (i) a double-
stranded, hybridized
RNA/DNA molecule, or combinations thereof. In some embodiments these
polynucleotides
include chemically modified nucleotides or non-canonical nucleotides. In
embodiments of the
19
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
method the polynucleotides include double-stranded DNA formed by
intramolecular
hybridization, double-stranded DNA formed by intermolecular hybridization,
double-stranded
RNA formed by intramolecular hybridization, or double-stranded RNA formed by
intermolecular hybridization. In some embodiments, the oligonucleotides may be
blunt-ended or
may comprise a 3' overhang of from 1-5 nucleotides of at least one or both of
the strands. Other
configurations of the oligonucleotide are known in the field and are
contemplated herein. In one
embodiment the polynucleotides include single-stranded DNA or single-stranded
RNA that self-
hybridizes to form a hairpin structure having an at least partially double-
stranded structure
including at least one segment that will hybridize to RNA transcribed from the
gene targeted for
suppression. Not intending to be bound by any mechanism, it is believed that
such
polynucleotides are or will produce single-stranded RNA with at least one
segment that will
hybridize to RNA transcribed from the gene targeted for suppression. In
certain other
embodiments the polynucleotides further includes a promoter, generally a
promoter functional in
a plant, for example, a pol II promoter, a pol III promoter, a pol IV
promoter, or a pol V
promoter.
The term "gene" refers to chromosomal DNA, plasmid DNA, cDNA, intron and exon
DNA, artificial DNA polynucleotide, or other DNA that encodes a peptide,
polypeptide, protein,
or RNA transcript molecule, and the genetic elements flanking the coding
sequence that are
involved in the regulation of expression, such as, promoter regions, 5' leader
regions, 3'
untranslated regions. Any of the components of the gene are potential targets
for the
oligonucleotides and polynucleotides of the present invention.
The trigger polynucleotide molecules are designed to modulate expression by
inducing
regulation or suppression of an endogenous HPPD gene in a plant and are
designed to have a
nucleotide sequence essentially identical or essentially complementary to the
nucleotide
sequence of an endogenous HPPD gene of a plant or to the sequence of RNA
transcribed from an
endogenous HPPD gene of a plant, including a transgene in a plant that
provides for a herbicide
resistant HPPD enzyme, which can be coding sequence or non-coding sequence.
Effective
molecules that modulate expression are referred to as "a trigger molecule, or
trigger
polynucleotide". By "essentially identical" or "essentially complementary" is
meant that the
trigger polynucleotides (or at least one strand of a double-stranded
polynucleotide or portion
thereof, or a portion of a single strand polynucleotide) are designed to
hybridize to the
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
endogenous gene noncoding sequence or to RNA transcribed (known as messenger
RNA or an
RNA transcript) from the endogenous gene to effect regulation or suppression
of expression of
the endogenous gene. Trigger molecules are identified by "tiling" the gene
targets with partially
overlapping probes or non-overlapping probes of antisense or sense
polynucleotides that are
essentially identical or essentially complementary to the nucleotide sequence
of an endogenous
gene. Multiple target sequences can be aligned and sequence regions with
homology in
common, according to the methods of the present invention, are identified as
potential trigger
molecules for the multiple targets. Multiple trigger molecules of various
lengths, for example
18-25 nucleotides, 26-50 nucleotides, 51-100 nucleotides, 101-200 nucleotides,
201-300
nucleotides or more can be pooled into a few treatments in order to
investigate polynucleotide
molecules that cover a portion of a gene sequence (for example, a portion of a
coding versus a
portion of a noncoding region, or a 5' versus a 3' portion of a gene) or an
entire gene sequence
including coding and noncoding regions of a target gene. Polynucleotide
molecules of the
pooled trigger molecules can be divided into smaller pools or single molecules
inorder to identify
trigger molecules that provide the desired effect.
The target gene RNA and DNA polynucleotide molecules are (Table 1, SEQ ID NO:
1-
32) sequenced by any number of available methods and equipment. Some of the
sequencing
technologies are available commercially, such as the sequencing-by-
hybridization platform from
Affymetrix Inc. (Sunnyvale, Calif.) and the sequencing-by-synthesis platforms
from 454 Life
Sciences (Bradford, Conn.), Illumina/Solexa (Hayward, Calif.) and Helicos
Biosciences
(Cambridge, Mass.), and the sequencing-by-ligation platform from Applied
Biosystems (Foster
City, Calif.), as described below. In addition to the single molecule
sequencing performed using
sequencing-by-synthesis of Helicos Biosciences, other single molecule
sequencing technologies
are encompassed by the method of the invention and include the SMRT.TM.
technology of
Pacific Biosciences, the Ion Torrent.TM. technology, and nanopore sequencing
being developed
for example, by Oxford Nanopore Technologies. A HPPD target gene comprising
DNA or RNA
can be isolated using primers or probes essentially complementary or
essentially homologous to
SEQ ID NO:1-32 or a fragment thereof. A polymerase chain reaction (PCR) gene
fragment can
be produced using primers essentially complementary or essentially homologous
to SEQ ID
NO:1-32 or a fragment thereof that is useful to isolate an HPPD gene from a
plant genome. SEQ
ID NO: 1-32 or fragments thereof can be used in various sequence capture
technologies to isolate
21
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
additional target gene sequences, for example, including but not limited to
Roche NimbleGen
(Madison, WI) and Streptavdin-coupled Dynabeads (Life Technologies, Grand
Island, NY) and
US20110015084, herein incorporated by reference in its entirety.
Embodiments of single-stranded polynucleotides functional in this invention
have
sequence complementarity that need not be 100 percent, but is at least
sufficient to permit
hybridization to RNA transcribed from the target gene or DNA of the target
gene to form a
duplex to permit a gene silencing mechanism. Thus, in embodiments, a
polynucleotide fragment
is designed to be essentially identical to, or essentially complementary to, a
sequence of 18 or
more contiguous nucleotides in either the target HPPD gene sequence or
messenger RNA
transcribed from the target gene. By "essentially identical" is meant having
100 percent
sequence identity or at least about 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,
93, 94, 95, 96, 97, 98, or
99 percent sequence identity when compared to the sequence of 18 or more
contiguous
nucleotides in either the target gene or RNA transcribed from the target gene;
by "essentially
complementary" is meant having 100 percent sequence complementarity or at
least about 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence
complementarity
when compared to the sequence of 18 or more contiguous nucleotides in either
the target gene or
RNA transcribed from the target gene. In some embodiments of this invention
polynucleotide
molecules are designed to have 100 percent sequence identity with or
complementarity to one
allele or one family member of a given target gene (coding or non-coding
sequence of a gene for
of the present invention); in other embodiments the polynucleotide molecules
are designed to
have 100 percent sequence identity with or complementarity to multiple alleles
or family
members of a given target gene.
In certain embodiments, the polynucleotides used in the compositions that are
essentially
identical or essentially complementary to the target gene or transcript will
comprise the
predominant nucleic acid in the composition. Thus in certain embodiments, the
polynucleotides
that are essentially identical or essentially complementary to the target gene
or transcript will
comprise at least about 50%, 75%, 95%, 98% or 100% of the nucleic acids
provided in the
composition by either mass or molar concentration. However, in certain
embodiments, the
polynucleotides that are essentially identical or essentially complementary to
the target gene or
transcript can comprise at least about 1% to about 50%, about 10% to about
50%, about 20% to
about 50%, or about 30% to about 50% of the nucleic acids provided in the
composition by
22
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
either mass or molar concentration. Also provided are compositions where the
polynucleotides
that are essentially identical or essentially complementary to the target gene
or transcript can
comprise at least about 1% to 100%, about 10% to 100%, about 20% to about
100%, about 30%
to about 50%, or about 50% to a 100% of the nucleic acids provided in the
composition by either
mass or molar concentration.
"Identity" refers to the degree of similarity between two polynucleic acid or
protein
sequences. An alignment of the two sequences is performed by a suitable
computer program. A
widely used and accepted computer program for performing sequence alignments
is
CLUSTALW v1.6 (Thompson, et al. Nucl. Acids Res., 22: 4673-4680, 1994). The
number of
matching bases or amino acids is divided by the total number of bases or amino
acids, and
multiplied by 100 to obtain a percent identity. For example, if two 580 base
pair sequences had
145 matched bases, they would be 25 percent identical. If the two compared
sequences are of
different lengths, the number of matches is divided by the shorter of the two
lengths. For
example, if there are 100 matched amino acids between a 200 and a 400 amino
acid protein, they
are 50 percent identical with respect to the shorter sequence. If the shorter
sequence is less than
150 bases or 50 amino acids in length, the number of matches are divided by
150 (for nucleic
acid bases) or 50 (for amino acids), and multiplied by 100 to obtain a percent
identity.
Trigger molecules for specific gene family members can be identified from
coding and/or
non-coding sequences of gene families of a plant or multiple plants, by
aligning and selecting
200-300 polynucleotide fragments from the least homologous regions amongst the
aligned
sequences and evaluated using topically applied polynucleotides (as sense or
anti-sense ssDNA
or ssRNA, dsRNA, or dsDNA) to determine their relative effectiveness in
inducing the
herbicidal phenotype. The effective segments are further subdivided into 50-60
polynucleotide
fragments, prioritized by least homology, and reevaluated using topically
applied
polynucleotides. The effective 50-60 polynucleotide fragments are subdivided
into 19-30
polynucleotide fragments, prioritized by least homology, and again evaluated
for induction of the
yield/quality phenotype. Once relative effectiveness is determined, the
fragments are utilized
singly, or again evaluated in combination with one or more other fragments to
determine the
trigger composition or mixture of trigger polynucleotides for providing the
yield/quality
phenotype.
23
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Trigger molecules for broad activity can be identified from coding and/or non-
coding
sequences of gene families of a plant or multiple plants, by aligning and
selecting 200-300
polynucleotide fragments from the most homologous regions amongst the aligned
sequences and
evaluated using topically applied polynucleotides (as sense or anti-sense
ssDNA or ssRNA,
dsRNA, or dsDNA) to determine their relative effectiveness in inducing the
yield/quality
phenotype. The effective segments are subdivided into 50-60 polynucleotide
fragments,
prioritized by most homology, and reevaluated using topically applied
polynucleotides. The
effective 50-60 polynucleotide fragments are subdivided into 19-30
polynucleotide fragments,
prioritized by most homology, and again evaluated for induction of the
yield/quality phenotype.
Once relative effectiveness is determined, the fragments may be utilized
singly, or in
combination with one or more other fragments to determine the trigger
composition or mixture
of trigger polynucleotides for providing the yield/quality phenotype.
Methods of making polynucleotides are well known in the art. Chemical
synthesis, in
vivo synthesis and in vitro synthesis methods and compositions are known in
the art and include
various viral elements, microbial cells, modified polymerases, and modified
nucleotides.
Commercial preparation of oligonucleotides often provides two
deoxyribonucleotides on the 3'
end of the sense strand. Long polynucleotide molecules can be synthesized from
commercially
available kits, for example, kits from Applied Biosystems/Ambion (Austin, TX)
have DNA
ligated on the 5' end in a microbial expression cassette that includes a
bacterial T7 polymerase
promoter that makes RNA strands that can be assembled into a dsRNA and kits
provided by
various manufacturers that include T7 RiboMax Express (Promega, Madison, WI),
AmpliScribe
T7-Flash (Epicentre, Madison, WI), and TranscriptAid T7 High Yield (Fermentas,
Glen Burnie,
MD). dsRNA molecules can be produced from microbial expression cassettes in
bacterial cells
(Ongvarrasopone et al. ScienceAsia 33:35-39; Yin, Appl. Microbiol. Biotechnol
84:323-333,
2009; Liu et al., BMC Biotechnology 10:85, 2010) that have regulated or
deficient RNase III
enzyme activity or the use of various viral vectors to produce sufficient
quantities of dsRNA. In
the present invention, HPPD gene fragments are inserted into the microbial
expression cassettes
in a position in which the fragments are express to produce ssRNA or dsRNA
useful in the
methods described herein to regulate expression on a target HPPD gene. Long
polynucleotide
molecules can also be assembled from multiple RNA or DNA fragments. In some
embodiments
design parameters such as Reynolds score (Reynolds et al. Nature Biotechnology
22, 326 - 330
24
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
(2004),Tuschl rules (Pei and Tuschl, Nature Methods 3(9): 670-676, 2006), i-
score (Nucleic
Acids Res 35: e123, 2007), i-Score Designer tool and associated algorithms
(Nucleic Acids Res
32: 936-948, 2004. Biochem Biophys Res Commun 316: 1050-1058, 2004, Nucleic
Acids Res
32: 893-901, 2004, Cell Cycle 3: 790-5, 2004, Nat Biotechnol 23: 995-1001,
2005, Nucleic
Acids Res 35: e27, 2007, BMC Bioinformatics 7: 520, 2006, Nucleic Acids Res
35: e123, 2007,
Nat Biotechnol 22: 326-330, 2004) are known in the art and may be used in
selecting
polynucleotide sequences effective in gene silencing. In some embodiments the
sequence of a
polynucleotide is screened against the genomic DNA of the intended plant to
minimize
unintentional silencing of other genes.
Ligands can be tethered to a polynucleotide, for example a dsRNA, ssRNA, dsDNA
or
ssDNA. Ligands in general can include modifiers, e.g., for enhancing uptake;
diagnostic
compounds or reporter groups e.g., for monitoring distribution; cross-linking
agents; nuclease-
resistance conferring moieties; and natural or unusual nucleobases. General
examples include
lipophiles, lipids (e.g., cholesterol, a bile acid, or a fatty acid (e.g.,
lithocholic-oleyl, lauroyl,
docosnyl, stearoyl, palmitoyl, myristoyl oleoyl, linoleoyl), steroids (e.g.,
uvaol, hecigenin,
diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, Friedelin,
epifriedelanol derivatized
lithocholic acid), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal),
carbohydrates, proteins,
protein binding agents, integrin targeting molecules, polycationics, peptides,
polyamines, and
peptide mimics. The ligand may also be a recombinant or synthetic molecule,
such as a synthetic
polymer, e.g., polyethylene glycol (PEG), PEG-40K, PEG-20K and PEG-5K. Other
examples of
ligands include lipophilic molecules, e.g, cholesterol, cholic acid,
adamantane acetic acid, 1-
pyrene butyric acid, dihydrotestosterone, glycerol (e.g., esters and ethers
thereof, e.g., C10,
C11, C12, C13, C14, C15, C16, C17,
C18, C19, or
C20 alkyl; e.g., lauroyl, docosnyl, stearoyl, oleoyl, linoleoyl 1,3-bis-
0(hexadecyl)glycerol,
1,3-bis-0(octaadecyl)glycerol), geranyloxyhexyl group, hexadecylglycerol,
borneol, menthol,
1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, 03-
(oleoyl)lithocholic acid, 03-
(oleoyl)cholenic acid, dodecanoyl, lithocholyl, 5.beta.-cholanyl, N,N-
distearyl-lithocholamide,
1,2-di-O-stearoylglyceride, dimethoxytrityl, or phenoxazine) and PEG (e.g.,
PEG-5K, PEG-20K,
PEG-40K). Preferred lipophilic moieties include lipid, cholesterols, oleyl,
retinyl, or cholesteryl
residues.
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Conjugating a ligand to a dsRNA can enhance its cellular absorption,
lipophilic
compounds that have been conjugated to oligonucleotides include 1-pyrene
butyric acid, 1,3-bis-
0-(hexadecyl)glycerol, and menthol. One example of a ligand for receptor-
mediated endocytosis
is folic acid. Folic acid enters the cell by folate-receptor-radiated
endocytosis. dsRNA
compounds bearing folic acid would be efficiently transported into the cell
via the folate-
receptor-mediated endocytosis. Other ligands that have been conjugated to
oligonucleotides
include polyethylene glycols, carbohydrate clusters, cross-linking agents,
porphyrin conjugates,
delivery peptides and lipids such as cholesterol. In certain instances,
conjugation of a cationic
ligand to oligonucleotides results in improved resistance to nucleases.
Representative examples
of cationic ligands are propylammonium and dimethylpropylammonium.
Interestingly, antisense
oligonucleotides were reported to retain their high binding affinity to mRNA
when the cationic
ligand was dispersed, throughout the oligonucleotide. See M. Manoharan
Antisense & Nucleic
Acid Drug Development 2002, 12, 103 and references therein.
A biologic delivery can be accomplished by a variety of methods including,
without
limitation, (1) loading liposomes with a dsRNA acid molecule provided herein
and (2)
complexing a dsRNA molecule with lipids or liposomes to form nucleic acid-
lipid or nucleic
acid-liposome complexes. The liposome can be composed of cationic and neutral
lipids
commonly used to transfect cells in vitro. Cationic lipids can complex (e.g.,
charge-associate)
with negatively charged, nucleic acids to form liposomes. Examples of cationic
liposomes
include, without limitation, lipofectin, lipofectamine, lipofectace, and
DOTAP. Procedures for
forming liposomes are well known in the art. Liposome compositions can be
formed, for
example, from phosphatidylcholine, dimyristoyl phosphatidylcholine,
dipalmitoyl
phosphatidylcholine, dimyristoyl phosphatidyl glycerol, dioleoyl
phosphatidylethanolamine or
liposomes comprising dihydrosphingomyelin (DHSM) Numerous lipophilic agents
are
commercially available, including Lipofectin (Invitrogen/Life Technologies,
Carlsbad, Calif.)
and EffecteneTM (Qiagen, Valencia, Calif.), In addition, systemic delivery
methods can be
optimized using commercially available cationic lipids such as DDAB or DOTAP,
each of which
can be mixed with a neutral lipid such as DOPE or cholesterol. In some eases,
liposomes such as
those described by Templeton et al. (Nature Biotechnology, 15:647-652 (1997))
can be used. In
other embodiments, polycations such as polyethyleneimine can be used to
achieve delivery in
vivo and ex vivo (Boletta et al., J. Am Soc. Nephrol. 7:1728 (1996)).
Additional information
26
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
regarding the use of liposomes to deliver nucleic acids can be found in U.S.
Pat. No. 6,271,359,
PCT Publication WO 96/40964 and Morrissey, D. et al. 2005. Nat Biotechnol.
23(8):1002-7.
In certain embodiments, an organosilicone preparation that is commercially
available as
Silwet L-77 surfactant having CAS Number 27306-78-1 and EPA Number:
CAL.REG.NO.
5905-50073-AA, and currently available from Momentive Performance Materials,
Albany, New
York can be used to prepare a polynucleotide composition. In certain
embodiments where a
Silwet L-77 organosilicone preparation is used as a pre-spray treatment of
plant leaves or other
plant surfaces, freshly made concentrations in the range of about 0.015 to
about 2 percent by
weight (wt percent) (e. g., about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04,
0.045, 0.05, 0.055,
0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.2, 0.3, 0.4, 0.5,
0.6, 0.7, 0.8, 0.9, 1.0, 1.1,
1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.5 wt percent)
are efficacious in preparing a
leaf or other plant surface for transfer of polynucleotide molecules into
plant cells from a topical
application on the surface. In certain embodiments of the methods and
compositions provided
herein, a composition that comprises a polynucleotide molecule and an
organosilicone
preparation comprising Silwet L-77 in the range of about 0.015 to about 2
percent by weight (wt
percent) (e. g., about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045,
0.05, 0.055, 0.06, 0.065,
0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9, 1.0, 1.1, 1.2, 1.3,
1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.5 wt percent) is used or
provided.
In certain embodiments, any of the commercially available organosilicone
preparations
provided such as the following Breakthru S 321, Breakthru S 200 Cat# 67674-67-
3, Breakthru
OE 441 Cat#68937-55-3, Breakthru S 278 Cat #27306-78-1, Breakthru S 243,
Breakthru S 233
Cat#134180-76-0, available from manufacturer Evonik Goldschmidt (Germany),
Silwet HS
429, Silwet HS 312, Silwet HS 508, Silwet HS 604 (Momentive Performance
Materials,
Albany, New York) can be used as transfer agents in a polynucleotide
composition. In certain
embodiments where an organosilicone preparation is used as a pre-spray
treatment of plant
leaves or other surfaces, freshly made concentrations in the range of about
0.015 to about 2
percent by weight (wt percent) (e. g., about 0.01, 0.015, 0.02, 0.025, 0.03,
0.035, 0.04, 0.045,
0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8,
0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.5
wt percent) are efficacious
in preparing a leaf or other plant surface for transfer of polynucleotide
molecules into plant cells
from a topical application on the surface. In certain embodiments of the
methods and
27
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
compositions provided herein, a composition that comprises a polynucleotide
molecule and an
organosilicone preparation in the range of about 0.015 to about 2 percent by
weight (wt percent)
(e. g., about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055,
0.06, 0.065, 0.07,
0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,
1.0, 1.1, 1.2, 1.3, 1.4, 1.5,
1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.5 wt percent) is used or provided.
Organosilicone preparations used in the methods and compositions provided
herein can
comprise one or more effective organosilicone compounds. As used herein, the
phrase "effective
organosilicone compound" is used to describe any organosilicone compound that
is found in an
organosilicone preparation that enables a polynucleotide to enter a plant
cell. In certain
embodiments, an effective organosilicone compound can enable a polynucleotide
to enter a plant
cell in a manner permitting a polynucleotide mediated suppression of a target
gene expression in
the plant cell. In general, effective organosilicone compounds include, but
are not limited to,
compounds that can comprise: i) a trisiloxane head group that is covalently
linked to, ii) an alkyl
linker including, but not limited to, an n-propyl linker, that is covalently
linked to, iii) a poly
glycol chain, that is covalently linked to, iv) a terminal group. Trisiloxane
head groups of such
effective organosilicone compounds include, but are not limited to,
heptamethyltrisiloxane.
Alkyl linkers can include, but are not limited to, an n-propyl linker. Poly
glycol chains include,
but are not limited to, polyethylene glycol or polypropylene glycol. Poly
glycol chains can
comprise a mixture that provides an average chain length "n" of about "7.5".
In certain
embodiments, the average chain length "n" can vary from about 5 to about 14.
Terminal groups
can include, but are not limited to, alkyl groups such as a methyl group.
Effective organosilicone
compounds are believed to include, but are not limited to, trisiloxane
ethoxylate surfactants or
polyalkylene oxide modified heptamethyl trisiloxane.
Si
Si
,o
si
(Compound I: polyalkyleneoxide heptamethyltrisiloxane, average n=7.5)..
28
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
In certain embodiments, an organosilicone preparation that comprises an
organosilicone
compound comprising a trisiloxane head group is used in the methods and
compositions
provided herein. In certain embodiments, an organosilicone preparation that
comprises an
organosilicone compound comprising a heptamethyltrisiloxane head group is used
in the
methods and compositions provided herein. In certain embodiments, an
organosilicone
composition that comprises Compound I is used in the methods and compositions
provided
herein. In certain embodiments, an organosilicone composition that comprises
Compound I is
used in the methods and compositions provided herein. In certain embodiments
of the methods
and compositions provided herein, a composition that comprises a
polynucleotide molecule and
one or more effective organosilicone compound in the range of about 0.015 to
about 2 percent by
weight (wt percent) (e. g., about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04,
0.045, 0.05, 0.055,
0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.2, 0.3, 0.4, 0.5,
0.6, 0.7, 0.8, 0.9, 1.0, 1.1,
1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.5 wt percent) is
used or provided.
Compositions include but are not limited components that are one or more
polynucleotides essentially identical to, or essentially complementary to an
HPPD gene sequence
(promoter, intron, exon, 5' untranslated region, 3' untranslated region), a
transfer agent that
provides for the polynucleotide to enter a plant cell, a herbicide that
complements the action of
the polynucleotide, one or more additional herbicides that further enhance the
herbicide activity
of the composition or provide an additional mode of action different from the
complementing
herbicide, various salts and stabilizing agents that enhance the utility of
the composition as an
admixture of the components of the composition.
In certain aspects, methods include one or more applications of a
polynucleotide
composition and one or more applications of a permeability-enhancing agent for
conditioning of
a plant to permeation by polynucleotides. When the agent for conditioning to
permeation is an
organosilicone composition or compound contained therein, embodiments of the
polynucleotide
molecules are double-stranded RNA oligonucleotides, single-stranded RNA
oligonucleotides,
double-stranded RNA polynucleotides, single-stranded RNA polynucleotides,
double-stranded
DNA oligonucleotides, single-stranded DNA oligonucleotides, double-stranded
DNA
polynucleotides, single-stranded DNA polynucleotides, chemically modified RNA
or DNA
oligonucleotides or polynucleotides or mixtures thereof.
29
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Compositions and methods are useful for modulating the expression of an
endogenous
HPPD gene (for example, US Pat. No. 7,297,541, U.S. Patent Publ. 20110185444,
and
20110185445) or transgenic HPPD gene (for example,U.S. Patent No: 7,312,379,
U.S. Patent
Publ. 20110191897) or HPPD inhibitor inactivating genes (US Pat. No.
6,268,549; 6,768,044;
7,312,379; 7,304,209; WO 96/38567, WO 99/24585) in a plant cell. In various
embodiments, an
HPPD gene includes coding (protein-coding or translatable) sequence, non-
coding (non-
translatable) sequence, or both coding and non-coding sequence. Compositions
can include
polynucleotides and oligonucleotides designed to target multiple genes, or
multiple segments of
one or more genes. The target gene can include multiple consecutive segments
of a target gene,
multiple non-consecutive segments of a target gene, multiple alleles of a
target gene, or multiple
target genes from one or more species.
Provided is a method for modulating expression of an HPPD gene in a plant
including (a)
conditioning of a plant to permeation by polynucleotides and (b) treatment of
the plant with the
polynucleotide molecules, wherein the polynucleotide molecules include at
least one segment of
18 or more contiguous nucleotides cloned from or otherwise identified from the
target HPPD
gene in either anti-sense or sense orientation, whereby the polynucleotide
molecules permeate
the interior of the plant and induce modulation of the target gene. The
conditioning and
polynucleotide application can be performed separately or in a single step.
When the
conditioning and polynucleotide application are performed in separate steps,
the conditioning can
precede or can follow the polynucleotide application within minutes, hours, or
days. In some
embodiments more than one conditioning step or more than one polynucleotide
molecule
application can be performed on the same plant. In embodiments of the method,
the segment can
be cloned or identified from (a) coding (protein-encoding), (b) non-coding
(promoter and other
gene related molecules), or (c) both coding and non-coding parts of the target
gene. Non-coding
parts include DNA, such as promoter regions or the RNA transcribed by the DNA
that provide
RNA regulatory molecules, including but not limited to: introns, 5' or 3'
untranslated regions,
and microRNAs (miRNA), trans-acting siRNAs, natural anti-sense siRNAs, and
other small
RNAs with regulatory function or RNAs having structural or enzymatic function
including but
not limited to: ribozymes, ribosomal RNAs, t-RNAs, aptamers, and riboswitches.
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
All publications, patents and patent applications are herein incorporated by
reference to
the same extent as if each individual publication or patent application was
specifically and
individually indicated to be incorporated by reference.
The following examples are included to demonstrate examples of certain
preferred
embodiments of the invention. It should be appreciated by those of skill in
the art that the
techniques disclosed in the examples that follow represent approaches the
inventors have found
function well in the practice of the invention, and thus can be considered to
constitute examples
of preferred modes for its practice. However, those of skill in the art
should, in light of the
present disclosure, appreciate that many changes can be made in the specific
embodiments that
are disclosed and still obtain a like or similar result without departing from
the spirit and scope
of the invention.
EXAMPLES
Example 1. Polynucleotides related to the HPPD gene sequences.
The target HPPD gene polynucleotide molecules have been found that naturally
occur in
the genome of Amaranthus palmeri, Amaranthus rudis, Amaranthus_thunbergii,
Amaranthus
graecizans, Amaranthus hybridus, Amaranthus viridis, Ambrosia trifida,
Kochia_scoparia,
Abutilon theophrasti, Conyza candensis, Digitaria sanguinalis, Euphorbia
heterophylla, Lolium
multiflorum, and Xanthium strumarium and include molecules related to the
expression of a
polypeptide identified as an HPPD, that include regulatory molecules, cDNAs
comprising coding
and noncoding regions of an HPPD gene and fragments thereof as shown in Table
1.
Polynucleotide molecules were extracted from these plant species by methods
standard in
the field, for example, total RNA is extracted using Trizol Reagent
(Invitrogen Corp, Carlsbad,
CA Cat. No. 15596-018), following the manufacturer's protocol or modifications
thereof by
those skilled in the art of polynucleotide extraction that may enhance recover
or purity of the
extracted RNA. Briefly, start with 1 gram of ground plant tissue for
extraction. Prealiquot 10
milliliters (mL) Trizol reagent to 15 mL conical tubes. Add ground powder to
tubes and shake to
homogenize. Incubate the homogenized samples for 5 minutes (min) at room
temperature (RT)
and then add 3 mL of chloroform. Shakes tubes vigorously by hand for 15-30
seconds(sec) and
incubate at RT for 3 min. Centrifuge the tubes at 7,000 revolutions per minute
(rpm) for 10 min
31
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
at 4 degrees C. Transfer the aqueous phase to a new 1.5 mL tube and add 1
volume of cold
isopropanol. Incubate the samples for 20-30 mm at RT and centrifuge at 10,000
rpm for 10 min
at 4 degrees C. Wash pellet with Sigma-grade 80 percent ethanol. Remove the
supernatant and
briefly air-dry the pellet. Dissolve the RNA pellet in approximately 200
microliters of DEPC
treated water. Heat briefly at 65C to dissolve pellet and vortex or pipet to
resuspend RNA pellet.
Adjust RNA concentraiton to 1-2 microgram/microliter.
DNA was extracted using EZNA SP Plant DNA Mini kit (Omega Biotek, Norcross GA,
Cat#D5511) and Lysing Matrix E tubes (Q-Biogen, Cat#6914), following the
manufacturer's
protocol or modifications thereof by those skilled in the art of
polynucleotide extraction that may
enhance recover or purity of the extracted DNA. Briefly, aliquot ground tissue
to a Lysing
Matrix E tube on dry ice, add 8001,t1 Buffer SP1 to each sample, homogenize in
a bead beater for
35-45sec, incubate on ice for 45-60 sec, centrifuge at >14000 rpm for lmin at
RT, add 10
microliter RNase A to the lysate, incubate at 65 C for 10min, centrifuge for
lmin at RT, add
2801,t1 Buffer 5P2 and vortex to mix, incubate the samples on ice for 5min,
centrifuge at
>10,000g for 10min at RT, transfer the supernatant to a homogenizer column in
a 2m1 collection
tube, centrifuge at 10,000g for 2min at RT, transfer the cleared lysate into a
1.5m1 microfuge
tube, add 1.5 volumes Buffer 5P3 to the cleared lysate, vortex immediately to
obtain a
homogeneous mixture, transfer up to 6501,t1 supernatant to the Hi-Bind column,
centrifuge at
10,000g for lmin, repeat, apply 1001,t1 65 C Elution Buffer to the column,
centrifuge at 10,000g
for 5min at RT.
Next-generation DNA sequencers, such as the 454-FLX (Roche, Branford, CT), the
SOLiD (Applied Biosystems, ), and the Genome Analyzer (HiSeq2000, Illumina,
San Diego,
CA) are used to provide polynucleotide sequence from the DNA and RNA extracted
from the
plant tissues. Raw sequence data is assembled into contigs. The contig
sequence is used to
identify trigger molecules that can be applied to the plant to enable
regulation of the gene
expression. The target DNA sequence isolated from genomic (gDNA) and coding
DNA
(cDNA) from the various weedy plant species for the HPPD gene and the
assembled contigs as
set forth in SEQ ID NOs 1-32 and Table 1.
Example 2. Polynucleotides of the invention related to the trigger molecules
32
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
The gene sequences and fragments of Table 1 were divided into 200
polynucleotide (200-
mer) lengths with 25 polynucleotide overlapping regions SEQ ID NO:33-596.
These
polynucleotides are tested to select the most efficacious trigger regions
across the length of any
target sequence. The trigger polynucleotides are constructed as sense or anti-
sense ssDNA or
ssRNA, dsRNA, or dsDNA, or dsDNA/RNA hybrids and combined with an
organosilicone
based transfer agent to provide a polynucleotide preparation. The
polynucleotides are combined
into sets of two to three polynucleotides per set, using 4-8 nmol of each
polynucleotide. Each
polynucleotide set is prepared with the transfer agent and applied to a plant
or a field of plants in
combination with a glyphosate containing herbicide, or followed by a
glyphosate treatment one
to three days after the polynucleotide application, to determine the effect on
the plant's
susceptibility to glyphosate. The effect is measured as stunting the growth
and/or killing of the
plant and is measured 8-14 days after treatment with the polynucleotide set
and glyphosate. The
most efficacious sets are identified and the individual polynucleotides are
tested in the same
methods as the sets are and the most efficacious single 200-mer identified.
The 200-mer
sequence is divided into smaller sequences of 50-70-mer regions with 10-15
polynucleotide
overlapping regions and the polynucleotides tested individually. The most
efficacious 50-70-mer
is further divided into smaller sequences of 25-mer regions with a 12 to 13
polynucleotide
overlapping region and tested for efficacy in combination with HPPD inhibitor
treatment. By
this method it is possible to identify an oligonucleotide or several
oligonucleotides that are the
most efficacious trigger molecule to effect plant sensitivity to glyphosate or
modulation of HPPD
gene expression. The modulation of HPPD gene expression is determined by the
detection of
HPPD siRNA moleclules specific to HPPD gene or by an observation of a
reduction in the
amount of HPPD RNA transcript produced relative to an untreated plant or by
merely observing
the anticipated phenotype of the application of the trigger with the
glyphosate containing
herbicide. Detection of siRNA can be accomplished, for example, using kits
such as mirVana
(Ambion, Austin TX) and mirPremier (Sigma-Aldrich, St Louis, MO).
The target DNA sequence isolated from genomic (gDNA) and coding DNA (cDNA)
from the various weedy plant species for the HPPD gene and the assembled
contigs as set forth
in SEQ ID NOs 1-32 were divided into polynucleotide fragments as set forth in
SEQ ID NO:33-
596
33
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
The gene sequences and fragments of Table 1 are compared and 21-mers of
contiguous
polynucleotides are identified that have homology across the various HPPD gene
sequences.
The purpose is to identify trigger molecules that are useful as herbicidal
molecules or in
combination with an HPPD inhibitor herbicide across a broad range of weed
species. The
sequences (SEQ ID NO: 597-1082 represent the 21-mers that are present in the
HPPD gene of at
least six of the weed species of Table 1. It is contemplated that additional
21-mers can be
selected from the sequences of Table 1 that are specific for a single weed
species or a few weeds
species within a genus or trigger molecules that are at least 18 contiguous
nucleotides, at least 19
contiguous nucleotides, at least 20 contiguous nucleotides or at least 21
contiguous nucleotides
in length and at least 85 percent identical to an HPPD gene sequence selected
from the group
consisting of SEQ ID NO:1-32.
By this method it is possible to identify an oligonucleotide or several
oligonucleotides
that are the most efficacious trigger molecule to effect plant sensitivity to
glyphosate or
modulation of HPPD gene expression. The modulation of HPPD gene expression is
determined
by the detection of HPPD siRNA moleclules specific to HPPD gene or by an
observation of a
reduction in the amount of HPPD RNA transcript produced relative to an
untreated plant.
Detection of siRNA can be accomplished, for example, using kits such as
mirVana (Ambion,
Austin TX) and mirPremier (Sigma-Aldrich, St Louis, MO).
The target DNA sequence isolated from genomic (gDNA) and coding DNA (cDNA)
from the various weedy plant species for the HPPD gene and the assembled
contigs as set forth
in SEQ ID NOs 1-32 were divided into fragments as set forth in SEQ ID NO: 597-
1082.
Example 3. Methods used in the invention related to treating plants or plant
parts with a topical
mixture of the trigger molecules.
Glyphosate-sensitive Palmer amaranth (A. palmeri R-22) plants were grown in
the
greenhouse (30 / 20 C day/night T; 14 hour photoperiod) in 4 inch square pots
containing Sun
Gro Redi-Earth and 3.5 kg/cubic meter Osmocote 14-14-14 fertilizer. Palmer
amaranth
plants at 5 to 10 cm in height were pre-treated with a mixture of eight 8
short (21-22mer) single-
strand antisense oligo DNA polynucleotides (ssDNAas) targeting HPPD shown in
Table 2 as
HPPD_OLIG01-8 (SEQ ID NO: 1083-1090, respectively) at two concentrations, 16
nmol and
80 nmol, formulated in 10 millimolar sodium phosphate buffer (pH 6.8)
containing 2%
34
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ammonium sulfate and 0.5% Silwet L-77. Plants were treated manually by
pipetting 10 jut of
polynucleotide solution on four fully expanded mature leaves, for a total of
40 microliters of
solution per plant. Twenty-four and forty-eight hours later, the plants were
treated with
mesotrione (Callisto , 4 lb ai per gallon; HPPD inhibitor) at 13 g ai/ha, or
atrazine (Aatrex
Nine-O , 90% w/w ai; Photosystem II inhibitor) at 170 g ai/ha using a track-
sprayer equipped
with a 9501E nozzle and calibrated to deliver 93 liters of solution per
hectare. Crop oil
concentrate (COC) at 1% was added to the herbicide treatments. Four
replications of each
treatment was conducted. Plant height was determined just before ssDNA
treatment and at
intervals upto twelve days after herbicide treatments to determine effect of
the oligonucleotide
and herbicide treatments.
Table 2. ssDNA HPPD oligonucleotides
HPPD_OLIG01 TCCGTAGCTTACATACCGAAG CTTCGGTATGTAAGCTACGGA
HPPD_OLIG02 TCCAAGTGAATAGGAGAAACA TGTTTCTCCTATTCACTTGGA
HPPD_OLIG03 AGCAGCTTCtgCGTCTTCTAC GTAGAAGACGcaGAAGCTGCT
HPPD_OLIG04 ACAGCACGCACGCCAAGACCG CGGTCTTGGCGTGCGTGCTGT
HPPD_OLIG05 CGaTGTAAGGAATTTGGtAAA TTTaCCAAATTCCTTACAtCG
HPPD_OLIG06 CGAGGGGATTGCAGCAGAAGA TCTTCTGCTGCAATCCCCTCG
HPPD_OLIG07 GTAGGAGaATacGGTGAAGTA TACTTCACCgtATtCTCCTAC
HPPD_OLIG08 GACCCCAAGaAAATCGTCTGC GCAGACGATTTtCTTGGGGTC
HPPD-T67 ATTGAGGAGTACGAGAAGACT AGTCTTCTCGTACTCCTCAAT
HPPD-T68 CTTGAACGTAAACAGGTTCCA TGGAACCTGTTTACGTTCAAG
The results of the treatments demonstrated that plants treated only with 16
nmol and 80
nmol of the ssDNA oligonucleotides that targets HPPD showed growth stunting
relative to the
buffer control of 35 percent and 46 percent, respectively. Four days after
treatment the plants
treated with ssDNA followed by mesotrione or atrazine at 24 hours showed
greater growth
stunting than plants treated with the herbicide only. Thus, plants treated
with ssDNA at 16 nmol
and 80 nmol followed by mesotrione resulted in 77 and 75 percent growth
reduction,
respectively, relative to the buffer control. Plants treated with ssDNA at 16
nmol and 80 nmol
followed by atrazine, resulted in 85 and 83 percent growth reduction,
respectively, relative to the
buffer control.
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Twelve days after treatment the ssDNA at 16 nmol and 80 nmol provided 6
percent and
20 percent reduction in plant growth, the treatments that included mesotrione
showed 91 and 89
percent growth reduction, compared to 48 percent control by mesotrione alone
(Figure 1). Plants
treated with ssDNA at 16 nmol and 80 nmol followed by atrazine at 24 hours
showed 50 and 74
percent growth reduction, compared to 29 percent control by atrazine alone.
Thus, mesotrione
and atrazine efficacy in Palmer amaranth can increase significantly by
treating the plants with
ssDNA that targets HPPD.
In another similar test, two pools of 5 double stand DNA oligonucleotides were
tested,
pool 1 contained HPPD-T67 (SEQ ID NO: 1091), HPPD-T68 (SEQ ID NO: 1092) and
OLIG01-3 of
Table 2. Pool 2 contained OLIGO 4-8 of Table 2. Plants were treated with
lOnmoles of each
oligonucleotide and sprayed with Diruon (DCMU (3-(3,4-dichloropheny1)-1,1-
dimethylurea, Bayer) and
scored 14 days after treatment for effect on plant growth and development. The
results indicate that the
oligonucleotides increased the diuron sensitivity of the treated plants upto
22 percent.
Example 4. A method to control weeds in a field.
A method to control weeds in a field comprises the use of trigger
polynucleotides that can
modulate the expression of an HPPD gene in one or more target weed plant
species. An analysis
of HPPD gene sequences from thirteen plant species provided a collection of 21-
mer
polynucleotides (SEQ ID NO:597-1082) that can be used in compositions to
affect the growth or
develop or sensitivity to glyphosate herbicide to control multiple weed
species in a field. A
composition containing 1 or 2 or 3 or 4 or more of the polynucleotides (SEQ ID
NO:597-1082)
would enable broad activity of the composition against the multiple weed
species that occur in a
field environment.
The method includes creating a composition that comprises components that
include at
least one polynucleotide of (SEQ ID NO:597-1082) or any other effective gene
expression
modulating polynucleotide essentially identical or essentially complementary
to SEQ ID NO:1-
32 or fragment thereof, a transfer agent that mobilizes the polynucleotide
into a plant cell and a
HPPD inhibiting herbicide and optionally a polynucleotide that modulates the
expression of an
essential gene and optionally a herbicide that has a different mode of action
relative to an HPPD
inhibitor. The polynucleotide of the composition includes a dsRNA, ssDNA or
dsDNA or a
combination thereof. A composition containing a polynucleotide can have a use
rate of about 1
36
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
to 30 grams or more per acre depending on the size of the polynucleotide and
the number of
polynucleotides in the composition. The composition may include one or more
additional
herbicides as needed to provide effective multi-species weed control. A field
of crop plants in
need of weed plant control is treated by spray application of the composition.
The composition
can be provided as a tank mix, a sequential treatment of components (generally
the
polynucleotide followed by the herbicide), a simultaneous treatment or mixing
of one or more of
the components of the composition from separate containers. Treatment of the
field can occur as
often as needed to provide weed control and the components of the composition
can be adjusted
to target specific weed species or weed families.
Table 1. HPPD gene polynucleotide sequences
SEQ ID NO SPECIES TYPE LENGTH Polynucleotide Sequence
1 Abutilon cDNA 713 TCCATAATCCAACGCAGACATTTCAGAGATTCATCCCCGA
theophrasti Contig AGAAATCAAAAATCCCTCAACAAAATGATTCAGATATGC
TTAAACAAAATATGAATTGAGCACAATATCATATTTGAC
ATTTATGTTGAAGTAGCAAAGGTTCGTATAGTTTATGTAT
GTGCAATTAAAACTAACAGTAACGGAATTCATTCTGACA
CTCCCTATATGCTGCTAGCAACTACCTCGATCTCTCAAGC
CTCGACAACGGTGGTGGATTCTGTAGATTGTTTGGCTTC
AAGAGACTTCTCGTATTCTTCAATGGATTTGAAGAGCTC
GGAAAAGTTGCCTTTCCCGAAACCTCCGCATCCTCCTTTC
TGGTATTGCTTTCCTTCTTCATCCTTCACCATGCACCCTAA
TCTCTGTATTATTTCTATGAATATCGTAGGCCTATCTCCA
ATGGGCTTAGTGAAAATCTGAAGCAGAGTGCCTTGATCA
TCTCTGTCAACCAAAATCCCCAACTCTTCACACTCCTTAAT
CTGCTCATCGCTCAAAATGTCCCCTGCCCTTTGCTTCAAT
TTCTTATAGTAAGTGGGCGGCGGCGATGGCATGAACTC
GAAACCACCCACCAAACTTCTCTTCCTCATTTCTCTCAGC
GTTCTGAATATATCTTCACTCACCAGAGCCAAATGTTGAA
CCCCGGCACCTTCGTTGTGTTCTAAATACGTTTGGATTT
2 Amaranth us cDNA 1234
CTTCTTCCCCGTCTGAGTTTTTATTACTTCACTTTCTCTCTC
graecizans Contig ATCATCTAACATGGGAACTTTGAAACCCGAAACTCAACC
CGACTCCGAATTCAAACTCGTGGGTTACTCCAACTTCATT
CGGGTTAACCCCAAATCTGACCGTTTTACTGTTAAGCGTT
TCCATCATATAGAGTTCTGGTGTGGCGATGCAACCAATG
TTAGCAGACGCTTTTCTTGGGGTCTTGGAATGCCTACCG
TTGCTAAATCTGACCTTTCTACTGGAAACTCTGTTCACGC
TTCTTTTCTTCTTCGTTCCGGTGACCTTTCTTTCCTCTTTAC
TTCACCTTACTCTCCTACCATGTCCATCCCTTCTTCTGCTG
CAATCCCCTCGTTTGATTTCAATCATTTTACCAAATTTGTT
ACATCGCACGGTCTTGGCGTGCGTGCTGTTGCCGTCGAA
GTAGAAGACGCAGAAGCTGCTTTTAATATCAGCGTTTCG
CACGGGGCTATCCCCTGTGTTTCTCCTATTCACTTGGAAA
37
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ACGGTGTCGTTTTATCTGAGGTTCATTTATATGGGGATG
TTGTGCTTCGTTATGTAAGCTACGGAAATGAATGTGGGG
ATGTGTTTTTTCTTCCTGGGTTTGAGCAAATGCCCGAGG
AATCCTCGTTTCGAGGACTTGATTTCGGCCTTCGAAGGTT
GGATCATGCTGTAGGGAATGTCCCTGAGTTGGCTCCTGC
AATTGCTTATTTGAAGAAGTTTACTGGGTTTCATGAGTTT
GCTGAGTTTACAGCTGAAGATGTTGGAACGAGTGAAAG
TGGGTTGAATTCAGCCGTATTGGCAAATAATGATGAAAT
GGTGTTGTTTCCAATGAATGAACCTGTGTATGGGACAAA
AAGGAAGAGTCAAATTCAAACTTATTTGGAGCATAATGA
AGGAGCTGGTGTACAACATTTGGCTTTGATGAGTGAAG
ATATATTTTGGACTTTAAGGGAGATGAGGAAGAGAAGT
GGTCTTGGTGGGTTTGAGTTTATGCCGTCGCCGCCTCCG
ACTTATTACCGGAATTTGAGGAACAGAGCTGCTGATGTA
TTGAGTGAGGAGCAGATGAAGGAGTGTGAAGAGTTGG
GGATTTTGGTGGATAAAGATGATCAGGGTACTTTGCTTC
AAATCTTCACTAAGCCTATTGGTGACAGGCCAACCATATT
TATCGAGATTATACAAAGAATCGGTTGCATGATGAAAGA
TGAAGACGGCAAG
3 Amaranthus cDNA 547 TCTTCCTGGGTTTGAGGAAATGCCGGAGGAATCGTCGTT
hybridus Contig TCGAGGACTTGATTTCGGCCTTCGAAGGTTGGATCATGC
TGTAGGGAATGTTCCCGAGTTGGCTCCTGCAATTGCTTA
TTTGAAGAAGTTTACTGGGTTTCATGAGTTTGCTGAGTTT
ACAGCTGAAGATGTTGGGACGAGTGAAAGTGGGTTGAA
TTCAGCCGTATTGGCAAATAATGATGAAATGGTGTTGTT
TCCAATGAATGAACCTGTGTATGGGACAAAAAGGAAGA
GCCAAATTCAAACTTATTTGGAGCATAATGAAGGAGCTG
GTGTACAACATTTGGCTTTGATGAGTGAAGATATATTTT
GGACTTTAAGGGAGATGAGGAAGAGAAGTGGTCTTGGT
GGGTTTGAGTTTATGCCGTCGCCGCCTCCGACTTATTACC
GGAATTTGAGGAATAGAGCTGCTGATGTATTGAGTGAG
GAGCAGATGAAGGAGTGTGAAGAGTTGGGGATTTTGGT
GGATAAAGATGATCAGGGTACTTTGCTTCAAATCTTCAC
TAAG
4 Amaranthus cDNA 1265 AGATGTGTATAAGAGACAGGTCTTGGCGTGCGTGCTGTT
palmeri Contig GCCGTCGAAGTAGAAGACGCCGAAGCTGCTTTTAATATC
AGCGTTTCGCACGGGGCTATCCCCTGTGTTTCTCCTATTC
ACTTGGAAAACGGTGTCGTTTTATCTGAGGTTCATTTATA
TGGGGATGTTGTGCTTCGGTATGTAAGCTACGGAAATG
AATGTGGGGATGTGTTTTTCTTCCTGGGTTTGAGGAAAT
GCCGGAGGAATCATCGTTTCGAGGACTTGATTTTGGCAT
TCGAAGGTTGGATCATGCTGTAGGGAATGTCCCTGAGTT
GGCTCCTGCAATTGCTTATTTGAAGAAGTTTACTGGGTTT
CATGAGTTTGCTGAGTTTACAGCTGAAGATGTTGGGACG
AGTGAAAGTGGATTGAATTCAGCCGTATTGGCAAACAAT
GATGAAATGGTGTTGTTTCCAATGAATGAACCTGTGTAT
GGGACAAAAAGGAAGAGCCAAATTCAAACTTATTTGGA
GCATAATGAAGGAGCTGGTGTACAGCATTTGGCTTTGAT
38
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
G A G TG AAG A CATATTTTG G A CTTTAAG G G AG AT G AG G A
AGAGAAGTGGTCTTGGTGGGTTTGAGTTTATGCCGTCGC
CG CCTCC G ACTTATTACC G GAATTTG AG G AACAG AG CTG
CTGATGTATTGAGTGAGGAGCAGATGAAGGAGTGTGAA
GAGTTGGGGATTTTGGTGGATAAAGATGATCAGGGTAC
TTTG CTTC AAAT CTT CA CC AAA CCTATT G G AG AC AG G C CA
A CCATATT CATCG A G ATTATC CAAA G AATTG GTTG C ATG
ATGAAAGATGAAGACGGCAAGATGTACCAAAAGGGTG
GTTGCGGAGGATTCGGAAAGGGAAACTTTTCAGAGCTG
TTCAAATCAATAGAGGAGTACGAGAAGACTCTTGAACGT
AAACAGGTTCCAGATACAGCTGCTGCATGATGAGCAGA
CTAAAATATTGTTGTCTTGCTGATGAAATGATAGAAAAG
GTTTGTTTCTTGGTACAATGCTCAACTTCAAAATTTTCTTT
ATTAAATAATGAAGTGTAAACTTATACAAACTGTGTCAT
ATATG G TG ATTG G TG ATC ATG G TTTAT G TA G AATG TATA
ACATAATTGATAATCTGTGTATATGCTGAATACTTACATA
CT G TG AAATC ATT CTG ATG G AAAC ATA CAATTG GT CA G T
AG CTG AG G CTG G TAG CTCCTCAG ATTAGTTTTTTTCAGTC
AAAATCGTAGATGTATAT
Amaranth us g DNA 3245 TTTTCTCTTTTATTTTTATCCAAAAATATCATGGGATGTCT
palm en Contig A G ATTG G AATAATTA G G G AG TAAAAA G TA
CC CCTTG ATT
ATG CA G A G CAAAAATAAATTG T CT G AATTT G AAATAAAT
ATCTACAAGAGTAAATTTTTCCATCTTATTCAAAGGTAAA
TG TTTG ATC CA CCTAC CT CTATAG ATATATTT CA G G G AAC
TAAATTG TCTTC AC CATTAAATTT G GTTA CTT G G TCTTTAA
AACCCAAATCATAGAAATTAATGATAAAATCAAAATAAA
AAAGATATTTAAATTCAAATTCAAACTAACTAATTTTAAA
TTACAAAATGAATATCTGTAATTTACAAAAGAAAGTATC
AAAAACATATGAAAATCTCAACATCTGAAAATTACAAAC
AAGTATTCTGTTTTTTCATTTTTTTTTTCTTTTTCGCTATTT
CCTTTCAAAAATAAAAGTAAATAAAAATATTCAAAAGCA
ATTCCATAAACAAAATCTTAGATATGTAAATCACAAAAA
CATTAGATCTAGAAAAAAAAAATTTCTTCCATTGCAAACC
CTTTTTCAACCTTCATAACTTCCACTACCATAATGAGGCC
AGTAAAGAGACAAAAGTCATTGAGTTGTTGTTGTGCAGT
TGATGATAAATGATGATAGAAGGGTTTATTIIII1TTTGA
AATGAATGGTTAGATTTTCTGACTTTTTATTTACCCTATA
ATGAATATCAAACAATTAACTCTATAAATTATTTAATACA
TTAAAATGTTTCATGTAATATGTCTCCTATATTATTTACCC
TTTAATTTTTAA G TG G G AACC AA G TATG T CTTAATTATCT
TTATTTTAATCAAATACGCGGTATACATGAAATAATCAAC
AAATG CAATTACTATG CTCG G ACG AG AG TAAATATAAT G
GGAGGAAGTTGTACATACAATTACGAAATAGTCTAAATA
AATAACGATAATTTGTAATATAAACAAACAAATCACACTT
ATATAAACAGATTTTATAGGGTGGAATCATTAGGATTCT
AATTTATCTTTTTTCTTCTTTTGTTTACTTTGCTGATATTTA
TTTTGTATTTTTCCTATTTCTCAAAAGGAAGACTAACACT
CAAATAAAATGATATTGAAATACAAAGCATCACCGGCCA
39
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
AGCCGAGATGACGAAACTATTTTGAATAATTATGATGAT
TTACAACTCCAAATAGAAGTAATTGATCAAGACTTTAGG
ACTTGGAAGTGTTGGGCAAAATCTTCCAGAGTCCAGGAT
AAGTGATAAGTGACGTATTTCCGTTACTCTTAAGTGTTAA
CAGCTTTTTGTCACGCAAGGAAAAGAAGACCGTGGACG
TCAACGATGACGTTGAATGTTCATCTTTACAGTCGCAGTC
AATCAATCTCTTTTTAGATCGATCTTCCACCTCAATTCTCC
GTTACAAATCAAATTCCATCTAGAACTTCTTTTTTATTATT
TTGACTCATAAATTCCCCCAAAAATACTTCTATTTTATTAT
AAATAAATTCCAATTTCTATGTTCTCCATTCATTACCACCC
ATTACTCCGTTTTCCAAACCACCATTTTCTCTCTCCTCCTTT
ACCGCTAACGCTACCACCATTTTCGCTTCTTCCCCGTCTG
AATTTTATTACTTCGCTTTCTCTATCATCATCTGACATGGG
TACTTTGAAACCCGAAACTCAACCCGATTCCGAATTCAAA
CTCGTGGGTTACTCCAACTTCGTTCGGGTTAACCCCAAAT
CTGACCGTTTTGCTGTTAAGCGTTTCCACCATATAGAGTT
TTGGTGTGGCGATGCAACCAATGTTAGCAGACGATTTTC
TTGGGGTCTTGGAATGCCTACCGTTGCTAAATCTGACCTT
TCTACAGGAAACTCTGTTCACGCTTCTTTTCTTCTTCGTTC
CGGTGACCTTTCTTTTCTCTTTACTTCACCTTACTCTCCTA
CCATGTCCATCCCTTCTTCTGCTGCAATCCCCTCGTTTGAT
TTCAATCATTTTACCAAATTCCTTACATCGCACGGTCTTG
GCGTGCGTGCTGTTGCCGTCGAAGTAGAAGACGCGGAA
G CTG CTTTTAACATCAG CGTTTC G CATG G G G CTATTCC CT
GTGTTTCTCCTATTCAATTGGAAAACGGTGTCGTTTTATC
TG AG GTTCATTTATATG G G GATGTTGTG CTTC G GTATGT
AAGCTACGGAAATGAATGTGGGGATGTGTTTTTTCTTCC
TGGGTTTGAGGAAATGCCGGAGGAATCATCGTTTCGAG
GACTTGATTTTGGCATTCGAAGGTTGGATCATGCTGTAG
G G AATGTC CCTG AGTTG G CTCCTG CAATTG CTTATTTG A
AGAAGTTTACTGGGTTTCATGAGTTTGCTGAGTTTACAG
CTGAAGATGTTGGGACGAGTGAAAGTGGATTGAATTCA
GCCGTATTGGCAAACAATGATGAAATGGTGTTGTTTCCA
ATGAATGAACCTGTGTATGGGACAAAAAGGAAGAGCCA
AATTCAAACTTATTTGGAGCATAATGAAGGAGCTGGTGT
ACAGCATTTGGCTTTGATGAGTGAAGACATATTTTGGAC
TTTAAGGGAGATGAGGAAGAGAAGTGGTCTTGGTGGGT
TTGAATTTATGCCGTCGCCGCCTCCGACTTATTACCGGAA
TTTGAGGAGCAGAGCTGCTGATGTATTGAGTGAGGAGC
AGATGAAGGAGTGTGAAGAGTTGGGGATTTTGGTGGAT
AAAGATGATCAGGGCACTTTGCTTCAAATCTTCACCAAA
CCTATTGGAGACAGGCCAACCATATTCATCGAGATTATC
CAAAGAATTGGTTGCATGATGAAAGATGAAGACGGCAA
GATGTACCAAAAGGGTGGTTGCGGAGGATTTGGAAAGG
GAAACTTTTCAGAGTTGTTCAAATCAATTGAGGAGTACG
AGAAGACTCTTGAACGTAAACAGGTTCCAGATACAGCTG
CTG CATG ATG AG CAG ACTGAAATATTGCTGTCTTGCTGG
TGGAAGCCATATAATGGTAATATGATAGAAAAGGTTTGT
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TGCTCAAAATTTTCTTTATTAAATAATGAAGTGTAAACTT
ATACAAACTGTGTCATATATG GTGATTGATGATCATG CA
TGGTTATGTAGAATGTATAACATAATTGATAATCTGTGT
ATATGCTGAAAACTTACATACTGTGAAATCATTCTGATAG
AAACATACAATTGGTGAGTAGCTGTCTCTTATACACATCT
6 Amaranthus gDNA 3416 G GAG GAATTTTTTTGTG
CATGTAAAATGTTTTCTCTCTAT
palm en Co ntig
TTTTTGATTTATGCTATTTTTTCTCTTTTATTTTTATCCAAA
AATATCATGGGATGTCTAGATTGGAATAATTAGGGAGTA
AAAAGTAC CC CTTG ATTATG CAG AG CAAAAATAAATTGT
CTGAATTTGAAATAAATATCTACAAGAGTAAATTTTTCCA
TCTTATTCAAAGGTAAATGTTTGATCCACCTACCTCTATA
GATATATTTCAGGGAACTAAAATTGTCTTCACCATTATAT
TTAGTTACTTGGTCTTTAAAACCCAAATCATAGAAATTAA
CGATAAAATCAAAATATAAAGATATTTAAATTCCAATTCA
AACTAACTAATTTTAAATTACAAAATGAATATCTGTAATT
TACAAAAGAAAGTATCAAAAACATATGAAAATCTCAACA
TCTGAAAATTAAAAAACAAGTATTTTGTTTCTTCATTTTTT
TCTTTTTCGCTATTTCCTTTCAAAAATAAAAGTAAATAAA
AATATTCAAAAGCAATTCCATAAACAAAATCTTAGATAT
GTAAATCACAAAAACATTAGATCTAGAAAAAAAAAATTT
CTTCCATTGCAAACCCTTTTTCAACCTTCATAACTTCCACT
ACCATAATGAG G CCAGTAAAGAGACAAAAGTCATTG AG
TTGTTGTTGTGCAGTTGATGATAAATGATGATAGAAGGG
TTTATTTTTTTTTTGAAATGAATG GTTAG ATTTTCTG ACTT
TTTATTTACCCTATATAGAATATCAAACAATTAACTCTATA
AATTATTTAATACATTAAAATGTTTCATGTAATATGTCTC
CTATATTATTTACCCTTTAATTTTTAAGTGGGAACCAAGT
ATGTCTTAATTATCTTTATTTTAATCAAATACGCGGTATA
CATGAAATAATCAACAAATGCAATTACTATGCTCGGACG
AG AGTAAATATAATG G GAG GAAGTTGTACATACAATTAC
GAAATAGTCTAAATAAATAACGATAATTTGTAATATAAA
CAAACAAATCACACTTATATAAACAGATTTTATAGGGTG
GAATCATTAGGATTCTAATTTATCTTTTTTCTTCTTTTGTTT
ACTTTGCTGATATTTATTTTGTATTTTTCCTATTTCTCAAA
AG GAAGACTAACACTCAAATAAAATGATATTGAAATACA
AAG CATCACCAG CCAAG C CG AG ATG ACAAAACTATTG G
CTAAGTG ATAACTG ATAAGTG AC GTATTTC CGTTACTCTC
AAGTCTTAACAG CTTTTTGTCACG CAAG G AAAAG AAG AC
CGTGGACGTCAACGGTGACGTTGAATGTTCATCTTTACA
GTCGCAGTCAATCAATCTCTTTTTAGATCGATCTTCCACC
TCAATTCTCCGTTACAAATCAAATTCCATCTAGAACTTCTT
TTTAATTATTTTG ACTCATAAATTC CC CCAAAAATACTTCT
ATTTTATTATAAATAAATTCCAATTTCTATGTTCTCCATTC
ATCACCACCCATTACTCCGTTTTCCAAACCACCATTTTCTC
TCTCCTCCATTACCCCTAACACAACTACCATTTTCGCTTCT
TC CC CGTCTG AGTCTTATTACATCG CTTTCTCTCTCATCAT
CTGACATGGGAACTTTGAAACCCGAAACTCAACCCGATT
CCGAATTCAAACTCGTGGGTTACTCCAACTTCGTTCGGG
41
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TTAACCCCAAATCTGACCGTTTTGCTGTTAAGCGTTTCCA
CCATATAGAGTTTTGGTGTGGCGATGCAACCAATGTTAG
CAGACGATTTTCTTGGGGTCTTGGAATGCCTATCGTCGC
TAAATCTGACCTGTCTACAGGAAACTCTGTTCACGCTTCT
TTTCTTCTTCGTTCCGGTGACCTTTCTTTTCTCTTTACTTCA
CCGTATTCTCCTACCATGTCCATCCCTTCTTCTGCTGCAAT
CCCCTCGTTTGATTTCAATCATTTTACCAAATTCCTTACAT
CGCACGGTCTTGGCGTGCGTGCTGTTGCCGTCGAAGTAG
AAGACGCCGAAGCTGCTTTTAATATCAGCGTTTCGCACG
GGGCTATCCCCTGTGTTTCTCCTATTCACTTGGAAAACGG
TGTCGTTTTATCTGAGGTTCATTTATATGGGGATGTTGTG
CTTCGGTATGTAAGCTACGGAAATGAATGTGGGGATGT
GTTTTTTCTTCCTGGGTTTGAGGAAATGCCGGAGGAATC
ATCGTTTCGAGGACTTGATTTTGGCATTCGAAGGTTGGA
TCATGCTGTAGGGAATGTCCCTGAGTTGGCTCCTGCAAT
TGCTTATTTGAAGAAGTTTACTGGGTTTCATGAGTTTGCT
GAGTTTACAGCTGAAGATGTTGGGACGAGTGAAAGTGG
ATTGAATTCAGCCGTATTGGCAAACAATGATGAAATGGT
GTTGTTTCCAATGAATGAACCTGTGTATGGGACAAAAAG
GAAGAGCCAAATTCAAACTTATTTGGAGCATAATGAAGG
AGCTGGTGTACAGCATTTGGCTTTGATGAGTGAAGACAT
ATTTTGGACTTTAAGGGAGATGAGGAAGAGAAGTGGTC
TTGGTGGGTTTGAATTTATGCCGTCGCCGCCTCCGACTTA
TTACCGGAATTTGAGGAGCAGAGCTGCTGATGTATTGA
GTGAGGAGCAGATGAAGGAGTGTGAAGAGTTGGGGAT
TTTGGTGGATAAAGATGATCAGGGCACTTTGCTTCAAAT
CTTCACCAAACCTATTGGAGACAGGTAGATTTTAATCTTG
CTTTCAATTGCTTTTGCTTGATTGATTGACTAGCCAATTTT
GATTGCATTTTGTTGCTTATATGACTTGATGATAATAGAT
GGTTTACCTTTCTCAGCTGTTCATTTGTAGCCAGTATAGA
TTCGTTCTAAAATATTTGCAACTGATTATGACATGTAGTA
GCAGAAAATGTCCCTATATTGGATGTTTGGCATAAATTA
AGCTTGGTTTTGCACTTATCCTCATTTATTTATAAATTCTA
AAACTTGTTAGTTGTAATTAAGTTAATGAGAACAAAGCC
TTAATATTCCTTCAAGGTGATTGTAGTTGGGGCACTAGTT
CTAACAATGGAAATTTGGAAATCTATTCCAACTGGTCCC
AAGTTAATCTTTGTTTGCAAGCCTGATTGGTTCAAATTAA
GGTTATTGTATTCTTGTATGAATTCGACTCAATGTAAATT
TGTTTAATGGAGCATCAATTTTTAATAGTTTTCGACCAAG
CAGTATTAGATATATTCGGGATTGAAATAATGCATCTAT
GAGTGTATAAAACCAAATGGCACATTTGATTAGAATAAA
AGAGAGTATAAGGCTAATTTCGTTTACCTAATATTTAAA
GCGACCCCTAAAATTCAATTGGCCTAAACCCATAAAGTT
CAAA
7 Amaranth us gDNA 3818 GAGTTCAAGATTAAAAGTTAAATTACATTTATGTGGGTT
palm en Contig TTATATAGGCAATGATTGCATTATATTGTTTTTCTTTTGGT
GGGAAGATTTTCCTTTTTAAAAAATTTTAATTTCCCTACA
TTTTCAAATGATGGAGGAATTTTTTTGTGCATGTAAAATG
42
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TTTTCTCTCTATTTTTTGATTTATGCTATTTTTTCTCTTTTAT
TTTTATCCAAAAATATCATGGGATGTCTAGATTGGAATA
ATTAGGGAGTAAAAAGTACCCCTTGATTATGCAGAGCAA
AAATAAATTGTCTGAATTTGAAATAAATATCTACAAGAG
TAAATTTTTCCATCTTATTCAAAGGTAAATGTTTGATCCA
CCTACCTCTATAGATATATTTCAGGGAACTAAATTGTCTT
CACCATTAAATTTGGTTACTTGGTCTTTAAAACCCAAATC
ATAGAAATTAATGATAAAATCAAAATAAAAAAGATATTT
AAATTCAAATTCAAACTAACTAATTTTAAATTACAAAATG
AATATCTGTAATTTACAAAAGAAAGTATCAAAAACATAT
GAAAATCTCAACATCTGAAAATTAAAAAACAAGTATTTT
GTTTCTTCATTTTTTTCTTTTTCGCTATTTCCTTTCAAAAAT
AAAAGTAAATAAAAATATTCAAAAGCAATTCCATAAACA
AAATCTTAGATATGTAAATCACAAAAACATTAGATCTAG
AAAAAAAAAATTTCTTCCATTGCAAACCCTTTTTCAACCT
TCATAACTTCCACTACCATAATGAGGCCAGTAAAGAGAC
AAAAGTCATTGAGTTGTTGTTGTGCAGTTGATGATAAAT
GATGATAGAAGGGTTTATTTTTTTTTTGAAATGAATGGTT
AGATTTTCTGACTTTTTATTTACCCTATATAGAATATCAAA
CAATTAACTCTATAAATTATTTAATACATTAAAATGTTTCA
TGTAATATGTCTCCTATATTATTTACCCTTTAATTTTTAAG
TGGGAACCAAGTATGTCTTAATTATCTTTATTTTAATCAA
ATACGCGGTATACATGAAATAATCAACAAATGCAATTAC
TATGCTCGGACGAGAGTAAATATAATGGGAGGAAGTTG
TACATACAATTACGAAATAGTCTAAATAAATAACGATAA
TTTGTAATATAAACAAACAAATCACACTTATATAAACAGA
TTTTATAGGGTGGAATCATTAGGATTCTAATTTATCTTTT
TTCTTCTTTTGTTTACTTTGCTGATATTTATTTTGTATTTTT
CCTATTTCTCAAAAGGAAGACTAACACTCAAATAAAATG
ATATTGAAATACAAAGCATCACCAGCCAAGCCGAGATGA
CAAAACTATTGGCTAAGTGATAACTGATAAGTGACGTAT
TTCCGTTACTCTCAAGTCTTAACAGCTTTTTGTCACGCAA
GGAAAAGAAGACCGTGGACGTCAACGGTGACGTTGAAT
GTTCATCTTTACAGTCGCAGTCAATCAATCTCTTTTTAGA
TCGATCTTCCACCTCAATTCTCCGTTACAAATCAAATTCCA
TCTAGAACTTCTTTTTTATTATTTTGACTCATAAATTCCCC
CAAAAATACTTCTATTTTATTATAAATAAATTCCAATTTCT
ATGTTCTCCATTCATTACCACCCATTACTCCGTTTTCCAAA
CCACCATTTTCTCTCTCCTCCTTTACCGCTAACGCTACCAC
CATTTTCGCTTCTTCCCCGTCTGAATTTTATTACTTCGCTT
TCTCTATCATCATCTGACATGGGAACTTTAAAACCCGAAA
CTCAACCCGATTCCGAATTCAAACTCGTGGGTTACTCCAA
CTTCGTCCGGGTTAACCCCAAATCTGACCGTTTTGCTGTT
AAGCGTTTCCACCATATAGAGTTTTGGTGTGGCGATGCA
ACCAATGTTAGCAGACGATTTTCTTGGGGTCTTGGAATG
CCTACCGTCGCTAAATCTGACCTGTCTACAGGAAACTCTG
TTCACGCTTCTTTTCTTCTTAGTTCCGGTGACCTTTCTTTT
CTCTTTACTTCACCTTACTCTCCTACCATGTCCATCCCTTCT
43
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TCTGCTGCAATCCCCTCGTTTGATTTCAATCATTTTACCAA
ATTCCTTACATCGCACGGTCTTGGCGTGCGTGCTGTTGCC
GTCGAAGTAGAAGACGCAGAAGCTGCTTTTAATATCAGC
GTTTCGCACGGGGCTATCCCCTGTGTTTCTCCTATTCACT
TGGAAAACGGTGTCGTTTTATCTGAGGTTCATTTATATG
GGGATGTTGTGCTTCGGTATGTAAGCTACGGAAATGAAT
GTGGGGATGTGTTTTTTCTTCCTGGGTTTGAGGAAATGC
CGGAGGAATCATCGTTTCGAGGACTTGATTTTGGCATTC
GAAGGTTGGATCATGCTGTAGGGAATGTCCCTGAGTTG
GCTCCTGCAATTGCTTATTTGAAGAAGTTTACTGGGTTTC
ATGAGTTTGCTGAGTTTACAGCTGAAGATGTTGGGACGA
GTGAAAGTGGGTTGAATTCAGCCGTATTGGCAAACAAT
GATGAAATGGTGTTGTTTCCGATGAATGAACCTGTGTAT
GGGACAAAAAGGAAGAGCCAAATTCAAACTTATTTGGA
GCATAATGAAGGAGCTGGTGTACAGCATTTGGCTTTGAT
GAGTGAAGACATATTTTGGACTTTAAGGGAGATGAGGA
AGAGAAGTGGTCTTGGTGGGTTTGAGTTTATGCCGTCGC
CGCCTCCGACTTATTACCGGAATTTGAGGAACAGAGCTG
CTGATGTATTGAGTGAGGAGCAGATGAAGGAGTGTGAA
GAGTTGGGGATTTTGGTGGATAAAGATGATCAGGGCAC
TTTGCTTCAAATCTTCACCAAACCTATTGGAGACAGGTAG
ATTTTAATCTTGCTTTCAATTGCTTTTGCTTGATGGATTGA
CTAGCCAATTTGATTGCATTTTGTTGCTTATATGACTTGA
TGCTAGATAGTTTACCTTTCTCAGCTGTTAAGTTGTAGCA
AGTATCTAATACATTCGTTCTGAAATATCTGAAATATTTG
CAACTGATTATGACATGTAGCGGGAGAAAATGTCCGTTT
GGCATAAATTAAGCTTGGTTTTGCACTTATCCTCATTTAT
TTATAAATTCTAAAACTTGTTAGTTGTAAGCTCCTTTCAG
TTGTCCTGAATTTAATTAAGTTAATGAGAACAAAGCCTTA
ATATTCCTTCAAGGTGATTGTAGTTGGGGCACTAGTTCT
AACAATGGAAATTTGGAAATCTATTCCAACTGGTCCCAA
GTTAATCTTTGTTTGCAAGCCTGATTGGTTCAAATTAAGG
TTATTGTATTCTTGTATGAATTCGACTCAATGTAAATTTG
TTTAATGGAGTATCAATTTTTAATAGTTTTCAACCAAGTA
GTATTAGATATATTCGGGATTGAAATAATGCATCTATGA
GTGTACAAAACCAAATGGCACATTTGATTAGAATAAAAG
AGAGTATAAGGCTAATTTCGTTTACCTAATATTTAAAGCG
ACCCCTAAAATTCAATTGGCCTAAACCCATAAAGTTCAAA
AGCAGAGAAGAACATAGAATAGTGCAGGTCCATTGGTA
ATGCACTAGGAGTTGGAGCTTTTATGGGTACAAGTGTGT
GGCTAGTTGGGGATGACTGTCTAGCATTGTCTAGGTGAA
AAGCTGAAGCCTTAAGCCATGAAGGTTTTGAGTAGAGG
TGTTCATTTGGGTCATCGGGTTGATTTCGGGTCAGATGT
TTCGGGTCGGTTTAAAATCGGGTTTTGTGTTCACATTGGT
TTTTACGTAATT
8 Amaranthus cDNA 775 AAATGAATGTGGGGATGTGTTTTTTCTTCCTGGGTTTGA
rudis Contig GGAAATGCCGGAGGAATCATCGTTTCGAGGACTTGATTT
CGGCCTTCGAAGGTTGGATCATGCTGTAGGGAATGTCCC
44
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TGAGTTGGCTCCTGCAATTGCTTATTTGAAGAAGTTTACT
GGGTTTCATGAGTTTGCTGAGTTTACAGCTGAAGATGTT
GGGACGAGTGAAAGTGGGTTGAATTCAGCCGTATTGGC
AAATAATGATGAAATGGTGTTGTTTCCAATGAATGAACC
AGTGTATGGGACAAAAAGGAAGAGTCAAATTCAAACTT
ATTTGGAGCATAATGAAGGAGCTGGTGTACAACATTTGG
CTTTGATGAGTGAAGATATATTCTGGACTTTAAGGGAGA
TGAGGAAGAGAAGTGGTCTTGGTGGGTTTGAGTTTATG
CCGTCGCCGCCTCCGACTTATTACCGGAATTTGAGGAAC
AGAGCTGCTGATGTATTGAGTGAGGAGCAGATGAAGGA
GTGTGAAGAGTTGGGGATTTTGGTGGATAAAGATGATC
AGGGTACTTTGCTTCAAATCTTCACCAAACCTATTGGAGA
CAGGCCAACTATATTTATCGAGATCATCCAAAGAATTGG
TTGCATGATGAAAGATGAAGACGGCAAGATGTACCAAA
AGGGTGGTTGCGGAGGATTTGGAAAGGGAAACTTTTCG
GAGCTTTTCAAATCAATTGAGGAGTACGAGAAGACTCTT
GAACGTAAACAGGTTCCAGATACAGCTGCTGCATGAGTT
9 Amaranthus cDNA 1204 CTTACATCGCACGGTCTTGGTGTGCGTGCTGTTGCTGTC
rudis Contig GAAGTAGAGGACGCAGAAGCTGCTTTTAATATCAGCGTT
TCCAACGGGGCTATTCCCTGTGTTTCTCCTATTCAATTGG
AAAACGGTGTCGTTTTATCTGAGGTTCATTTATATGGGG
ATGTTGTGCTTCGCTATGTAAGCTACGGAAATGAACGTG
GGGATGTGTTTTTTCTTCCTGGGTTTGAGGAAATGCCGG
AGGAATCGTCGTTTCGAGGACTTGATTTCGGCCTTCGAA
GGTTGGATCATGCTGTAGGGAATGTTCCCGAGTTGGCTC
CTGCAATTGCTTATTTGAAGAAGTTTACTGGGTTTCATGA
GTTTGCTGAGTTTACAGCTGAAGATGTTGGGACGAGTG
AAAGTGGGTTGAATTCAGCCGTATTGGCAAATAATGATG
AAATGGTGTTGTTTCCAATGAATGAACCTGTGTATGGGA
CAAAAAGGAAGAGTCAAATTCAAACTTATTTGGAGCATA
ATGAAGGAGCTGGTGTACAACATTTGGCTTTGATGAGTG
AAGATATATTTTGGACTTTAAGGGAGATGAGGAAGAGA
AGTGGTCTTGGTGGGTTTGAGTTTATGCCGTCGCCGCCT
CCGACTTATTACCGGAATTTGAGGAATAGAGCTGCTGAT
GTATTGAGTGAGGAGCAGATGAAGGAGTGTGAAGAGTT
GGGGATTTTGGTGGATAAAGATGATCAGGGTACTTTGCT
TCAAATCTTCACTAAGCCTATTGGTGACAGGCCAACTATA
TTTATCGAGATCATCCAAAGAATTGGTTGCATGATGAAA
GATGAAGACGGCAAGATGTACCAAAAGGGTGGTTGCGG
AGGATTTGGAAAGGGAAACTTTTCGGAGCTTTTCAAATC
AATTGAGGAGTATGAGAAGACTCTTGAACGTAAACAGG
TTCCAGATACAGCTGCTGCATGAGCAGACTAAAATATTG
CTGAAACGCAGGCTGCAGCCATATGTTAGAACAGTCATT
CTGATGGAAACACTCAAGCGGTGAGTAGCTGAGGTTGG
TGATGCTGAAGTCGAGTCGGTATTTGGATCATCTTACAA
TTACAGTGCAAGGATAGTAATGAAGCATGTAAACAGCTC
CTCAGATTAGTTTTTTCCAGTCATAATCGTAGATGTATAT
GAGAAAATTTAAATTGCTCTTTTAAGTTAATGAAAA
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
Amaranth us gDNA 511 TCATCAACAACAAAAGAGTTGAAATTCTAATAATAATCC
rudis Co ntig CAGTAAGCAGTGAGTAAGATCAAATGGAGAGTCAGTTA
GTAGCTAATCATACAAAACCATTAAAGCTACAAAGTTAC
TCTAATTTCTTAAGATCAAACCCAAAATCTGATCGTTTCA
AAGTGAAAAGGTTCCACCACATTGAGTTCTGGTGTGGTG
ATGCAACCAACACTAGCCTTTTATTTTCGTTAGGGCTTGG
CATG C CTATG GTTG CCAAATC CG ATCTCTCCACAG G CAA
CCTTATACATGCCTCCTACGTCTTACGTAGTGGCGAACTT
TGTTTC GTATTCAC G G CTC CTTACTCTCC GTCATC CATG CT
CACAACTG CATCAATTCCTTCGTTTG ACTACAGTG C G CAC
GCCTCTTTTGTGTCCTGTCATGGCCTTGGTGTTCGCGCTG
TGGCCCTTGAGGTGGAGAACGCTGAATCCGCCTTTAGG
ATTAGTGTTGCAGCAGGAGCTCATCCGTCAGCCCCACC
11 Amaranthus gDNA 770 AATCATTTTAC CAAATTCCTTACATCG CAC G GTCTTG
G CG
rudis Contig TGCGTGCTGTTGCTGTCGAAGTAGAAGACGCAGAAG CT
GCTTTTAATATCAGCGTTTCCAACGGGGCTATTCCCTGTG
TTTCTCCTATTCACTTGGAAAACGGTGTCGTTTTATCTGA
GGTTCATTTATATGGGGATGTTGTGCTTCGGTATGTAAG
CTACGGAAATGAATGTGGGGATGTGIIII1TCTTCCTGG
GTTTGAGGAAATGCCGGAGGAATCATCGTTTCGAGGAC
TAGATTTCG G CCTTCGAAG GTTG GATCATG CTGTAG G GA
ATGTC CCTG AGTTG G CTCCTG CAATTG CTTATTTG AAG AA
GTTTACTG G GTTTCATG AGTTTG CTG AGTTTACAG CTG A
AGATGTTGGGACGAGTGAAAGTGGGTTGAATTCAGCCG
TATTGGCAAATAATGATGAAATGGTGTTGTTTCCAATGA
ATGAACCAGTGTATGGGACAAAAAGGAAGAGTCAAATT
CAAACTTATTTG G AG CATAATG AAG G AG CTG GTGTACAA
CATTTGGCTTTGATGAGTGAAGATATATTCTGGACTTTAA
GGGAGATGAGGAAGAGAAGTGGTCTTGGTGGGTTTGA
GTTTATG CC GTCG C CG C CTCC G ACTTATTAC CG G AATTTG
AGGAACAGAGCTGCTGATGTATTGAGTGAGGAGCAGAT
GAAGGAGTGTGAAGAGTTGGGGATTTTGGTGGATAAAG
ATGATCAGGGTACTTTGCTTCAAATCTTCAC
12 Amaranth us gDNA 1412 ACCACCATTTTCGTTTCTTCCCCGTCTGAGTTTTATTACTT
rudis Co ntig CACTTTCTCTCTCATCATCTGACATGGGAACTTTGAAACC
CGAAAATCAACCCGATTCCGAATTCAAACTCGTGGGTTA
CTCCAACTTTGTTCGGGTTAACCCCAAATCTGACCGTTTT
ACTGTTAAGCGTTTCCATCATATAGAGTTTTGGTGTGGC
GACGCAACCAATGTTAGCAGACGATTTTCTTGGGGTCTT
G GAATG CCTACCGTCG CTAAATCTGACCTTTCTACG G GA
AACTCTGTTCACGCTTCTTTTCTTCTTCGTTCCGGTGACCT
TTCTTTCCTTACTTCACCTTACTCCCCTACCATGTCCATCC
CTTCTTCTGCTGCAATCCCCTCGTTTGATTTCAATCATTTT
ACCAAATTCCTTACATC G CAC G GTCTTG G C GTG CGTG CT
GTTGCTGTCGAAGTAGAAGACGCAGAAGCTGCTTTTAAT
ATCAGCGTTTCCAACGGGGCTATTCCCTGTGTTTCTCCTA
TTCACTTGGAAAACGGTGTCGTTTTATCTGAGGTTCATTT
ATATG G G G ATGTTGTG CTTCG GTATGTAAG CTAC G G AAA
46
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TGAATGTG G G GATGTGTTTTTTCTTCCTG G GTTTGAG GA
AATGCCG GAG GAATCTTCGTTTCGAG GACTTGATTTCG G
CCTTCGAAGGTTGGATCATGCTGTAGGGAATGTCCCTGA
GTTGGCTCCTGCAATTGCTTATTTGAAGAAGTTTACTGG
GTTTCATGAGTTTGCTGAGTTTACAGCTGAAGATGTTGG
GACGAGTGAAAGTGGGTTGAATTCAGCCGTATTGGCAA
ATAATGATGAAATGGTGTTGTTTCCAATGAATGAACCAG
TGTATGGGACAAAAAGGAAGAGTCAAATTCAAACTTATT
TG GAG CATAATGAAG GAG CTG GTGTACAACATTTG G CTT
TGATGAGTGAAGATATATTCTGGACTTTAAGGGAGATGA
GGAAGAGAAGTGGTCTTGGTGGGTTTGAGTTTATGCCG
TCGCCGCCTCCGACTTATTACCGGAATTTGAGGAACAGA
GCTGCTGATGTATTGAGTGAGGAGCAGATGAAGGAGTG
TGAAGAGTTGGGGATTTTGGTGGATAAAGATGATCAGG
GTACTTTGCTTCAAATCTTCACCAAACCTATTGGAGACAG
GTAGTTTTTAATCTTGCTTTCAATTGCTTTTGATTAATTGA
TTGATTAGCCAATTTGATGATTGCATTTTGTTGCTTGTAT
GACTTGATGATATATGGTTTACCTTTTCTCAGCTGTTCAG
TTGTAGCAAGTATTTCTAATCCGTTCTGAAATACTCCATT
CGCAACTGATTGTGACATGTTGTGCAGAAAATTATGGAA
AATGAGAAAATGTCCCTATATTG GAAGATTG GT
13 Amaranthus cDNA 707 CCCGAGTTGGCTCCTGCAATTGCTTATTTGAAGAAGTTTA
thunbergii Contig CTGGGTTTCATGAGTTTGCTGAGTTTACAGCTGAAGATG
TTGGGACGAGTGAAAGTGGGTTGAATTCAGCCGTATTG
GCAAATAATGATGAAATGGTGTTGTTTCCAATGAATGAA
CCTGTGTATGGGACAAAAAGGAAGAGCCAAATTCAAAC
TTATTTG GAG CATAATGAAGGAG CTG GTGTACAACATTT
G G CTTTGATGAGTGAAGATATATTTTG GACTTTAAG G GA
GATGAGGAAGAGAAGTGGTCTTGGTGGGTTTGAGTTTA
TGCCGTCGCCGCCTCCGACTTATTACCGGAATTTGAGGA
ATAGAGCTGCTGATGTATTGAGTGAGGAGCAGATGAAG
GAGTGTGAAGAGTTGGGGATTTTGGTGGATAAAGATGA
TCAG G GTACTTTGCTTCAAATCTTCACTAAG CCTATTG GT
GACAGGCCAACCATATTTATCGAGATTATCCAAAGAATT
GGATGCATGATGAAAGATGAGGACGGCAAGATGTACCA
AAAG G GTG GTTGTG GAG GATTTG GAAAG G GAAACTTTT
CG GAG CTGTTCAAATCAATTGAG GAGTATGAGAAGACT
CTTGAACGTAAACAGGTTCCAGATACAGCTGCTGCATGA
GCAGACTAAAATATTGCTGAAACGCAGGCTGCAGCCATA
TGTTAGAACAG
14 Amaranth us CD NA 1267 AACCACCATTTTCTCTCTCCTCCATTACCACTAACACTCCC
viridis Co ntig ACCATTTTCGTTTCTTCCCCGTCTGAGTCTTATTACTTCGC
TTTCTCTCACATCATCTGACATGGGAACTTTGAAACCCGA
AACTCAGCCCGATTCCGAATTCAAACTCGTGGGATACTC
CAACTTCGTTCGGGTTAACCCCAAATCTGACCGTTTTACT
GTTAAGCGTTTTCATCATATAGAGTTTTGGTGTGGCGAT
GCAACCAATGTTAGCAGACGATTTTCTTGGGGTCTTGGA
ATGCCTACCGTTGCTAAATCTGACCTTTCTACTGGAAACT
47
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
CTGTTCACGCTTCTTTTCTTCTTCGTTCCGGTGACCTTTCT
TTTCTCTTTACTTCACCTTACTCTCCTACCATGTCCGTCCCT
TCTTCTGCTGCAATCCCCTCGTTTGATTTCAATCATTTTAC
CAAATTCCTTACATCGCACGGTCTTGGTGTGCGTGCTGTT
GCTGTCGAAGTAGAAGACGCAGAAGCTGCTTTTAATATC
AGCGTTTCCAACGGGGCTATTCCCTGTGTTTCTCCTATTC
AATTGGAAAACGGTGTCGTTTTATCTGAGGTTCATTTATA
TGGGGATGTTGTGCTTCGGTATGTAAGCTACGGAAATG
AATGTGGGGATGTGTTTTTCTTCCTGGGTTTGAGGAAAT
GCCGGAGGAATCGTCGTTTCGAGGACTTGATTTCGGCCT
TCGAAGGTTGGATCATGCTGTAGGGAATGTTCCCGAGTT
GGCTCCTGCAATTGCTTATTTGAAAAAGTTTACTGGGTTT
CATGAGTTTGCTGAGTTTACAGCTGAAGATGTTGGGACG
AGTGAAAGTGGGTTGAATTCAGCCGTATTGGCAAATAAT
GATGAAATGGTGTTGTTTCCAATGAATGAACCTGTGTAT
GGGACAAAAAGGAAGAGCCAAATTCAAACTTATTTGGA
GCATAATGAAGGAGCTGGTGTACAACATTTGGCTTTGAT
GAGTGAAGATATATTTTGGACTTTAAGGGAGATGAGGA
AGAGAAGTGGTCTTGGTGGGTTTGAGTTTATGCCGTCGC
CGCCTCCGACTTATTACCGGAATTTGAGGAATAGAGCTG
CTGATGTATTGAGTGAGGAGCAGATGAAGGAGTGTGAA
GAGTTGGGGATTTTGGTTGACAGAGATGATCAAGGCAC
TCTGCTTCAAATTTTCACTAAGCCCATTGGAGATAGGCCT
ACGATATTCATAGAAATAATACAGAGATTAGGGTGCATG
GTGAA
15 Ambrosia cDNA 637 CCGGTTTACGGGACGAAGAGGAAGAGTCAGATACAGAC
trifida Contig ATATTTGGAACATAATGAAGGGGCAGGGGTGCAGCATT
TGGCGTTGGCGAGTGAGGATATATTTAGGACATTGAGG
GAGATGAGGAAAAGGAGTGGGGTGGGTGGGTTTGAGT
TTATGCCATCTCCGCCGCCTACTTATTATCGGAATTTGAA
GAACAGGGCGGGCGATGTGTTGTCGGATGAGCAGATTA
AGGAGTGTGAGGAGTTGGGGATATTGGTGGATAAGGA
TGATCAGGGGACTTTGCTTCAGATTTTTACCAAGCCTGTT
GGTGATAGGCCGACGATATTCATAGAGATAATTCAGAG
AGTAGGATGTATGATGAAGGATGAAGAAGGAAAGGTG
CAGCAGAAGGCGGGCTGTGGAGGATTTGGTAAAGGGA
ACTTTTCGGAGCTTTTTAAATCGATTGAGGAATATGAAA
AGACACTGGAAGCAAGAACCTGAAGCCACATGAAAACC
ACACACAAATAATCTTTCATGAGATTTTAAAATCTAATGA
TTATGCATCTGTGGATTCTATACAACAAACAGATCCTGAA
AATATAGGATATCAACTTTACAATAAGTTATGTAATATGC
ATCTCATGATTATCAATGTATT
16 Am brosia CD NA 718 TACCTCACAAACCCAATCCTCCATACTTCCGTGTTCTCTAC
trifida Co ntig TACTGTTCCACTTTATTAATCTTACCCAACCCCTTCTCATC
TATTTCCCCCCTACCTCACAAACATAACCCAAATAAAAAA
TAAAATTAAAATAAAAAATAAAATGGAACTGAACCCACC
CTCGTTGACCCCGTCGTCGCCGGAGACAACTCCGACCAC
TCCAACCACCCCATCTCCGCCTTCAAGCTAGTCGGCTTCA
48
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
AAAACTTCATCCGTAACAACCCTAAGTCCGACAAATTCTC
CGTCAAATCCTTCCACCACATCGAGTTCTGGTGCTCCGAC
GCCACCAACGCCGCCCGTCGCTTCTCATGGGGTCTCGGC
ATGCCTATTACTTACAAATCCGACCTTTCTACCGGTAACC
ATACCCACGCCTCTTATCTCCTTAACTCCGGCCACCTTAA
CTTCCTCTTCACCGCCCCTTATTCCCCCACCATCTCCACCA
CCACCACCACCGCCTCCATCCCGTCGTTCTCCCACTCCGC
CTGCCGTCACTTCACCGCCTCCCACGGCCTTGCTGTCCGT
GCCATCGCCGTTGAAGTTCAAGACGCTGAAATCGCTTTC
TCCGTTAGTGTCGCTAACGGCGCTAAACCCTCATCTCCAC
CTATCACCCTTGGCCACGACGACGTCGTTTTGTCAGAAG
TTCAACTCTACGGTGACGTCGTTTTACGTTATATTAGTTA
17 Am brosia gDNA 54 CTCCGAGGCGTTTTGGGTCCAAAATCCGAAGCGCGGGG
trifida Contig CTTAAAGCGCGAGGCG
18 Am brosia g DNA 719 CTTCATGTAGTTCAGCGCTTTTTGGCAAAAAAAGCGTTTT
trifida Co ntig TCTTGGAGCCTTGTGCCTCAAACGCTTAAAGTGCGCCCC
AGGCGAGCTTTTTTAAACCAAGGAACACGCACAAGCACT
CCACCAATAGTTCAATGCCGTGCTAACCAGTGGGATTAA
CTAGTGGAAGCTGGATTCAAACATGCTAGAGTGGAAAT
ATATTTTTTTTAATGTTTGGATATGCATATTTAACCATTAT
AGCATAATATTAATGACAAGGGTTGTAAATTGGTATGCA
AATTGTTTGAGCAGGCCGACGATATTCATAGAGATAATT
CAGAGAGTAGGATGTATGATGAAGGATGATGAAGGAA
AGGTGCAGCAGAAGGCGGGTTGTGGAGGATTTGGTAAA
GGGAACTTTTCGGAGCTTTTTAAATCGATTGAGGAATAT
GAAAAGACACTGGAAGCAAGAACCTGAAGCCACATGAA
AACCACACAAATAATCTTTAATGAGATCTTAAAATCTAAT
GATTATGCATCTGTGGATTCTATACAACAAACAGATCCT
GAAAATATAGGATATCAACTTTACAATAAGTTATGTAAT
ATGCATCTCATGATTATCAATGTATTAATTTATTTTTATGT
TGCTGTTTTCGGTTTAGTTTTTGTTCGTTGGTGTTGGGCC
GGCTCTTCTTCTATTTCGTTCTTGATCCATTTGAAGTTGAA
GGCGAAATTTAGG
19 Am brosia gDNA 845 GCAGTTGAGCTCTACGGCTCACTGAAACAGACCTTTAAA
trifida Co ntig CCATGAACAAGGTTTATGTGTAGGTAAACTAACTTTGGA
CCAAAAAGCTGTTTTTTTAACCTTCACAATTTGTTTCATG
GAAGGTTTTCCTTTTTGTTCAGTTGACATGTTTCTAAACG
GGACAAATAAACATACATCTATGCCTATTGCACATATAG
CATCAACCACCTCACTCCCATGTGGCCCTCACAACAAGGT
TGTAAAAATCGGGACTAGTCGCCGACTAGTCCCCGATAA
ATCGGTGATCGGAGGTCTACTGATTAATTTTTCATTAATC
ACTCAATTAGTCGGAATCGGCCCAAGCCGGTCCAAGCCG
GCCAAAGTCGGCCGAAGTCGGAGCTAGTCGCCAAAGAA
TTCCGTTTGAAGTTGGCTTAAAAACATGCTTTCATCCCAC
AAACTGATCCATTACCCCAAAAAACCAAAGTTAAAAACC
TGACCTGGATCCCTAAATGCTTCATAATCCGGCAAACCTT
TCTGTTCCGGCGAACCTTTCTGTTTCCGGCGACCCATTTG
GAGCAGGTGGAGTTGGTTTTGTTCAGTCTTTTGCGGCGT
49
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ATAATGAAAGTG GTAGTGAGTAG G GTTTTTAAGTTTG GA
TCTTTTTATATTTAACCCCTTATAGTTTTACTAGTTTATATT
TTGTCCCTTAACTTATATATTTATACATAATAAGCATAAA
GTTAATGTTATATATATACAAATTAACCCTCTACATCTTTA
CTAGTCTATATTTGGTCCTCTAACTTATACATCTATACAA
AAAAAGCATAAAATTAATGTTATATATATATAAATTTATA
AAATTATACATA
20 Am brosia g DNA 1024 TCGTCGTTTCAGGAGCTGGATTACGGTATCCGGCGGCTA
trifida Contig GATCACGCTGTGGGGAACGTACCGGAGTTAGCACCAGC
AGTGGAATATATAAAATCGTTTACCGGGTTTCACGAGTT
TGCTGAGTTTACAGCAGAGGATGTGGGAACGAGTGAGA
GTGGACTCAACTCGGTGGTGTTGGCTTGCAATAGTGAG
ATGGTATTAATACCTCTGAATGAGCCGGTTTACGGGACG
AAGAGGAAGAGTCAGATACAGACATATTTGGAACATAA
TGAAGGGGCAGGGGTGCAGCATTTGGCGTTGGCGAGT
GAGGATATATTTAGGACATTGAGGGAGATGAGGAAAAG
GAGTGGGGTGGGTGGGTTTGAGTTTATGCCGTCTCCGC
CGCCTACTTATTATCGGAATTTGAAGAATAGGGCGGGCG
ATGTGTTGTCGGATGAGCAGATTAAGGAGTGTGAGGAG
TTGGGGATATTGGTGGATAAGGATGATCAGGGGACTTT
GCTTCAGATTTTTACCAAGCCTGTTGGTGATAGGTATTGT
TTTTCGTTAATGTAGCGTTACTTGAATTCGTAATTATGTG
TTTAAACTTTAAACTAGATAGTATTAAGGCTTATGCAATA
TGTATTGTTCCCCTAGAGGACGAGGGTTCTAGACTCTAG
TTCCGTAATGTAGTGATAAAGGTGTAGATTAAGAGTAGG
ATTAGCGGGTGTGTTAGTTAGCGGTTTTAACAAGAAAAA
CACATAATATGTTGAAAGAACAATAACAAGAATG G CAA
ACATAAAAAAGGAAAAGCCATAAAGGTTGTCATTCTATA
ATTTGCTTGCATTCAAGATTCTTACTAGGATTGTATTATT
ATGTGGTTACTAAACTCTATTCAAGTATAAAAACATGAA
ACCCCTTCACATAAGGAAAAAGAAATATGTATGTTTTAA
AATGGATCATCTTTTCCCTTGTGTCACGATTGCCAATGTT
TTTTTTGTTGACCATGAGAACCGTTGGTGAACACGCCTT
GGTTTAAAAAAGCGCG
21 Co nyza CD NA 1610 TATGGTATTGCATTGTTTCATTCAATTGTACATAATCCAC
canadensis Contig AAATACATATGGTGATAATCATGTTCTTTGAGTCAAGAA
GATATAAACATTATACATAGGCAGTTTTCATGCAGTGGC
AGTTGGTTCAGTGGTGTTTCGTGCTTCCAGCGTCTTCTCG
TATTCTTCAATAGATTTGAAGAGCTCTGAGAAATTGCCCT
TGCCAAATCCTCCACAGCCTGGCTTCTGTTGCACCTTGCC
TTCATCATCTTTCAGCATACACCCTACTCTCTGAATAATCT
CTATGAATATAGTTGGCCTATCACCAACAGGCTTGGTGA
AAATCTGAAGCAAAGTTCCCTGATCATCTCTATCAACCAA
AATCCCCAATTCCTCACATTCCTTAATCTGTTCGTCACTCA
ACACGTCCCCGACCCTATTCTTCAAATTCTTATAATAAGT
AGGCGGTGGAGACGGCATAAACTCAAAACCACCGACAC
TACTCCGTTTTCTCATCTCTCTCAAAGTCCTAAAAATATCC
TCACTCGCCAACGCCAAATGCTGCACACCAGCTCCCTCAT
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TATGTTCCAAATACGTCTGTATCTGGCTCTTCCTTTTCGTT
CCATAAACTG GCTCGTTCATCGGTATCAAAACCGTTTCAC
TATTACACGCTAATACAACCGAATTAAGCCCGCTCTCACT
CGTTCCTACATCCTCTGCCGTAAATTCAGCAAATTCGTGA
AATCCAGTG AAG GACTTCACGTAGTCTACTG CCG GAG CT
AG CTCCG G CACGTTTCCTACG G CGTGATCTAACTTATGA
ATTCCGTAATTAAGTTCATGAAACGACGACGTTGCGTCC
ACAGGCTCAAAACCCGGTAGGAAATTAGTAGTAACATCA
TAATTAGTGTTTTTAAAACTAACATATCTCAAAACGACAT
CGCCGTACAGTTTAACTTCAGCCAAAACGACGTCGTTATT
TCCTAGAGTGACCGGAGCTGACGACGGTTTAGCACCGT
GAG CGATACTAACAGAATAAG CGATTTCAG CGTCTTCAA
CTTCAACGGCGATAGACCGTACAGCGAGGCCGTGAGTG
GCGGTGAAGTTCCGGCAAGCAGTGTGAGAGAAAGTAG
GAATAGACGATGTGGAACCGGTGGTGGAGATGGTGGT
GGAATAAGGTGCGGTGAAGAGGAAGTTGAGCTGGCCG
GAGTTAATAAG GTAAGAAG CGTGAGTGTTGTTACCG GT
GGAGAGATCGGATTTGTAAAGAAGCGGCATGCCGAGAC
CCCAAGAGAAGCGGCGGGCGGTGTTGGTGGCGTCGGA
ACACCAGAATTCGACGTGGTG GAATTTTTTGACGGTGAA
TTTGTCGGATTTAGGGTTTTGACGGATGAAGTTTTTGAA
GCCGACGAGTTTGTAAGTGGCGGAG GTGGTGGTAGTGG
TTTGTTGTTGTCCGGTGAGTGTGTTTCCGTTTGCTGCTTC
AGTTACCATTTTGTTTTTATTAATTTGAATGTATAGATAG
AAATATGAAGTAGATATATAGAATGATAGATATAGATAC
AGTACAAGTAGTTGAGGGGTTGGATGATGGAGATGAAG
AAGAACACGGAAGTGGTTTATTTTCTTTGGGTGCTATTA
AUG
22 Co nyza g DNA 4963 AACACGAATGGGCTAGCTAGCTGATGAATTTAATGTATA
canadensis Contig TATGTCTTTAAAAACCACTTTCATGGGCTACTTGTGTTTTT
GATGAGTTTTTCAACATCATTCTCATCTTACCTTCTTACAA
TG GTTCACCATATTG CTTCGTTTGTCGTCTCCTG CATG GT
TATCGAATTTATTTTTTCAAATTATATTACTATTATCTTTTT
GTTTTCTGATTTCTCACATGTAATTTACATTATGAGTTTCA
CCATCCGTATGTAAATTGTAAAATAAATCACAAATTTG GT
TTTTAACCATCAACTAAATTCATTGAAATCCTTAAGTTAT
AACCCATTTGAGGTTATAGATTATGAGAGTAGATTCCTA
TTTTCTCTTTGGCTTATGTATCCTTAATTATGTTTGAATTG
ATTCTAACTTTATTATATTTTAGGAATTACTTAACTTCAAA
AATCTCAACACGTCATATAATGCTTTTTGTGGATGGATGC
TTTTGACCCATTTCGTTGAAAACTTATGTCGACACACATA
TCTGACAAACTTGTACTCGTATATCCTTTATCGCATATGC
TATAGTATAATATTCGAAATTTAATCTCAAGATAATTTTC
CCAAAAGGTCATATTAATTGAATTGAGATTAATTCCTACC
TAACATATATAGATATATTGTGTTGGTGTTATCCTCTTTG
GAGTTTTAGTCGCGCATGTATTCTAAGAAAATGGTAATT
TTGAACTTATATTGATGGTCTAAATTTTATCCTATCACTA
AAATTTCAGTCATGTTTCCTAGCTAATTAATTTGGGTTCA
51
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ATCCAGGTATTCTAAATAAGTTTTGTAAATACATGTCTAT
TATCATAATGAAACATAGAAAAACCCGTAAAGTAAAAAT
GTCTATATTTTTAGTGGCAAATTATTAATGTTGCTATAAT
GAAAAGAGAAGATTCAACCTTTTGTACATCATAAAAAAT
GTTATTCTACATTATGCTAATTTTACATTAGACTTCATAGT
TTTGAAAACTTTCAAATGAAGGGACTTAAATTTTAAATTT
AAAGATGATGTCATAAATTAGTTAGATAAAAGTTAAATA
ATTAATAAGAAAAGGTCTAATGATACCAAATAAAATTTT
CTTAAAAAAGTATTAATGTCATTACAATTTTATTTTATTTA
TATAAGAGAAGATAATAGATTTTCTTGTATAAAAAACTT
ACCTGTAAACTTCTATATAAACTTTTTAGAAAAATAATTT
AAAACGGTCTCAAATATCGTTATTTCCGAACATACAAAA
ACCCAAAACCTAATCCATTTAATTATATTGTAAGACCTCG
ATTAGCTTAATTTATTTTGAAACCTATTTACAAATGAGTT
TGGCATGATATGAACTTTTTTGCATTTACATATGGCTGTA
AACGAACTGAACAGTTCACGAACAATTCATGAACCGTTC
GGCGGGAGGTTCGTTCGTGTTAGTTCGTTTAGTTAAATG
AATGAACATGAACAAAGCTCTCGTTCGTTCATTTACGTTC
ATGAACGTTCGATAGTCTGTTCGTGAACTTTAGTTCGTCT
ATGTTCATGAACTGTCGTTCGTGAACAATAATTTGATTAT
GTTCATTTACACACACATACATAATCAACTGTACTATAAA
AATAGTTTAAATATAAATATTTTTTTATATAATATATATTA
TTAATATCTAATTATTTAAGAAAAAGTTTAAATAAAATAC
TTAATTTATAAATATTTCGTTCGTTTGTGTTCGTGTACATT
TGTTCATGAACACAAATGAACGAACATGAACAAGTCATT
ATGTTCGTTTATCTGTTCGTTAAGTTAAATGAACGAACGA
ACACGAACAAGGTCTCGTTTGTGTTCGTTCGGTTCGTTTA
CGGCCCTTAATTACATGTGAAGTTAATAAATAAAAATAA
AGTTCATCAAAATTAAACCTATGGTTGGAGATAAAACCA
GTCAGCCTTACGTGTGGAAACTATCCTACTCTACAATTAA
TAGCACCCAAAGAAAATAAACCACTTCCGTGTTCTTCTTC
ATCTCCATCATCCAACCCCTCAACTACTTGTACTGTATCTA
TATCTATCATTCTATATATCTACTTCATATTTCTATCTATAC
ATTCAAATTAATAAAAACAAAATGGTAACTGAAGCAGCA
AACGGAAACACACTCACCGGACAACAACAAACCACTACC
ACCACCTCCGCCACTTACAAACTCGTCGGCTTCAAAAACT
TCATCCGTCAAAACCCTAAATCCGACAAATTCACCGTCAA
AAAATTCCACCACGTCGAATTCTGGTGTTCCGACGCCAC
CAACACCGCCCGCCGCTTCTCTTGGGGTCTCGGCATGCC
GCTTCTTTACAAATCCGATCTCTCCACCGGTAACAACACT
CACGCTTCTTACCTTATTAACTCCGGCCAGCTCAACTTCC
TCTTCACCGCACCTTATTCCACCACCATCTCCACCACCGG
TTCCACATCGTCTATTCCTACTTTCTCTCACACTGCTTGCC
GGAACTTCACCGCCACTCACGGCCTCGCTGTACGGTCTA
TCGCCGTTGAAGTTGAAGACGCTGAAATCGCTTATTCTG
TTAGTATCGCTCACGGTGCTAAACCGTCGTCAGCTCCGG
TCACTCTAGGAAATAACGACGTCGTTTTGGCTGAAGTTA
AACTGTACGGCGATGTCGTTTTGAGATATGTTAGTTTTA
52
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
AAAACACTAATTATGATGTTACTACTAATTTCCTACCGGG
TTTTGAGCCTGTGGACGCAACGTCGTCGTTTCATGAACTT
AATTACGGAATTCATAAGTTAGATCACGCCGTAGGAAAC
GTGCCGGAGCTAGCTCCGGCAGTAGACTACGTGAAGTC
CTTCACTG G ATTTCAC G AATTTG CTG AATTTACG G CAG A
GGATGTAGGAACGAGTGAGAGCGGGCTTAATTCGGTTG
TATTAGCGTGTAATAGTGAAACGGTTTTGATACCGATGA
ACGAGCCAGTTTATGGAACGAAAAGGAAGAGCCAGATA
CAGACGTATTTGGAACATAATGAGGGAGCTGGTGTGCA
G CATTTG G CGTTG G CG AGTG AG G ATATTTTTAG G ACTTT
GAGAGAGATGAGAAAACGGAGTAGTATCGGTGGTTTTG
AGTTTATGCCGTCTCCACCGCCTACTTATTATAAGAATTT
GAAGAATAGGGTCGGGGACGTGTTGAGTGACGAACAG
ATTAAG G AATGTG AG G AATTG G G G ATTTTG GTTG ATAG
AGATGATCAGGGAACTTTGCTTCAGATTTTCACCAAGCC
TGTTGGTGATAGGTATGTCTATGTTAACTTTATCAGTGAT
TGTGCATTTGTCCATTTTGTTGAATTCGTAAAACATGAGA
TTAAATACCTGCAATATGTTTTGCTTACATTGAATCTAGG
CCAGGTTTTCAGTGAACAAGTACCATAAATGTATAATGT
AGGTCTAGTCTTGTTAATGATCAGTGATCAATAGTGCAT
ACATTGAATGACGAATTGACAACTAGTTTCTAATAGAAT
GTGAAATATAAAGTGAATGTCACAAAAGCTGTTATCTTA
TCTATTTTAGTTGTAATGGACCAATGGTTGGACTGTTTGA
AAGTGTGCTTACAATCAAGATTCGAGATTGTTACTAGGA
TG CTAG CG CTAG GTATATATCATATG GTGTCTG AG CTCT
ATGGTAGTATAAATTGTGAATACACTAAACATCTCCCAA
AAATATTTGAGTAACCGATCAATCTACTAGTTATTGCAAT
GCCAAACATCTCTTTAAACAACTACTTATTGTAAAGCCAT
ACTACATCAACACACCAAAAATCTATCTCCCACAACCCCC
GTTTTACTTGGGTTATGAACTTAGTATAGTTATTCAAAAT
AATCACTTTCAAAATGGATCCAACACATCTGAAACTGGT
CACATTTGAGTTCTTATCTTTCAAATAATTTGTAATTCATA
TCAGGCTCAGCTTCATGGGGTCTGGCCTTTGTCTGTGTG
TTTGTGTTGTGTCTTTTCTGGTGTGATCTAATTCGGTATG
CATATTGTTTGAGCAGGCCAACTATATTCATAGAGATTAT
TCAGAGAGTAGGGTGTATGCTGAAAGATGATGAAGGCA
AGGTGCAACAGAAGCCAGGCTGTGGAGGATTTGGCAAG
GGCAATTTCTCAGAGCTCTTCAAATCTATTGAAGAATAC
GAGAAGACGCTGGAAGCACGAAACACCACTGAACCAAC
TGCCACTGCATGAAAACTGCCTATGTATAATGTTTATATC
TTCTTGACTCAAAGAACATGATTATCACCATATGTATTTG
TGGATTATGTACAATTGAATGAAACAATGCAATACCATA
TGTGATGTGATTTATATAGAATAACAATAGATGTCATTCA
TATATGCCGTTCCTGTTTTAGTAATTGTGTGTTGGTGGTG
TGTTGCAAGTTCCAATCAGCTGTATATAATGCCTAAATAT
TCAATTTGACCTCCATTAAGGATCCATTGTGCAGATTCTT
TGTTTCTGTCTTAAAAGTGTGGGAGACTTGAAACACATC
TGTAAAACTGAACCAGATCTGAATCGAGCTGAATGGAA
53
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
GCGG CGCAGGTCTGCTCTGTGGTTCCACTTACAACAAAC
AATTGTTCATGGTACGTCGCCTCTTCATAGCCAGTGTTTA
TTGTAAGAAAG CATTGTTTAG G CGAAAAAG GAAAAG GT
GATTTATGTAAGAAAAGGTAGTGCTATTAAGGTTATGTT
CC CCATG AACAAACAG G GTAAATTCATACAG GATCAACT
TTTAAATGATACTATTAAAG GTCATCTACTTCTGTTTC CC
ATGCTTGTGCCAAGCTCAAATTTAGACGAAACCAAAACA
G G ATG AG AAAACTAATTAACACATATTTTAGTAAG CAAT
TACAGCTATATATCATACTATCATTAACAATTACATCAAC
AATCTGAAAAGTTG CAT
23 Conyza g DNA 5610 ATTAAAAACACGAATGGGCTAGCTAGCTGATGAATTTAA
canadensis Co ntig TGTATATATGTCTTTAAAAACCACTTTCATGGGCTACTTG
TGTTTTTGATGAGTTTTTCAACATCATTCTCATCTTACCTT
CTTACAATG GTTCACCATATTG CTTCGTTTGTCGTCTC CT
GCATGGTTATCGAATTTATTTTTTCAAATTATATTACTATT
ATCTTTTTGTTTTCTGATTTCTCACATGTAATTTACATTAT
GAGTTTCACCATCCGTATGTAAATTGTAAAATAAATCACA
AATTTGGTTTTTAACCATCAACTAAATTCATTGAAATCCT
TAAGTTATAACCCATTTG AG GTTATAG ATTATG AG AGTA
GATTCCTATTTTCTCTTTGGCTTATGTATCCTTAATTATGT
TTGAATTGATTCTAACTTTATTATATTTTAGGAATTACTTA
ACTTCAAAAATCTCAACACGTCATATAATGCTTTTTGTGG
ATG GATG CTTTTG ACC CATTTC GTTG AAAACTTATGTCG A
CACACATATCTGACAAACTTGTACTCGTATATCCTTTATC
G CATATG CTATAGTATAATATTCG AAATTTAATCTCAAG A
TAATTTTCCCAAAAG GTCATATTAATTG AATTG AG ATTAA
TTCCTACCTAACATATATAGATATATTGTGTTGGTGTTAT
CCTCTTTG G AGTTTTAGTC GC G CATGTATTCTAAGAAAAT
G GTAATTTTGAACTTATATTGATG GTCTAAATTTTATC CT
ATCACTAAAATTTCAGTCATGTTTCCTAGCTAATTAATTT
GGGTTCAATCCAGGTATTCTAAATAAGTTTTGTAAATACA
TGTCTATTATCATAATG AAACATAG AAAAAC CC GTAAAG
TAAAAATGTCTATATTTTTAGTGGCAAATTATTAATGTTG
CTATAATG AAAAG AG AAG ATTCAACCTTTTGTACATCAT
AAAAAATGTTATTCTACATTATG CTAATTTTACATTAG AC
TTCATAGTTTTGAAAACTTTCAAATGAAGGGACTTAAATT
TTAAATTTAAAGATGATGTCATAAATTAGTTAGATAAAA
GTTAAATAATTAATAAGAAAAGGTCTAATGATACCAAAT
AAAATTTTCTTAAAAAAGTATTAATGTCATTACAATTTTA
TTTTATTTATATAAG AG AAG ATAATAG ATTTTCTTGTATA
AAAAACTTACCTGTAAACTTCTATATAAACTTTTTAG AAA
AATAATTTAAAACGGTCTCAAATATCGTTATTTCCGAACA
TACAAAAACCCAAAACCTAATCCATTTAATTATATTGTAA
GACCTCGATTAGCTTAATTTATTTTGAAACCTATTTACAA
ATGAGTTTGGCATGATATGAACTTTTTTGCATTTACATAT
G G CTGTAAAC G AACTG AACAGTTCACG AACAATTCATG A
ACCGTTCG GCG G GAG GTTCGTTCGTGTTAGTTCGTTTAG
TTAAATGAATGAACATGAACAAAGCTCTCGTTCGTTCATT
54
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TACGTTCATGAACGTTCGATAGTCTGTTCGTGAACTTTAG
TTCGTCTATGTTCATGAACTGTCGTTCGTGAACAATAATT
TGATTATGTTCATTTACACACACATACATAATCAACTGTA
CTATAAAAATAGTTTAAATATAAATATT 1 1 1 1 1 ATATAATA
TATATTATTAATATCTAATTATTTAAGAAAAAGTTTAAAT
AAAATACTTAACTTATAAATATTTCGTTCGTTTGTGTTCG
TGTACATTTGTTCATGAACACAAATGAACGAACATGAAC
AAGTCATTATGTTCGTTTATCTGTTTGTTAAGTTAAATGA
ACGAACGAACACGAACAAGGTCTCGTTTGTGTTCGTTCG
GTTCGTTTACGGCCCTTAATTACATGTGAAGTTAATAAAT
AAAAATAAAGTTCATCAAAATTAAACCTATGGTTGGAGA
TAAAACCAGTCAGCCTTACGTGTGGAAACTATCCTACTCT
ACAATTAATAGCACCCAAAGAAAATAAACCACTTCCGTG
TTCTTCTTCATCTCCATCATCCAACCCCTCAACTACTTGTA
CTGTATCTATATCTATCATTCTATATATCTACTTCATATTT
CTATCTATACATTCAAATTAATAAAAACAAAATGGTAACT
GAAGCAGCAAACGGAAACACACTCACCGGACAACAACA
AACCACTACCACCACCTCCGCCACTTACAAACTCGTCGGC
TTCAAAAACTTCATCCGTCAAAACCCTAAATCCGACAAAT
TCACCGTCAAAAAATTCCACCACGTCGAATTCTGGTGTTC
CGACGCCACCAACACCGCCCGCCGCTTCTCTTGGGGTCT
CGGCATGCCGCTTCTTTACAAATCCGATCTCTCCACCGGT
AACAACACTCACGCTTCTTACCTTATTAACTCCGGCCAGC
TCAACTTCCTCTTCACCGCACCTTATTCCACCACCATCTCC
ACCACCGGTTCCACATCGTCTATTCCTACTTTCTCTCACAC
TGCTTGCCGGAACTTCACCGCCACTCACGGCCTCGCTGT
ACGGTCTATCGCCGTTGAAGTTGAAGACGCTGAAATCGC
TTATTCTGTTAGTATCGCTCACGGTGCTAAACCGTCGTCA
G CTCC G GTCACTCTAG G AAATAAC G AC GTC GTTTTG G CT
GAAGTTAAACTGTACGGCGATGTCGTTTTGAGATATGTT
AGTTTTAAAAACACTAATTATGATGTTACTACTAATTTCC
TACCGGGTTTTGAGCCTGTGGACGCAACGTCGTCGTTTC
ATGAACTTAATTACGGAATTCATAAGTTAGATCACGCCG
TAGGAAACGTGCCGGAGCTAGCTCCGGCAGTAGACTAC
GTGAAGTCCTTCACTGGATTTCACGAATTTGCTGAATTTA
CGGCAGAGGATGTAGGAACGAGTGAGAGCGGGCTTAA
TTCG GTTGTATTAG CGTGTAATAGTG AAAC G GTTTTG AT
ACCGATGAACGAGCCAGTTTATGGAACGAAAAGGAAGA
GCCAGATACAGACGTATTTGGAACATAATGAGGGAGCT
GGTGTGCAGCATTTGGCGTTGGCGAGTGAGGATATTTTT
AG G ACTTTG AG AG AG ATG AG AAAAC G G AGTAGTATC G G
TG GTTTTG AGTTTATG CC GTCTCCAC CG C CTACTTATTAT
AAGAATTTGAAGAATAGGGTCGGGGACGTGTTGAGTGA
CG AACAG ATTAAG G AATGTG AG G AATTG G G G ATTTTG G
TTGATAGAGATGATCAGGGAACTTTGCTTCAGATTTTCA
CCAAG C CTGTTG GTG ATAG G AG G C CAACTATATTCATAG
AGATTATTCAGAGAGTAGGGTGTATGCTGAAAGATGAT
GAAGGCAAGGTGCAACAGAAGCCAGGCTGTGGAGGAT
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TTGGCAAG GG CAATTTCTCAG AG CTCTTCAAATCTATTG
AAGAATACGAGAAGACGCTGGAAGCACGAAACACCACT
GAACCAACTGCCACTGCATGAAAACTGCCTATGTATAAT
GTTTATATCTTCTTGACTCAAAGAACATGATTATCACCAT
ATGTATTTGTGGATTATGTACAATTGAATGAAACAATGC
AATACCATATGTGATGTGATTTATATAGAATAACAATAG
ATGTCATTCATATATGCCGTTCCTGTTTTAGTAATTGTGT
GTTGGTGGTGTGTTGCAAGTTCCAATCAGCTGTATATAA
TGCCTAAATATTCAATTTGACCTCCATTAAGGATCCATTG
TG CAG ATTCTTTGTTTCTGTCTTAAAAGTGTG G G AG ACTT
G AAACACATCTGTAAAACTG AACCAG ATCTG AATCG AG C
TGAATGGAAGCGGCGCAGGTCTGCTCTTTGGTTCCACTT
ACAACAAACAATTGTTCATGGTACGTCG CCTCTTCATG GC
CAGTGTTTATTGTAAGAAAGCATTGTTTAGGCGAAAAAG
GAAAAGGTGATTTATGTAAGAAAAGGTAGTGCTATTAA
GGTTATGTTCCCCATGAACAAACAGGGTAAATTCATACA
GGATCAACTTTTAAATGATACTATTAAAGGTCATCTACTT
CTGTTTCCCATG CTTGTG CCAAG CTCAAATTTAG ACG AAA
CCAAAACAGGATGAAAAAACTAATTAACACATATTTTAG
TAAGCAATTACAGCTATATATCATACTATCATCAACAATC
TGAAAAGTTGCATACAATTTATCGTTTATTCCTGTCAAGT
GATGACATGAAAAATACCATTTAGTTTACACGTACTCAG
ATATG CCAATAATAG AG G GACTTTTTCTATATG AG AACA
TACATG ATGTTCATAATTCATAATTTACTTG ATACG G CAA
GGTACTTGGTATGGCGTCCTTGTGCAATTGTTTTTCCGGT
CTTTTTGTTCCTTAATTCAACG GTCACAACAG CAATAG CC
TTCCCAACACGCAATGTTTTTGCCTCTATCTCAATCTCGTC
CTGTAAGAAAATTGCATCCTTAACAAAATTTTACTCAAAG
ACGCATCTATGGTACGAAGTACAAACCAAAGATTTTCAG
TAAGTCGTGCAAAACCTTTATGCATACTGCAACTACTCAA
ACTTCACATCTTATG CCTAAAATCAAAG ACCCCAAAG AA
GCCTTGAGTTCAAAATCCAAGAATTTCTGTCAGCTACAG
GGGACAGGTTCAACCCATTTACATACAAATGGGTCAAAA
TGGGTTATGTTATTCTGTGTTTCTGCCAAACCAGACCTGG
CACGTACTAAAACTCACCCATTACCCAACCCACCTACCCA
GCCCCCCTTTTTACCAACATGCATTTTGCTTTTGCAACCCT
GTTG CTTCAAG CATTCAACTATTCAAGTAG CAAG ATCG A
AAG AACTTATACAAAAAGTTG CCATTTATG ATTAAGTG A
AG CCTTAATG ACACCAAATCAGTTATTATAG CATTACAAT
G G G AG AG CTTCAACAG AAAAGTTATCAAGTCTTCTCCAA
CAAG ATCATG AG CTCATTTTCAATTTTATATCAAACG GTA
GCAATAACGAAAGTAAATCTGGTGGCTCAAGGTAAAAC
CTCATAACCTTTGATGGCATAATAACTTCCAGACCAACTA
AACACCAAGGTGGAAGTTATTACTTTGTGCTAATGATAG
CAGTTACAAACATAAAAAATCTGGTCGGCTTCGTTCAGT
TTTCTGAAATACCAATATCGTCTGACAAGGTGCCATCTTC
ATATTCAGAGTCACTTCATGATCAACTCTTGTGGGGTTTC
AAACTCAAGAACGTTTTAAATACATTCATTTAATATTTTT
56
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ATCTCCAGAATACTACTCAACACTTTCCTGTAAGGTCTTC
AATTTCAGGGGGAAAAAAACCCAAAATTCAAGGAATCCT
GCTATTAGTGTATCGTTTCTTGATAGCAAAGCTTTCATTT
ACAATCTCTAACAACA 11111 ACTTCAAAATTTTATCATAA
TGCTCTTTAGGAAAATGTTGACGGTATGAATATGAGATC
AGGATATCAAAAGAACAAAATATTTATTTTGTTCTTAAGT
TGCAAACCGCACAAGAGTTGATCATGCAGTGTTCGCGAA
TTTGAAGATGGCACCTTGTTAGGCAACATTGG
24 Euphorbia cDNA 386 TTGTTTCTGCCGAAATTCGAGCCGGTAGATGAGGCGTCG
heterophylla Contig TCGTTTCCGTTGGATTACGGGATTCGACGGCTAGATCAC
GCGGTTGGAAATGTACCGGATCTTGCTCCGGCGGTTTCG
TATGTGAAGAAGTTCACCGGATTCCACGAGTTCGCTGAG
TTCACGGCGGAGGATGTAGGGACGAGTGAGAGCGGAT
TGAACTCGGTGGTGTTGGCTAACAACGAAGAAACGGTA
CTGCTGCCGATGAATGAACCGGTGTTTGGGACGAAGAG
GAAAAGTCAGATACAGACGTATTTGGAGCACAATGAAG
GAGCTGGAGTACAGCATTTGGCGCTTGTGAGTGCTGAT
ATTTTCAATACTTTGAGAGAGATGAGGAGGAGGAGTGC
GAT
25 Euphorbia gDNA 2639 GACAATTAATAAAAAAAACGTAAAGACTACCTTTAATTG
hetero phyl la Co ntig GAGGAGAGGAAAACACCACGTTTAAAAATCCCGTTGTTA
TCCGATTGATGAAAAAAAAGATTAACACGTTACGACTTC
TCCATTCAATAATCCATTTTCTTTATCTTATAAATAATTTG
AAATCCCATCCTCCTCGTTCTCCGTTCACCAGAAAAAACA
GAAATGGGAAAAGACACATCAGCTGCCGCCGAAGCATT
CAAGCTCGTCGGATTTTCCAATTTCGTCAGAATCAATCCC
CGGTCCGACCGTTTCCCGGTCAAGCGCTTCCACCACGTC
GAGTTCTGGTGCTCCGACGCAACCAACACCGCTCGCCGC
TTCTCATGGGGCCTCGGGATGCCGTTCGTCGCCAAATCG
GATCTCTCCACCGGCAACGTCACCCACGCCTCCTACCTCC
TCCGCTCCGGCGACCTCAATTTCCTCTTCACAGCTCCCTA
CTCTCCCTCCATAGCCGCCATGGAGAATCTCTCCGATACT
GCTACCGCATCAATCCCTACTTTCTCCCGCGACGTTTTCC
TCGATTTCTCCGCCAAACACGGCCTCGCCGTCCGAGCTA
TAGCAATCGAAGTGGAGGACGCTGCAGTTGCCTTCAATA
CTAGTGTTGCTCAAGGCGCGGTTCCGGTGGCCGGACCT
GTAGTGCTCGATAATCGCGCTTCGGTAGCGGAGGTTCAC
TTGTACGGCGACGTCGTTTTGCGGTACGTCAGTTACCTA
AACTCTGATGACTGTTTGTTTCTGCCGAAATTTGAGGCG
GTAGATGAGGAGGCGTCGTTTCCGTTGGATTACGGGAT
CCGGCGGCTAGATCACGCGGTTGGAAATGTACCGGATC
TTGCTCCGGCGGTTTCGTATGTGAAGAAGTTCACCGGAT
TCCACGAGTTCGCTGAGTTCACGGCGGAGGATGTAGGG
ACGAGTGAGAGCGGATTGAACTCGGTGGTGTTGGCTAA
CAACGAAGAAACGGTACTGCTGCCGATGAATGAACCGG
TGTTTGGGACGAAGAGGAAAAGTCAGATACAGACGTAT
TTGGAGCACAATGAAGGAGCTGGAGTACAGCATTTGGC
GCTTGTGAGTGCTGATATTTTCAATACTTTGAGAGAGAT
57
CA 02848576 2014-03-12
WO 2013/040021 PC T/US2012/054842
GAG GAG GAG GAGTG CGATTG G G G GATTTGAGTTTATG C
CGTCTCCTCCGCCGACATATTACCGGAATTTGAAGAAGA
G A GTTG G AG ATATTTTG A GT G AT G AAC AG ATTAAG G A G
TGT G AA G AATTAG G G ATTCTG G TG G ACAG G G ATG AT CA
AG G GAC CTTG CTT CAGATTTTC ACTAAACCTGTG G GAGA
TAG GTATTTCTATCTTCTTCTTCATTGTTTTCACTTACAAT
ACCTTTTTCCATTGAAAATTCTTTGTTTCTTGTGTTTCTCTT
ATATGTGTT G G CTG CTATACTAT G GTTG ATA G AG AATTA
GAATTTAGCGTGTTCAAAACTCAATTCTTTATCTTTATCTT
TA G CCTTAG GTC ATTTTG G G ATTG CTTT CAAACT G ATTTG
ATTATGTTACTAATTAATTAGTACGAAGGACTAACATGT
GTTGTTCTAAGCTAAAATATATTCTATAAAGCTAAAATAT
CTTAATAA G CAATAC CAAACTA G CC CTTAAAT G CATA GTT
AGACCCTAAATTTGACAACTTTTATAACTTGGCGCCTCTA
ATTTACAAATGTCTTCGCCAACCTCTTGAACTGGCAAAAG
TTTTCACTGCAACCCCTAGGTGCCACGTGTCACCTTGTGA
TTGATTTGACTTTTCAAAGATGTCAAAATTTTTTATTTTCC
TC CCTCTAATC AAAA G GTG AC AA GTG ATATTG A GTA G G G
GTCTGTAGTGAATACTTTCCCCAAGTTGAGACATCCAGA
AATCG GAG G CGTCATGTGATAAAAGTTG CTTAGTTAAG G
GAG CTTAATATGTATTAAG CCTTTTCGCTACCTTGCCATT
TAAATCCTTAGTCCAAGCAAAATATACAAAAATTAGTTA
G AACTTTATG ATTCAG AACCTACGTAACTTTAATTTG ACC
A GTA GTTCTAT CTTAT G CATG C CA G CC AT GTTG ACTG GT
GAACTTATATTCAATTTTGCTATTCAAGTAAATCCTTATCC
ATCAATCCGAATCAAAAGATTTTAATGTTAGGTTAAACTT
GTACGATTCAAAACTTAGGTTGTACTTTTTGACTAGTAGT
TCTATTATGTATGTGTATATATAATGGGGTTTTTTTTCTGT
AG G CCAACGATTTTCGTAGAGATAATACAGAGAGTAG G
GTGTATGCTAAAGGACGAAGCAGGGAGAGAATACCAGA
AG G GTG GATGTG G CG GTTTTG GTAAG G GAAACTTTTCG
G AGTTATTCAAATCCATTG AAG AATACG AG AAAACACTG
G AAG C CAAACG AACTG C ACAAG C ATAG A G GTTA GTA G G
GAATTTGATGATACCCATAAATAATGGTTGTTACTTGTTG
CCTT GTAATAAGTTTA GTTAAATG ATG ACT GT G CCTG CA
AATTGGAATGTTCTCTAATTGTTGGTTGATATTGTTGTAA
AATGTAAACTATGATGTTACTATAAAGTATAGTTGTGGT
TATCGTGTCTCTTCTTTTGGAATCTGAAGTTTCGATATTTT
TTTGGGG
26 Euphorbia g D NA 6569 TGACTGAAATTAAATTTTAATTATTTG CAAAG CTTACG
GT
heterophyl la Co ntig GAAATTAAACTCTAACCATTAAAATTTTAATGAGTCAAAA
TTG AC CG AAATGTTCATGTCATAAATTTAG ATAATCCTTT
CAGATATGTACGTGAAACCATGTACCTAAATTGTAGTCA
G ATTG CTAAAC CC CCTTC G AAAATG AATG AAATG ATATG
ATATGCTATGCTATGTATTTTAAGGATTATTTTATAGTAA
CTTTGTTTATAATTTACTTTATATGATCATCATCCAATTAA
CTTTCACCTCACTAATTCAATGATTGAAATGGACTAAGTA
ATTTTACTTAATAAAAAAATAAAATCACTATAACCTACAC
58
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
ATATTTTTAAAAATAACACCATAATTTATTAAAGGACATT
TAATTGAAGTAGAAAATTATATAATTACTCGCTAATAAAT
TTTCAATTGGAGGAGAGGAAAACACCACGTTTAAAAATC
CCGTTGTTATCCGATTGACGAAAAAAAAGATTAACACGT
CACGACTTCTCCATTCAATAATCCATTTTCTTTATCTTATA
AATAATTTGAAATCCCATCCTCCTCGTTCTCCGTTCACCA
GAAAAAACAGAAATGGGAAAAGACACGTCAGCCGCTGC
CGAAGCATTCAAGCTCGTCGGATTTTCCAATTTCGTCAG
AATCAATCCCCGGTCCGACCGTTTCCCGGTCAAGCGCTT
CCACCACGTCGAGTTCAGGTGCTCCGACGCAACCAACAC
CGCTCGCCGCTTCTCATGGGGCCTCGGGATGCCGTTCGT
CGCCAAATCGGATCTCTCCACCGGCAACGTCACCCACGC
CTCCTACCTCCTCCGCTCCGGCGACCTCAATTTCCTCTTCA
CAG CTCCCTACTCTCCCTC CATAG CCG CCATG GAG AATCT
CTCCGATACTGCCACCGCATCAATCCCTACTTTCTCCCGC
GACGTTTTCCTCGATTTCTCCGCCAAACACGGCCTCGCCG
TCCGAGCTATAGCCATTGAAGTGGAAGATGCTGCGATTG
CTTTCACTACCAGCGTTGCTCAAGGCGCGATTCCGGTGG
CCGGACCTATTGTGCTCGATAATCGTGCTTCAGTTGCGG
AGGTCCACTTGTACGGCGACGTCGTTTTGCGGTACGTCA
GTTATCTAAACTCCGATAGTTGCTTGTTTCTGCCGAAATT
CGAGCCGGTAGATGAGGCGTCGTCTTTCCCGTTGGATTA
CGGGATTCGACGGCTAGATCACGCGGTTGGAAATGTGC
CGGAATTATCTCCGGCGGTTTCGTATGTGAAACAGTTCA
CCGGATTCCATGAGTTCGCCGAGTTCACGGCGGAGGAT
GTGGGGACGAGTGAGAGCGGATTGAACTCGGTGGTGTT
GGCTAATAACGAAGAAACGGTTTTACTACCGTTGAATGA
ACCG GTGTATG G CACAAAG AG GAAAAGTCAGATACAAA
CGTATTTGGAGCACAACGAAGGGGCTGGAGTACAGCAT
TTAGCACTTGTGAGTGCGGATATATTTAACACTTTGAGA
GAGATGAGGAAGAGGAGTGGCGTTGGGGGATTTGAGT
TTATGCCGTCTCCTCCGCCCACATATTACCGGAATTTGAA
GAAGAGAGTCGGGGATATTTTGAGCGATGAACAGATTA
AGGAATGTGAAGAATTAGGGATTTTGGTGGATAGGGAT
GATCAAGGGACCTTGCTTCAGATTTTCACTAAACCTGTG
GGAGATAGGTATGTCAATCAATCTTGTGAAATGATTAGT
TGTTCTATAATTACTTATGTGATTTACATTCTTAGAGTCTG
TAAATTCTTGTGATCATAAATTTGTTGGCTTGGATACCAT
ATTAATATTATCCTTAATTTAGAATGTCAAAGTTATGTTC
TGTCTTTACAATGCCGTTGAAATCGTTATTTATCAAGTCC
AAGCAAACGGTCCTAAAATGTCCTTTAACTTACTGGTTCG
GAATCTCATCTGTTCAATTTGATTAGTAGTTCCATCTTTTA
GTATATACGCCAGGCGCCAGACATGTTGATTTGTGAGTT
TTTGTTATTTGGAATCTCAAAGTTGAGTTTTTTCTATCTAT
AAAAAGTAGCTCAAATCCTTAGTTATCAAGTCAAAACCC
AAAGATCCTATTATTAACTTGGATCTGAAATTATATCGCT
TTCTGGTTTATTTCTAAATTTGGTGGTCACTTGATTTCTCA
TCTTGACAAGTGAATTCATCTGGACATAGTTGGTCTTTTA
59
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
TGGGATGAATGGATGTGCTGTTTTTGCAGGCCAACCATT
TTCGTTGAAATAATTCAGCGAGTCGGGTGTATGGTCAAG
GATGAAGCAGGGAGAGAATACCAGAAGGGTGGGTGTG
GCGGTTTCGGTAAGGGAAACTTCTCGGAGTTATTCAAAT
CAATCGAG GAATATGAGAAAACATTG GAG GCCAAACGA
ACTGCAGAAGCAGCTCGAGCATAAAATAAAGGTTAGTA
TGGAAGATGATATGCATACATAAATAAAGGTTGGCTGTT
GTTTATTACGTTGTAATATTCTACTCCAATGATGCTGTTA
TTGTCTGAAAATACCAGTGCCTGCGAATTGGAATGTTCT
CTAATTGTTAGGAACAACTGGAATCATTGTATATCGTAA
ACTATGGTTCATTAAAAGTTAAAAACATATATATGATATG
ATTAATATAGAATTACTCCCTTTATTTGGAATCTAAAGAT
TCATTTCTCAGTTTCTTTCTGGGCGATTTTGAGCATTTCTG
TACTTAAATTCTGCGCGAATACACCCACCAAGCCCTAGCT
AGCTTGGTGGTTACCTTTTAAGGGTGTTGGAAACCTAAA
TTAGAAAAGATTTCAGTTTAATTTATGTCATTTTATATAT
AAAAGTTTGAAACTTTTTTATTCAAAATAAGTTGATTGAT
AAATTGAAATCAATTAGCTTTGTAGCAGATGTTCACCCA
AATCTAATATAAATATATTATAAATCTAATATATTTCTGTT
AACAAACTTATAATATATTAATAAATACAATTGCAAAGA
CAAAGAGACTTATATTAGAATTATAACATAATTTTTTATA
AATATATTAGATACGTATATCTTATAATTGTAACATATAA
AAGATTTTATAGTAAATATGTGTTATAAGTCTAAAATAA
GCCTTTTTAAGTTTAATACAAGTCTCTTTGTGTAACACCC
CGGGTTCGACCGATTGACCCCCACAAACCAACACAAGTC
TTTCTAGTAAGCTTTGCCTTGAGATTGTTCCAAGTCAAGG
ACGCTCAACTTTGGAGTTCTCCCATATAAGCTCCTGAAAA
GAAGGTGTAACTTGTTGGTATAGGCAGCAGTACCAATCA
AACCTTTTTAAGTCCCTTTCCACTTTAATGTCCCTTTCTAT
TGATATAATTTTATTGACTTTATGTAATCAAATGTTTATTC
ATCCCGTGTTTTTTTATTCATTATGTTTTAATTTTTTAATTA
GTCAAAATATAATATCTAAAAAATCTATCAAATTTGGGCT
CGGCTCGGCTTGACTCATTAACATCCGACTCTCTACCTCT
TACTTTTATTAAATACATTTGTGTTTTTCAGTTGTACGTTC
CTTCTCATATTTACATTTCCCTTTTTTCTTTTCTTTTTAATTT
ATTTTTTATTTATTTCGCAAATCGTTGATTTTCTCGGTATG
CTGCTTTATAATTTTTTGTTCGTCTCGTTTTTATCTTCGAA
AGTATATTCATGTTGATATACTTTTTCAAGTTCTTATTTTC
AAAGATATGTAACAAATGACATAAACATTATCCAGCAAA
AATCAGTAAATTACTAGCATTTCACCAACAAAATACTAGC
ATTTTACCCGTGACGAAAAGTTTGAAAAAAATATATAAA
AAAAATCAAACAAAAATCATTTTTATACCAACATTATACC
ATGTATGAAAAAATAAAACTGATCATAAACATAAAGAAA
TCAAACAAAATTCACCTTATCTTAATATTTTACCAAGAGT
GAAGGACCAAACATAAACATGTTTTACGAAAAAAATCAA
ACAAAAATCATTTCACACTAGCATTTTATTAACAAAATCT
CGATATATTATCAGTAAAATACCAACATTTTATCAACAAA
ATACCATCATTTGAGAGGAGGTTCGAGTGCGCCTTCGCC
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
GTTCTGCGGCGGCTTCTTTGACGGTGGAGAAAGCATAG
CTGCGTGATGGAGGCAGAAGAGGGGTTGATGAAATTGG
GTTGGATTGAAGTGGAATTGAGTCAATGAGGCTAGGTG
ATAG G GTG AG ATG ATG CATG ACTC G AATTG GTG GTTG A
TCGCAGAGGTGGAGGTGGCGATTGGCCGGCGGAGAAG
ACGGCAAATAGATGTTTTTGGGCGGAGTACAAAGCGCC
TTAAATCCTAGCAAAGGCTGATGAAAATAAAAAAGGGT
AATGCTGCACTTTTATCTACTTTGTGCAATATCTATATAC
AGTATTTATTATCATCTTATTCCTTTTATTTATTTCTTTCAT
CTTTTATGGGAGTTGAAATTCTTTCTAGATATTCTTTTCTT
TTTGCTAAATTTTTCTGCTCATTGTCATACACTTGCTTGGT
AAACTGAATCTCAAACCAAATAATGAAATCTGAAGTATG
TATCCACAGAATCGCAATGCTCATCGACGGAAGTAGAAG
G G G AAAACTG CTGTTG G AGTTG AG GTATATAATCTG CA
GTTGAAATCGACGTTGTGTATGTAATTTTGAATTGAACA
AGAGCGAAACCTAGTTTTCTATGATCTGTACCTGGCGTA
TAAGAATTCCATCAATATCGGCAGGGCGATGCGTTAATA
TTGCATTAACACCGGTGGTGAGAAGGGAGCTAATTGCTT
GAAATCCGCTGGCATGCCGCAATGTTGATATGTCACATA
AATGCGACTAAGTGTGACTTATCTTGAAGAGGAGTGAA
ATTGGGGAAACGACTAAGAGTGACTTATCAAGAAGTGT
GATTACCATGCAACTAAGTGCGACACGGTGAAACGACTC
GACTCCTGCAGCCACCACCAAATTTCACAATTTCATATAG
GTAAAAGGGAGACGATCAGAAAGAGGGGAAACAAAAC
ACAAAGAGAGGGAAAAGAAATGTTGGAGGGACTGAAA
TTATAGAAGGGGTAAAATTAGAAACAAAAAAAATTATA
AGGTGTTGTAAGTAGAAATTAAATTACGAGCAAAAGTTG
GTTGAAAATAAAAATGAAGATATTGTGATAAATTATTTC
TTTTTTTTTATATTTGACCAACTTACATTGTAAAGCCTGTA
ATTTTTATTAATTTCGCATTATAGCCATAAAAAGTTATTCC
AATCTATGAAGTTGTGACTTTGCGGAACATATTTTCCGA
AAAACTTATTTTTCAAGTTTTTTAAATAGTAAGAAAAAGG
AAATTTTAAATTATAATAACATAATAGGTAGTAAATATAA
ATAGTATATATTTATAATTCAAATAATTATCAGGAAATCT
TATTTATTTTATGAAATTTCTAGGTAAAATTAATTTAGTC
ATGACTAAGTGTTGTTTCTCACAAAATTGTAATCATAATC
AAACTAAATTTTGATATCGAGAAACACAAAATGAGCATT
TGTTGAAAGAGACTTATAGGTCGAGTCTTAACAAACTTG
ATAAGATTATAAAATTGTCTAGCATAAACTCCTCATGCAG
CGAAACAATAATGTATGATTACAATCATAAGCCAATGTT
CATGTTGGATAAACCACACGATAACTAATTCTAGAATCTC
TCAAGAGTCTAAATAATTTCTATGCACACTTTTAAATTTA
TTTAAGCTTCATAGTGAAATATTAGCTTGTGCTACACTAA
TTTACATTGTACGTTATTTTCAATGGAATGACAACTTTAT
TTTGTGCCCATAGTGCATAACAGTAAAATTTCAGTTCAAT
GATTTCATATATTATTTTTTATATTACGAAGTTTTAGGTTT
TTGGATTTTAGATTACAATCGAGACCATAGCAAGAGTTG
AAACATGCAAATGAGATTTAAGCTTAAAAAAATGTTATA
61
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
AAATTATTAACATTTAG CACTTATAGTAGCTACAAAAATT
TGAAGGATTGAATATTTCTAAATATTACAAAGTATAAACT
TAAATATCAACAAATATGATTCATGGAGTTTGAGTTAAG
TATAATTTAACAATATATCAATGATCGAGTTTTTTGCAAA
AATCATAAATATTAGCTCAATTTGAAGAACTTAACAAAG
CACTCAAAACTTTAATTGAAAACAAAAATTTAAGGTTAA
GGGCTTATATATATAAAAAAAAATTCAAAGTATGAAAGC
AATTTCGGACTTCAATTTTTATAATTTTTGATTCATAACGA
ACTATTAAATTATTGATAAATATACTTCTGCATAGAGTCC
AAAAAATTATAAGGCCGGCCTAATAAAGCCTATGATAGA
ATCCTATAGAAACATTGTTGACCCAAGCACAGGCCGAGT
GAACTCGTGGCTGAGTTTCTATGCTAAGAGTTTTGATCA
TGTGTAAGAATAAACTAAGTAAGAATAACATTAAATAAA
TAATTGAATCTTTACATA
27 Xa nth i urn CD NA 1567
AGAAATAAAAGACACATATGTTCGTGAGGTTATGACACC
strum a rium Contig TTTGGTTGATGTTGTAGCCAGTGATTCTAGTGCAACACT
AATCGATTTCCACACCTTGTGGGTAAGTCATCAATATTCA
AG G GTACCTGTTTTTGAACAACGTGTTGATAATATAGTC
GGTATTGCATATGCAATGGATCTATTAGACTATGTTCAA
AAGGGAGACCTTTTAGAAAGTACCACGGTGGGGGATAT
GGCTCATAAACCTGCTTATTTTGTGCCTGATTCAATGTCG
GTATGGAATCTTCTTAGAGAATTTCGCATTAGGAAGGTA
CACATGG CTGTTGTCCTGAACGAATACGGTGGGACAGTT
GGAATTGTAACACTAGAAGACGTGGTTGAAGAAATTGTT
GGTGAAATTTCTTCAACCCACGCCTCTTATCTCCTTAAAT
CCGGCCAACTTAACTTCCTCTTCACCGCCCCTTATTCCCCT
TCCATCTCATCCACCACAACCACCGCCTCCATCCCTTCCTT
TTCTCACTCCACCTGTCGCCACTTCACCTCCTCCCACGGC
CTCGCTGTTCGTGCCATCGCCGTTGAAGTCCATGACGCC
GAACTCG CTTTCTCCGTTAGCGTCGCTCACGGCGCTAAA
GCCTCCGGATACCATAATCCAGCTCTTCAAACGACGACG
TTTCTCCACAGCTTCAAACCCAGGCAAAACATATTGTTAT
TATTATTATTGTTTGTAACTAATATAACGCAAAACGACGT
CGCCGTAGAGTTGAACTTCTGATAAGACGACGTCGTTAT
GACCGAGGGTGATAATCCGGAGGGTTGACCACGCAGTG
GGGAACGTGCCGGAGTTAGCACCGGCAGTGGAATATAT
AAAATCATTTACTGGATTTCACGAGTTTGCTGAGTTTACG
GCGGAGGATGTGGGAACGAGTGAGAGTGGACTAAACT
CGGTGGTTTTGGCTTGCAATAGTGAGATGGTATTGATAC
CGATGAATGAACCGGTTTACGGGACGAAGAGGAAGAGT
CAGATACAGACGTATTTGGAACATAATGAAGGGGCGGG
GGTTCAGCATTTGGCGTTGGCTAGTGAGGATATATTTAG
GACGTTAAGGGAGATGAGGAAAAGGAGTGGGGTTGGT
GGCTTTGAGTTTATGCCGTCTCCCCCTCCTACTTATTATA
GGAATTTGAAGAATAGGGTGGGCGATGTGTTGTCTGAT
GAACAGATTAAG GAGTGTGAAGAATTG G G GATATTG GT
TGATAGAGATGATCAGGGGACTTTGCTTCAGATTTTTAC
CAAGCCTGTTGGTGACAGGCCGACGATATTCATAGAGAT
62
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
AATTCAGAGAGTAGGGTGTATGGTGAAGGATAATGAAG
GAAAGGAGCAGCAGAAGGCAGGGTGTGGAGGGTTTGG
CAAAGGGAACTTCTCAGAGCTTTTTAAATCCATTGAGGA
ATATGAGAAGACATTGGAAGCAAGAGCCACCACTGAAG
CCACTGCTGCTGCATGAAAACCACCCATGAATAATCTTCA
TGAGATTTTATAATCTAATGATTATGTATCTGTGGATTCT
ATACGAAC
28 Digitaria CD NA 892 TTGTGAAGTTGGTGTCATATATTTCAAGATCTGTTCGTAT
sanguinalis Contig AGAATCCACAGATACATAATCATTAGATTATAAAATCTCA
TGAAGATTATTCATGGGTGGTTTTCATGCAGCAGCAGTG
GCTTCAGTGGTGGCTCTTGCTTCCAATGTCTTCTCATATT
CCTCAATGGATTTAAAAAGCTCTGAGAAGTTCCCTTTGCC
AAACCCTCCACACCCTGCCTTCTGCTGCTCCTTTCCTTCAT
TATCCTTCACCATACACCCTACTCTCTGAATTATCTCTATG
AATATCGTCGGCCTGTCACCAACAGGCTTGGTAAAAATC
TGAAGCAAAGTCCCCTGATCATCTCTATCAACCAATATCC
CCAATTCTTCACACTCCTTAATCTGTTCATCAGACAACAC
ATCGCCCACCCTATTCTTCAAATTCCTATAATAAGTAGGA
GGGGGAGACGGCATAAACTCAAAGCCACCAACCCCACT
CCTTTTCCTCATCTCCCTTAACGTCCTAAATATATCCTCAC
TAGCCAACGCCAAATGCTGAACCCCCGCCCCTTCATTATG
TTCCAAATACGTCTGTATCTGACTCTTCCTCTTCGTCCCGT
AAACCGGTTCATTCATCGGTATCAATACCATCTCACTATT
GCAAGCCAAAACCACCGAGTTTAGTCCACTCTCACTCGTT
CCCACATCCTCCGCCGTAAACTCAGCAAACTCGTGAAAT
CCAGTAAATGATTTTATATATTCCACTGCCGGTGCTAACT
CCGGCACGTTCCCCACTGCGTGGTCAAGCCTCCGGATAC
CATAATCCAGCTCTTCAAACGACGACGTTTTCTCCACAGC
TTCAAACCCAGGCAAAAACATATTGTTATTATTATTATTG
TTTTTGTAACTAAT
29 Digitaria cDNA 975 GCCGCCACCGCCTCCCTCCCCTCCTTCTCCGCCCCCGCCG
sanguinalis Contig CGCGCCGCTTCGCCTCCGACCACGGCCTCGCCGTGCGCG
CCGTAGCGCTCCGCGTCGCCGACGCCGAGGACGCCTTCC
GCGCCAGCGTCGCCAACGGGGCGCGCCCGGCGTTCGAG
CCCGTCGAGCTCGGCCTCGGCTTCCGCCTCGCCGAGGTC
GAGCTCTACGGCGACGTCGTGCTCCGCTACGTCAGCTAC
CCGGACGCCGCGGATTTGCCCTTCCTGCCGGGCTTCGAG
GACGTCGTCATCAGCAACCCAGGGGCGGTGGACTACGG
GCTGAGGCGCTTCGACCACATCGTCGGCAACGTCTCGGA
GCTGGCGCCGGTGGCCGCGTACGTCGCCGGATTCACGG
GGTTCCACGAGTTCGCCGAGTTCACGGCGGAGGACGTG
GGCACGGCGGAGAGCGGGCTCAATTCCGTGGTGCTCGC
CAACAACTCCGAGAACGTGCTGCTCCCGCTCAACGAGCC
GGTGCACGGCACCAAGCGCCGCAGCCAGATACAGACAT
ACCTGGACCACCACGGCGGCCCTGGAGTGCAGCACATC
GCGCTGGCTAGCGACGACGTGCTCAGGACACTGCGGGA
GATGCAGGCGCGCTCCGCCATGGGTGGGTTTGAGTTCA
TGGAGGCTCCGCCACCCACTTACTATGAGGGTGTGAGG
63
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
CGGCGCGCCGGGGACGTGCTCTCGGAGGAGCAGATAAA
GGAGTGCCAGAAACTGGGGGTGCTGGTGGACAGGGAT
GACCAGGGAGTGTTGCTCCAAATCTTCACCAAGCCAGTG
GGGGACCCAACGTTTTTCTTGGAGATAATCCAAAGGATT
GGGTGCATGGAGAAGGATGAGCAGGGAAAGGACTACC
AGAAGGGCGGCTGTGGCGGGTTTGGCAAGGGAAACTTC
TCACAG CTGTTCAAGTCTATTG AG G AGTATG AG AAGTC C
CTTG AAG C G AAG CAA
30 Koch ia c DNA 1266 ACCACCGCCTCAACCGAGTTCAAGCTGGTGGGTTACTCC
sco pa ria Co ntig AACTTC GTCC G AGTTAACC CCATGTCC G AC
CTCTTCTC CG
TCAAAAAATTCCACCACATCGAGTTCTGGTGCGGCGACG
CGACCAACGTCAGCCGTCGCTTCTCATGGGGTCTAGGCA
TGCCGGCGGTCGCTAAATCCGACCTCTCCACCGGAAACT
CCGTACACGCTTCGTACCTCCTTCGCTCAGGCGACCTCTC
CTTC CTCTTCACCTCC CC GTACTCC CCTTCTCTCTCCTCC CC
CTCTTC CG CTG CAATACC CAC GTTTG ATTTCTCTCTCTTCT
CCTCTTTTATCACCTCCCACGGCATCGGGGTTCGCGCCGT
TGCACTCGAGGTCGACGATGCCGAGGTTGCTTTCAATAC
GAGCGTCTCCCACGGCGCAATCCCTGGTTCTCCCCCGAT
TAAGCTCGGAAACGGCGTCGTTTTGTCCGAGGTCAGCCT
CTACGGCGACGTCGTTCTTCGCTACGTGAGCTACGGAGG
TGAGACAGAGAAAGCGGATACGAATTCGAATTCATGGT
TTCTTCCTGGGTTCGAGGAAATGCCGGAGGAATCGTCGT
TTCGAGGGCTCGATTTCGGGCTCCGGAGACTAGACCATG
CGGTGGGGAATGTCCCGGAGCTAGGGAAAGCAATCGA
GTATGTGAAGAAGTTCACTGGGTTTCACGAATTTGCTGA
GTTTACAGCTGACGATGTTGGGACGAGTGAAAGTGGGC
TGAATTCGGCTGTGCTGGCGAACAACTCGGAGACGGTG
TTGATTCCGATGAACGAGCCGGTTTACGGGACGAAGAG
G AAG AGTCAAATTCAG ACATACTTG G AG CACAATG AAG
GAGCTGGGGTTCAGCATTTGGCATTGATGAGTGAGGAT
ATATTCTGGACTCTTAGGGAGATGAGGAAGCGGAGCGG
GCTCGGTGGGTTCGAGTTTATGCCAGCACCGCCGCCTAC
GTATTATCGGAACCTGAGGAATCGTGTCGGGGATGTGTT
GAGTGAAGAACAGATGAAGGAGTGTGAAGAGTTGGGG
ATATTGGTTGATAAGGATGATCAGGGCACTCTGCTCCAG
ATTTTTACTAAG CATATTG GTG ACC CAACTATGTTCATTG
AG ATTATCCAAAG AATTG G CTG CATG ATG AAAG ATG AA
GAAGGCAAGGTGTACCAAAAGGGAGGCTGTGGAGGAT
TTG G G AAG G G AAACTTTTCAG AG CTTTTCAAATCTATCG
AAGAGTATGAGAAGACACTTGAA
31 Lolium cDNA 783 CTCGGCCACGGGTTTGGCTTCGCGGAGGTGGAGCTAGC
multiflorum Contig CGGGGACAGCGTTCTCCGCTTCGTGAGCTACCCGGACG
GCACCGACGTGTCCTTCCTGCCGGGGTTCCAGGACGTGG
CGAGCGCCGGCGGGGCGCCGGACTTCGGGCTCACCCGG
TTTGACCACGTCGACGTTAACATCCCGGAGCTGGCACCC
GTCGCCGCCAATGTTGCCGGCTTCACCGGGTTCCACAAA
TTCTGGGAGTTCACCGCGGACGACGTGTGCCCGGAAGA
64
CA 02848576 2014-03-12
WO 2013/040021 PCT/US2012/054842
GAGCGGGGTGAACGGCGTGGTGATCGCCAACAACTCAG
AGAACGTGCTGCTCAGTATCTTGGAGCCGGTGTTCGGCA
CCAAGCTGCGGAGCCATGTCGAGACGTTCCTGGACCACC
ACGGTGGCCCGGGCATACAGCACCTGGCAATGACCAGC
CACGACATCCTTGGCGCGCTCAGGAAAATCCGAGCTCGG
TCCTCCATGGGCGGGTTTGAGCTCCTGCCGCCGCCGCCG
GCCAGCTACTATGACGGTGTAAGGCAGCGCGCCGGGGA
CGTGCTGTCGGAAGAACAGATCAAGGAGTGCCAAGAGC
TGGGCGTGCGGGTGGACAGAGGGTATGAGGACGGAGT
TGTGCTCCAAGTCTTCACCAAACCGGCGGGAGACCCAAC
CTTACTGTTAG AGTTTATCCAAAG AATC G G GTG CATG GT
CAAGGACGAGAACCAGCAGGAATACCAGAGAGGTGGA
TGTGGCGGGTTTGCCAAAGGGAACGTTTCTGAACTCATC
AAGGACATTGAGGAC
32 Lolium
cDNA 1041 ACCGATCGCTTCCACGTGATGGATTTCCACCACGTCGAG
multiflorum Contig TTTTGGTGCGCCGATGCCGCCTCGGCCGCCGCACGGTTC
TCCTTCGGGCTCGGCGTGCCACTCGCCGCGCAGTCCGAC
CTCTCCACGGGGAACACTGCGCACGCCTCACGCCTACTA
CGCGCACGCTCGGGCTCTCTCTCGTTCCTCTTCACCGCGC
CGTACGCGCCGCACGTCGCCGACTCGGCGACCACCGCG
TCCCTGCCCTCCTTCTCGGCGGACGCCGCGCGGCGCTTC
ACGGGCACCCACGGCGGCCTGGCCGTGCGTGCCGTGGC
CGTCCGCGTCGCTGACGCGGCCGAGGCCTTCGTCGCGA
GCGTGGACGCCGGAGCGCGGCCAGCCTGCGCCCCGACT
GATCTCGGCCACGGGTTTGGCTTCGCGGAGGTGGAGCT
AGCCGGGGACAGCGTTCTCCGCTTCGTGAGCTACCCGG
ACGGCACCGACGTGTCCTTCCTGCCGGGGTTCCAGGACG
TGGCGAGCGCCGGCGGGGCGCCGGACTTCGGGCTCACC
CGGTTTGACCACGTCGACGTTAACATCCCGGAGCTGGCA
CCCGTCGCCGCCAATGTTGCCGGCTTCACCGGGTTCCAC
AAATTCTGGGAGTTCACCGCGGACGACGTGTGCCCGGA
AGAGAGCGGGGTGAACGGCGTGGTGATCGCCAACAACT
CAGAGAACGTGCTGCTCAGTATCTTGGAGCCGGTGTTCG
GCACCAAGCTGCGGAGCCATGTCGAGACGTTCCTGGAC
CACCACGGTGGCCCGGGCATACAGCACCTGGCAATGAC
CAGCCACGACATCCTTGGCGCGCTCAGGAAAATCCGAGC
TCGGTCCTCCATGGGCGGGTTTGAGCTCCTGCCGCCGCC
GCCGGCCAGCTACTATGACGGTGTAAGGCAGCGCGCCG
GGGACGTGCTGTCGGAAGAACAGATCAAGGAGTGCCAA
GAGCTGGGCGTGCGGGTGGACAGAGGGTATGAGGACG
GAGTTGTGCTCCAAGTCTTCACCAAACCGGCGGGAGACA
GG
